documents incorporated reference document part proxy statement annual meeting part iiistockholders held april filed securities exchange commission within days close fiscal year covered reporttable contents p age part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item properties item legal proceedings item submission matters vote security holders executive officers registrant part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data financial statements notes consolidated financial statements report independent registered public accounting firm b supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures consent independent registered public accounting firm independent auditors consent ex deferral program ex special separation program separated employees ex special separation program bridged employees ex special separation program separated retirement eligible employees ex supplemental retirement plan ex plan deferred payment directors 's compensation ex computation ratios earnings fixed charges ex subsidiaries merck co inc ex power attorney ex certified resolution board directors ex certification ex certification ex certificaion ex certificationtable contents part tem business merck co inc merck company global researchdriven pharmaceutical company discovers develops manufactures markets broad range innovative products improve human animal health companys operations principally managed products basis comprised two reportable segments pharmaceutical segment vaccines infectious diseases segment pharmaceutical segment includes human health pharmaceutical products marketed either directly merck joint ventures products consist therapeutic preventive agents sold prescription treatment human disorders merck sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccines infectious diseases segment includes human health vaccine infectious disease products marketed either directly merck case vaccines also joint venture vaccine products consist preventative pediatric adolescent adult vaccines primarily administered physician offices merck sells human health vaccines primarily physicians wholesalers physician distributors government entities infectious disease products consist therapeutic agents treatment infection sold primarily drug wholesalers retailers hospitals government agencies companys professional representatives communicate effectiveness safety value pharmaceutical vaccine products health care professionals private practice group practices managed care organizations financial information information pharmaceutical segment vaccines infectious diseases segment see item managements discussion analysis financial condition results operations item financial statements supplementary data overview company continued address business challenges midst evolving pharmaceutical industry environment revenue declined driven largely lower sales fosamax alendronate sodium treatment prevention osteoporosis fosamax fosamax plus alendronate sodiumcholecalciferol lost market exclusivity substantially formulations united states february april respectively result company experiencing significant decline sales united states within fosamax franchise also contributing decline lower sales zocor simvastatin companys statin modifying cholesterol lost us market exclusivity partially offsetting declines higher sales januvia sitagliptin phosphate janumet sitagliptin phosphate metformin hydrochloride treatment type diabetes isentress raltegravir antiretroviral therapy treatment hiv infection address business industry challenges merck faces company remains focused innovation customer value order drive growth business help position merck future success company made significant progress reengineering operations research development initiatives rollout new commercial model continuation mercks supply strategy activities enable company optimize product portfolio invest growth opportunities emerging markets merck bioventures business development merck continues efforts diversify companys scientific portfolio internal programs external research collaborations company focused developing novel bestinclass followon treatments patients primary care specialty care hospital settings additionally merck research laboratories pursuing portfolio treatment modalities includes small molecules vaccines also biologics peptides rna interference rnai merck moving diversify portfolio creating new division merck bioventures leverages unique technology platform followon novel biologics company numerous active clinical programs across companys major research franchises bone respiratory immunology endocrine cardiovascular diabetes obesity infectious diseases neuroscience oncology vaccines company currently nine candidates phase iii clinical development table contents anticipates submitting two new drug applications nda us food drug administration fda respect two candidates mk telcagepant investigational compound treatment migraines mk rolofylline investigational compound treatment acute heart failure addition company anticipates submitting nda mkc ezetimibe combined atorvastatin investigational medication treatment dyslipidemia developed merckschering plough joint venture also company anticipates regulatory action two supplemental filings submitted fda one gardasil mercks hpv vaccine use males one isentress firstinclass integrase inhibitor treatment hiv infection expanded indication use treatment nave patients commercial side company rolling customercentric selling model designed provide competitive advantage help build trust customers improve patient outcomes strategy employs use new marketing technologies complement new customercentered approach moves away traditional frequencybased sales marketing approach also creates efficiencies eliminating redundancies core functions across sales organization manufacturing side merck made significant progress three years since began engineering create lean flexible costeffective capability company continues address manufacturing issues working build additional capacity vaccines biologics well support mercks expansion emerging markets assist goal company shifting investments developed markets emerging markets commensurate size strategic importance opportunity october company announced global restructuring program restructuring program reduce cost structure increase efficiency enhance competitiveness discussed merck rolling new customercentric selling model additionally company make greater use outside technology resources centralize common sales marketing activities consolidate streamline operations mercks manufacturing division focus capabilities core products outsource non core manufacturing also merck expanding access worldwide external science basic research global operating strategy designed provide sustainable pipeline focused translating basic research productivity latestage clinical success increase efficiencies basic research operations consolidate work support given therapeutic area one four locations provide efficient use research facilities result closure three basic research sites located tsukuba japan pomezia italy seattle end part restructuring program company expects eliminate approximately positions active employees vacancies across areas company worldwide end approximately company eliminated total reductions occur united states part restructuring program company streamlining management layers reducing total number senior midlevel executives globally approximately company however continues hire new employees business requires restructuring program expected completed end total pretax costs estimated billion billion company recorded pretax restructuring costs million related restructuring program company estimates twothirds cumulative pretax costs result future cash outlays primarily employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested merck expects restructuring program yield cumulative pretax savings billion billion connection certain transactions astrazeneca lp azlp company recorded aggregate pretax gain billion included income expense net received net proceeds azlp billion see note consolidated financial statements information earnings per common share eps assuming dilution including impact gain distribution azlp per share restructuring costs per share addition eps reflects favorable impact certain tax items items discussed fully notes consolidated financial statements table contents product sales sales companys products follows millions p harmaceutical singulair cozaarhyzaar fosamax januvia cosopttrusopt zocor maxalt propecia arcoxia vasotecvaseretic janumet proscar emend pharmaceutical vaccine infectious disease product sales included pharmaceutical segment p harmaceutical segment revenues v accines infectious diseases gardasil proquadmmr iivarivax rotateq zostavax hepatitis vaccines vaccines primaxin cancidas isentress crixivanstocrin invanz infectious disease vaccine infectious disease product sales included pharmaceutical segment v accines infectious diseases segment revenues ther segment revenues total segment revenues ther presented net discounts returns pharmaceutical primarily includes sales human pharmaceutical products revenue companys relationship azlp primarily relating sales nexium well prilosec revenue azlp billion billion billion respectively pharmaceutical also reflected certain supply sales including supply sales associated companys arrangement dr reddys laboratories sale generic simvastatin sales vaccine infectious disease products nonus subsidiaries included pharmaceutical segment amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd includes nonreportable human animal health segments revenues primarily comprised miscellaneous corporate revenue sales related divested products businesses supply sales included segment results table contents companys pharmaceutical products include therapeutic preventive agents generally sold prescription treatment human disorders among singulair montelukast sodium leukotriene receptor antagonist chronic treatment asthma relief symptoms allergic rhinitis cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate vaseretic enalapril maleatehydrochlorothiazide companys significant hypertension andor heart failure products fosamax fosamax plus mercks osteoporosis products treatment case fosamax prevention osteoporosis januvia janumet treatment type diabetes cosopt dorzolamide hydrochloride timolol maleate ophthalmic solution trusopt dorzolamide hydrochloride ophthalmic solution mercks largestselling ophthalmological products zocor mercks statin modifying cholesterol maxalt rizatriptan benzoate acute migraine product propecia finasteride product treatment male pattern hair loss arcoxia etoricoxib treatment arthritis pain proscar finasteride urology product treatment symptomatic benign prostate enlargement emend aprepitant prevention chemotherapyinduced postoperative nausea vomiting companys vaccine infectious disease products include gardasil vaccine help prevent cervical vulvar vaginal cancers precancerous dysplastic lesions genital warts caused hpv types varivax varicella virus vaccine live vaccine help prevent chickenpox proquad measles mumps rubella varicella virus vaccine live pediatric combination vaccine measles mumps rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine measles mumps rubella rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infants children zostavax zoster vaccine live vaccine help prevent shingles herpes zoster primaxin imipenem cilastatin sodium cancidas caspofungin acetate antibacterialantifungal products isentress crixivan indinavir sulfate stocrin efavirenz antiretroviral therapies treatment hiv infection invanz ertapenem sodium treatment infection discussion sales companys products see item managements discussion analysis financial condition results operations us product approvals january fda approved emend fosaprepitant dimeglumine injection mg prevention chemotherapyinduced nausea vomiting emend injection provides new option day one substitute emend mg taken orally part recommended threeday regimen prior fda decision european union eu january granted marketing approval emend injection known ivemend eu action applies eu member countries well norway iceland august merck announced fda approved expanded label cancidas makes first echinocandin therapy approved united states treatment pediatric patients aged three months years indicated fungal infections september fda approved gardasil prevention vulvar vaginal cancers caused hpv types approval based data combined analysis three studies demonstrated efficacy safety gardasil patients vioxx us product liability settlement september merck announced voluntary worldwide withdrawal vioxx arthritis acute pain medication companys decision effective immediately based new threeyear data prospective randomized placebocontrolled clinical trial approve adenomatous polyp prevention vioxx november company announced entered agreement settlement agreement law firms comprise executive committee plaintiffs steering committee federal multidistrict vioxx litigation well representatives plaintiffs counsel texas new jersey california state coordinated proceedings resolve state federal myocardial infarction mi ischemic stroke claims filed date united states settlement agreement also applies tolled claims signed parties several meetings three four judges overseeing coordination current claims vioxx litigation settlement agreement applies us legal residents allege mi occurred united states table contents october deadline enrollment settlement program defined approximately individuals eligible settlement program whose claims dismissed expected dismissed near future tolled claims appear abandoned submitted materials required enrollment settlement program represents approximately eligible mi claims previously registered settlement program terms settlement agreement merck could exercise right walk away settlement agreement thresholds requirements met company waived right august waiver right triggered mercks obligation pay fixed total billion payments made installments settlement funds first payment million made august additional payment million made october additional payments made periodic basis going forward needed fund payments claims administrative expenses joint ventures company number joint ventures relating pharmaceutical vaccines infectious diseases segments p harmaceutical company scheringplough corporation scheringplough entered agreements create separate equallyowned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas december cholesterolmanagement partnership agreements expanded include countries world excluding japan october zetia ezetimibe marketed ezetrol outside united states first new class cholesterollowering agents launched united states july vytorin marketed inegy outside united states combination product containing active ingredients zetia zocor approved united states previously disclosed january company announced results effect combination ezetimibe highdose simvastatin vs simvastatin alone atherosclerotic process patients heterozygous familial hypercholesterolemia enhance clinical trial imaging trial patients heterozygous familial hypercholesterolemia rare genetic condition causes high levels ldl bad cholesterol greatly increases risk premature coronary artery disease previously reported despite fact ezetimibesimvastatin mg vytorin significantly lowered ldl bad cholesterol simvastatin mg alone significant difference treatment ezetimibesimvastatin simvastatin alone prespecified primary endpoint change thickness carotid artery walls two years measured ultrasound also significant differences treatment ezetimibesimvastatin simvastatin four prespecified key secondary endpoints percent patients manifesting regression average carotid artery intimamedia thickness ca imt proportion patients developing new carotid artery plaques mm changes average maximum ca imt changes average ca imt plus average common femoral artery imt enhance compared simvastatin alone ezetimibesimvastatin significantly lowered ldl bad cholesterol well triglycerides creactive protein crp ezetimibesimvastatin indicated reduction crp enhance study overall safety profile ezetimibesimvastatin generally consistent product label enhance study designed powered evaluate cardiovascular clinical events improved reduction highrisk subjects presenting acute coronary syndrome improveit trial underway designed provide cardiovascular outcomes data ezetimibesimvastatin patients acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrated simvastatin established march results enhance reported annual scientific session american college cardiology july efficacy safety results simvastatin ezetimibe aortic stenosis seas study announced seas designed evaluate whether intensive lipid lowering vytorin mg would reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patients asymptomatic mild moderate aortic stenosis indication statin therapy vytorin failed meet primary end point reduction major cardiovascular events also significant difference key secondary end point aortic valve events however reduction group patients taking vytorin compared placebo key secondary end point ischemic cardiovascular table contents events vytorin indicated treatment aortic stenosis incremental benefit vytorin cardiovascular morbidity mortality demonstrated simvastatin established study patients group took vytorin mg higher incidence cancer group took placebo also nonsignificant increase deaths cancer patients group took vytorin versus took placebo cancer cancer deaths distributed across major organ systems company believes cancer finding seas likely anomaly taken light available data support association vytorin august fda announced investigating results seas trial announcement fda also cited interim data two large ongoing cardiovascular trials vytorin study heart renal protection sharp improveit clinical trials increased risk cancer combination simvastatin plus ezetimibe sharp trial expected completed improveit trial scheduled completion around fda determined time findings seas trial plus interim data ongoing trials prompt patients stop taking vytorin cholesterol lowering drug company merckscheringplough pharmaceuticals msp partnership committed working regulatory agencies evaluate available data interpretations data however company believe changes clinical use vytorin warranted previously disclosed company joint venture partner scheringplough received several letters addressed companies house committee energy commerce subcommittee oversight investigations oi ranking minority member senate finance committee collectively seeking combination witness interviews documents information variety issues related enhance clinical trial sale promotion vytorin well sales stock corporate officers addition since august companies received three additional letters oi including one dated february seeking certain information documents related seas clinical trial previously disclosed companies received subpoenas new york new jersey state attorneys general offices letter connecticut attorney general seeking similar information documents addition company received five civil investigative demands cids multistate group state attorneys general jointly investigating whether companies violated state consumer protection laws marketing vytorin finally september company received letter civil division department justice doj informing doj investigating whether companies conduct relating promotion vytorin caused false claims submitted federal health care programs company cooperating investigations working scheringplough respond inquiries addition company become aware served approximately civil class action lawsuits alleging common law state consumer fraud claims connection msp partnerships sale promotion vytorin zetia certain lawsuits allege personal injuries andor seek medical monitoring actions filed transferred federal court coordinated multidistrict litigation us district court district court new jersey district judge dennis cavanaugh parties presently engaged motions practice briefing also previously disclosed april merck shareholder filed putative class action lawsuit federal court eastern district pennsylvania alleging merck chairman president chief executive officer richard clark violated federal securities laws april member company employee retirement income security act erisa plan filed putative class action lawsuit company certain officers directors alleging breached fiduciary duties erisa company entered agreement astra ab astra develop market astra products united states company astra formed equally owned joint venture developed marketed astras new prescription medicines united states including prilosec omeprazole first class medications known proton pump inhibitors slows production acid cells stomach lining company astra restructured joint venture whereby company acquired astras interest joint venture renamed kbi inc kbi contributed kbis operating assets new us limited partnership named astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange table contents general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights company earns certain partnership returns well ongoing revenue based sales current future kbi products partnership returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing companys share undistributed partnership gaap earnings astrazeneca merger triggered partial redemption march mercks interest certain azlp product rights upon redemption merck received billion azlp amount based primarily multiple mercks average annual variable returns derived sales former astra usa inc products three years prior redemption limited partner share agreed value merck recorded billion pretax gain partial redemption partial redemption mercks interest product rights result change mercks limited partner interest described item managements discussion analysis certain adjustments company recorded aggregate pretax gain billion conjunction restructuring astra purchased option asset option payment million recorded deferred income buy mercks interest kbi products excluding gastrointestinal medicines nexium esomeprazole prilosec nonppi products asset option exercisable first half exercise price equal net present value march projected future pretax revenue received company nonppi products appraised value merck also right require astra purchase interest appraised value february company advised azlp would exercise asset option thus million remains deferred addition company granted astra option shares option buy mercks common stock interest kbi therefore mercks interest nexium prilosec exercisable two years astras exercise asset option astra also exercise shares option combined annual sales two products fall minimum amount provided case long astrazenecas asset option exercised exercise price shares option based net present value estimated future net sales nexium prilosec determined time exercise subject certain trueup mechanisms company formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned joint venture also includes canada significant joint venture products pepcid ac famotidine overthecounter form companys ulcer medication pepcid famotidine well pepcid complete overthecounter product combines companys ulcer medication antacids calcium carbonate magnesium hydroxide v accines company pasteur mrieux connaught sanofi pasteur sa formed joint venture market human vaccines europe collaborate development combination vaccines distribution existing eu european free trade association company sanofi pasteur contributed among things european vaccine businesses equal shares joint venture known pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintains presence directly affiliates branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributors rest territory ther company rhnepoulenc sa sanofiaventis sa combined respective animal health businesses form merial limited merial fully integrated animal health company standalone joint venture owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species competition markets company conducts business highly competitive often highly regulated global efforts toward health care cost containment continue exert pressure product pricing access table contents competition involves intensive search technological innovations ability market innovations effectively longstanding emphasis research development company well prepared compete search technological innovations additional resources meet competition include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products joint ventures licenses refining sales marketing efforts address changing industry conditions enhance product portfolio company also continues pursue external alliances however introduction new products processes competitors may result price reductions product replacements even products protected patents example number compounds available treat diseases typically increases time resulted slowing growth sales certain companys products legislation enacted states united states particularly area human pharmaceutical products allows encourages instances absence specific instructions prescribing physician mandates use generic products containing active chemical innovators product rather brandname products governmental pressures toward dispensing generic products significantly reduced sales certain companys products longer protected patents zocor lost market exclusivity us company experienced significant decline zocor sales thereafter fosamax fosamax plus lost marketing exclusivity united states result events company experiencing significant declines fosamax fosamax plus us sales also trusopt cosopt lost market exclusivity united states october result company experiencing significant decline sales products distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccines sold primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices managed care organizations raw materials raw materials supplies generally available multiple sources purchased worldwide normally available quantities adequate meet needs companys pharmaceutical vaccines infectious diseases segments government regulation investigation pharmaceutical industry subject global regulation regional country state local agencies particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states food drug administration modernization act fda modernization act passed culmination comprehensive legislative reform effort designed streamline regulatory procedures within fda improve regulation drugs medical devices food legislation principally designed ensure timely availability safe effective drugs biologics expediting premarket review process new products key provision legislation reauthorization prescription drug user fee act permits continued collection user fees prescription drug manufacturers augment fda resources earmarked review human drug applications helps provide resources necessary ensure prompt approval safe effective new drugs united states government expanded health care access enacting medicare prescription drug improvement modernization act signed law december prescription drug coverage began january legislation supports companys goal improving access medicines expanding insurance coverage preserving marketbased incentives pharmaceutical innovation time legislation ensure prescription drug costs controlled competitive pressures encouraging appropriate use medicines us congress considered may consider proposals increase governments role pharmaceutical pricing medicare program table contents proposals may include removing current legal prohibition secretary health human services intervening price negotiations medicare drug benefit program plans pharmaceutical companies may also include mandating payment rebates pharmaceutical utilization medicare drug benefit plans addition congress may consider proposals allow certain conditions importation medicines countries many years pharmaceutical industry federal state oversight approval process new drugs drug safety advertising promotion drug purchasing reimbursement programs formularies variously review company believes continue able conduct operations including introduction new drugs market regulatory environment one type federal initiative contain federal health care spending prospective capitated payment system first implemented reduce rate growth medicare reimbursement hospitals system establishes advance flat rate reimbursement health care patients payor fiscally responsible type payment system cost containment systems widely used public private payors caused hospitals health maintenance organizations customers company costconscious treatment decisions including decisions regarding medicines made available patients company continues work private federal employers slow increases health care costs companys efforts demonstrate medicines help save costs areas encouraged use companys medicines helped offset effects increasing cost pressures also federal state governments pursued methods directly reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities disproportionate share hospitals hospitals meeting certain criteria provide minimum discounts defined nonfederal average manufacturer price purchases certain components federal government department veterans affairs department defense initiatives states seek rebates beyond minimum required medicaid legislation cases patients beyond eligible medicaid federal vaccines children entitlement program us centers disease control prevention cdc funds purchases recommended pediatric vaccines public sector price immunization medicaideligible uninsured native american certain underinsured children company awarded cdc contract supply pediatric vaccines vaccines children program january patients previously eligible medicaid also medicare beneficiaries years older disabled left stateadministered medicaid system covered new medicare prescription drug benefit outside united states company encounters similar regulatory legislative issues countries business primary thrust governmental inquiry action toward determining drug safety effectiveness often mechanisms controlling prices reimbursement prescription drugs profits prescription drug companies eu adopted directives concerning classification labeling advertising wholesale distribution approval marketing medicinal products human use companys policies procedures already consistent substance directives consequently believed material effect companys business addition certain countries within eu recognizing economic importance researchbased pharmaceutical industry value innovative medicines society working industry representatives improve competitive climate variety means including market deregulation january european commission ec launched sector inquiry pharmaceutical markets rules eu competition law part inquiry companys offices germany inspected authorities january preliminary report ec issued november ec stated confirmed original hypothesis competition pharmaceutical sector may restricted distorted indicated decline innovation measured number novel medicines reaching market alleged instances delayed market entry generic medicines public consultation period respect preliminary report expired january ec issued inquiries respect subject investigation ec alleged company subsidiaries table contents engaged unlawful practices final report planned later company cooperating ec sector inquiry company subject jurisdiction various regulatory agencies therefore subject potential administrative actions actions may include seizures products civil criminal sanctions certain circumstances company may deem advisable initiate product recalls company believes able compete effectively within environment company subject number privacy data protection laws regulations globally legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority us states requiring security breach notification patents trademarks licenses patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage fda modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant exclusivity provisions reauthorized prescription drug user fee act passed september current us patent law provides additional patent term patent term restoration periods patented product regulatory review fda patent portfolios developed products introduced company normally provide market exclusivity company following key us patent protection including patent term restoration pediatric exclusivity major marketed products p roduct ear expiration us cancidas comvax cozaar crixivan compound formulation emend gardasil hyzaar invanz compound composition isentress januviajanumet compound salt maxalt compound primaxin propecia recombivax rotateq pending patent term restoration singulair zetiavytorin ezetimibe component products zolinza zostavax table contents basic patent also effect sustiva stocrin bristolmyers squibb company exclusive license company sells sustiva united states canada certain european countries company markets stocrin countries throughout world expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states certain countries market exclusivity may available relevant law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset general increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties information respect companys patents see patent litigation risk factors worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalties received patent knowhow licenses rights amounted million company also paid royalties amounting billion patent knowhow licenses holds r esearch development companys business characterized introduction new products new uses existing products strong research development program approximately people employed companys research activities research development expenses billion billion billion company maintains ongoing commitment research broad range therapeutic areas clinical development support new products company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development mercks research development model designed increase productivity improve probability success prioritizing companys research development resources disease areas unmet medical needs scientific opportunity commercial opportunity merck managing research development portfolio across diverse approaches discovery development balancing investments appropriately novel innovative targets potential major impact human health developing bestinclass approaches delivering maximum value companys new medicines vaccines new indications new formulations another important component mercks sciencebased diversification based expanding companys portfolio modalities include small molecules vaccines also biologics peptides rnai merck moving diversify portfolio creating new division merck bioventures leverages unique platform followon novel biologics company continue pursue appropriate external licensing opportunities company began implementing new model basic research global operating strategy new model align franchise function clear roles responsibilities align resources table contents disease area priorities balance capacity across discovery phases allow company act upon programs highest probability success additionally strategy designed expand companys access worldwide external science incorporate external research key component companys early discovery pipeline order translate basic research productivity latestage clinical success development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug vaccine may marketed united states recorded data preclinical clinical experience included nda drug biologics license application bla vaccine submitted fda required approval companys scientists discover new small molecule compound believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase ii studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness data phase ii trials satisfactory company commences largescale phase iii trials confirm compounds efficacy safety upon completion trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed vaccine development follows general pathway drugs preclinical testing focuses vaccines safety ability elicit protective immune response immunogenicity premarketing vaccine clinical trials typically done three phases initial phase clinical studies conducted normal subjects evaluate safety tolerability immunogenicity vaccine candidate phase ii studies doseranging studies may enroll hundreds subjects finally phase iii trials typically enroll thousands individuals provide necessary data effectiveness safety successful company submits regulatory filings appropriate regulatory agencies also stage proposed manufacturing facility undergoes preapproval inspection production vaccine progress examined detail united states fda review process begins complete nda submitted received fda pursuant prescription drug user fee act fda review period targets ndas supplemental ndas either six months priority review ten months standard review within days receipt nda fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review review timelines defined fda generally act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information days extensions review period communicated company fda act application issuing approval letter complete response letter company anticipates filing nda fda mk telcagepant investigational oral calcitonin generelated peptide receptor antagonist represents new mechanism treatment migraine demonstrated efficacy comparable zolmitriptan effective triptan phase iii clinical program company also anticipates filing nda fda mk rolofylline potential firstinclass selective adenosine antagonist phase iii investigational drug evaluated treatment acute heart failure table contents additionally company anticipates filing nda fda mkc ezetimibe combined atorvastatin investigational medication treatment dyslipidemia developed merckscheringplough joint venture company also anticipates regulatory action two supplemental filings submitted fda one gardasil mercks hpv vaccine use males one isentress firstinclass integrase inhibitor treatment hiv infection expanded indication use treatment nave patients january company received second complete response letter fda regarding supplemental bla sbla use gardasil women ages though agency completed review response merck provided july recommended merck submit additional data month study completed initial sbla included data collected average months enrollment study number prespecified endpoints met following review final results study merck anticipates providing response agency fourth quarter letter affect current indications gardasil females ages letter relate sbla submitted december use gardasil males february data several phase iii isentress studies presented th conference retroviruses opportunistic infections montreal canada new subgroup analyses phase iii study startmrk compared isentress efavirenz one leading antiretrovirals prescribed previously untreated treatmentnave hivinfected patients isentress found effective efavirenz suppressing viral load provided improvements immune system function across broad spectrum patient subpopulations weeks use isentress previously untreated hivinfected patients investigational use drug medicines taken combination tenofoviremtricitabine addition results two phase iii studies switchmrk evaluating effect switching patients whose hiv controlled lopinavirritonavirbased regimen regimen containing isentress tablets showed isentress significantly improved total cholesterol triglycerides nonhdlcholesterol study also showed isentress demonstrate noninferior virologic efficacy maintaining viral load suppression result viral load findings trials merck discontinued two studies merck currently nine products phase iii development including mk mk discussed mk deforolimus novel mtor mammalian target rapamycin inhibitor evaluated treatment cancer drug candidate jointly developed commercialized ariad pharmaceuticals inc agreement reached phase iii study succeed patients metastatic softtissue bone sarcomas way company continues anticipate filing nda fda v ninevalent hpv vaccine development expand protection cancercausing hpv types phase iii clinical program underway merck anticipates filing bla fda mk odanacatib highly selective inhibitor cathepsin k enzyme evaluated treatment osteoporosis phase iii program ongoing merck continues anticipate filing nda fda mka drug candidate combines extendedrelease er niacin novel flushing inhibitor laropiprant mka demonstrated ability lower ldlcholesterol ldlc raise hdl cholesterol hdlc lower triglycerides significantly less flushing traditional extended release niacin alone high ldlc low hdlc elevated triglycerides risk factors associated heart attacks strokes april merck received nonapprovable action letter fda response nda mk meeting discuss letter fda stated additional efficacy safety data required suggested company wait results treatment hdl reduce incidence vascular events hpsthrive cardiovascular outcomes study expected completed january merck anticipates filing nda fda mka table contents july company announced tredaptive also known mka approved marketing countries eu iceland norway tredaptive approved treatment dyslipidemia particularly patients combined mixed dyslipidemia characterized elevated levels ldlc triglycerides low hdlc patients primary hypercholesterolemia heterozygous familial nonfamilial tredaptive used patients combination statins cholesterol lowering effects statin monotherapy inadequate tredaptive used monotherapy patients statins considered inappropriate tolerated launch tredaptive europe markets delayed due manufacturingrelated issue merck committed quickly resolving issue making tredaptive available europe soon possible countries around world merck continues pursue regulatory approvals mka mkb drug candidate combines novel approach raising hdlc lowering triglycerides er niacin combined laropiprant proven benefits simvastatin one combination product merck seek approval mkb united states files complete response relating mka mk anacetrapib inhibitor cholesteryl ester transfer protein shown promise lipid management raising hdlc reducing ldlc without raising blood pressure phase iii study initiated enrollment cardiovascular outcomes study planned begin company anticipates filing nda fda beyond mkc combines januvia pioglitazone another type diabetes therapy company anticipates filing nda fda october merck announced seek regulatory approval taranabant investigational medicine treat obesity discontinued phase iii clinical development program taranabant obesity available phase iii data showed efficacy adverse events dose related greater efficacy adverse events higher doses therefore careful consideration company determined overall profile taranabant support development obesity december company terminated collaboration dynavax technologies corporation dynavax development v investigational hepatitis b vaccine entered october merck dynavax received notification fda regarding two companies response agencys request safety information relating clinical hold two investigational new drug ind applications v issuing clinical hold march fda requested review clinical safety data including available information single case wegeners granulomatosis uncommon disease blood vessels inflamed reported phase iii clinical trial dynavax merck previously provided response fda september october correspondence fda advised companies balance risk versus potential benefit longer favored continued clinical evaluation v healthy adults children companys clinical pipeline includes candidates multiple disease areas including anemia atherosclerosis cancer diabetes heart failure hypertension infectious diseases migraine neurodegenerative diseases psychiatric diseases osteoporosis pain respiratory disease company supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies company completed number transactions including research collaborations preclinical clinical compounds technology transactions across broad range therapeutic categories september merck japan tobacco inc jt signed worldwide licensing agreement develop commercialize jtt investigational oral osteoanabolic bone growth stimulating agent treatment osteoporosis disease reduces bone density strength results increased risk bone fractures jtt investigational oral calcium sensing receptor antagonist currently evaluated jt phase ii clinical trials japan effect increasing bone density phase clinical trials outside japan terms agreement merck gained worldwide rights except japan develop commercialize jtt certain related compounds jt received upfront payment million table contents company recorded research development expense eligible receive additional cash payments upon achievement certain milestones associated development approval drug candidate covered agreement jt also eligible receive royalties sales drug candidates receive marketing approval license agreement merck jt remain effect expiration royalty milestone obligations may terminated event uncured material breach party agreement may also terminated merck without cause initial commercial sale jtt giving six months prior notice jt thereafter giving one year prior notice thereof jt license agreement may also terminated immediately merck merck determines due safety andor efficacy concerns based available scientific evidence cease development jtt andor withdraw jtt market permanent basis february merck entered definitive agreement insmed inc insmed purchase insmeds portfolio followon biologic therapeutic candidates commercial manufacturing facilities located boulder colorado terms agreement merck pay insmed aggregate million cash acquire rights boulder facilities insmeds pipeline followon biologic candidates insmeds followon biologics portfolio includes two clinical candidates ins investigational recombinant granulocyte colony stimulating factor gcsf evaluated ability prevent infections patients cancer receiving chemotherapy ins pegylated recombinant gcsf designed allow less frequent dosing agreement provides initial payments million ins ins merck pay insmed remaining balance upon closing transaction expected end first quarter without milestone royalty obligations chart reflects companys current research pipeline february candidates shown phase iii include specific products candidates shown phase ii include advanced compound specific mechanism given therapeutic area small molecules biologics given mk number designations vaccine candidates given vnumber designations backup compounds regardless phase development additional indications therapeutic area additional claims line extensions formulations inline products shown clinical programs merck bioventures division included phase alzheimers disease v anemia mk cancer mk mk mk mk mk mk mk vv cardiovascular mk mk mk phase diabetes mk infectious disease mk neurologic mk neutropenia ins ins psychiatric disease mk mk mk respiratory disease mk phase ii atherosclerosis mk mkcancer mk diabetes mk mk mk infectious disease mk v v insomnia mk neurologic mk osteoporosis mk jtt psychiatric disease mk respiratory disease mkc mk sarcopenia mk phase iii acute heart failure mk rolofylline atherosclerosis mka extendedrelease niacinlaropiprant mkb extendedrelease niacinlaropiprant simvastatin mk anacetrapib cancer mk deforolimus ap diabetes mkc hpv v migraine mk telcagepant osteoporosis mk odanacatib table contents product service marks appearing type form different surrounding text trademarks service marks owned licensed merck subsidiaries affiliates including zetia vytorin trademarks owned entities merckscheringplough partnership except noted cozaar hyzaar registered trademarks ei du pont de nemours company wilmington de prilosec nexium trademarks astrazeneca group us trademarks vasotec vaseretic owned biovail laboratories incorporated e mployees december company approximately employees worldwide approximately employed united states including puerto rico approximately worldwide employees company represented various collective bargaining groups october company announced global restructuring program restructuring program reduce cost structure increase efficiency enhance competitiveness part restructuring program company expects eliminate approximately positions active employees vacancies across areas company worldwide end total reductions occur united states part restructuring program company streamlining management layers reducing total number senior midlevel executives globally approximately merck rollout new customercentric selling model designed provide merck meaningful competitive advantage help physicians patients payers improve patient outcomes company also make greater use outside technology resources centralize common sales marketing activities consolidate streamline operations mercks manufacturing division focus capabilities core products outsource noncore manufacturing addition merck expanding access worldwide external science basic research global operating strategy designed provide sustainable pipeline focused translating basic research productivity latestage clinical success increase efficiencies basic research operations consolidate work support given therapeutic area one four locations provide efficient use research facilities result closure three basic research sites tsukuba japan pomezia italy seattle end e nvironmental matters company believes compliance material respects applicable environmental laws regulations company incurred capital expenditures approximately million environmental protection facilities company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million million million estimated million years amounts consider potential recoveries parties company taken active role identifying providing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million december although possible predict certainty outcome environmental matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures material adverse effect companys financial position results operations liquidity capital resources year g eographic area information companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states sales sales companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions table contents recent years company expanding operations countries located latin america middle east africa eastern europe asia pacific changes government policies economic conditions making possible company earn fair returns business developing areas sometimes less stable offers important opportunities growth time financial information geographic areas companys business discussed item financial statements supplementary data vailable information companys internet website address wwwmerckcom company make available free charge investor information portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished securities exchange commission sec companys corporate governance guidelines charters board directors six standing committees available companys website wwwmerckcomaboutcorporategovernance information available print stockholder requests company tem risk factors carefully consider information set forth including following risk factors deciding invest companys securities risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations prospects could materially adversely affected risks also contains forwardlooking statements involve risks uncertainties companys results could materially differ anticipated forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results company faces significant litigation related vioxx september company voluntarily withdrew vioxx arthritis acute pain medication market worldwide december approximately product liability lawsuits involving approximately plaintiff groups alleging personal injuries resulting use vioxx filed company state federal courts united states company also defendant approximately purported class actions related use vioxx suits referred vioxx product liability lawsuits discussed november company announced entered agreement settlement agreement law firms comprise executive committee plaintiffs steering committee federal multidistrict vioxx litigation well representatives plaintiffs counsel texas new jersey california state coordinated proceedings resolve state federal mi claims filed date united states settlement agreement also applies tolled claims signed parties several meetings three four judges overseeing coordination current claims vioxx product liability litigation settlement agreement applies us legal residents allege mi occurred united states october deadline enrollment settlement program approximately individuals eligible settlement program whose claims dismissed expected dismissed near future tolled claims appear abandoned submitted materials required enrollment settlement program represents approximately eligible mi claims previously registered settlement program terms settlement agreement merck could exercise right walk away settlement agreement thresholds requirements met company waived right august waiver right triggered mercks obligation pay fixed total billion payments made installments settlement funds first payment million made august additional payment table contents million made october additional payments made periodic basis going forward needed fund payments claims administrative expenses plaintiff groups described currently vioxx settlement program december plaintiff groups otherwise eligible settlement program participated claims remained pending merck addition claims plaintiff groups eligible program remained pending merck number plaintiff groups subject motions dismiss failure comply courtordered deadlines since december hundreds plaintiff groups since dismissed claims certain individual thirdparty payors remain pending new jersey court counsel purporting represent large number thirdparty payors threatened file numerous additional actions discovery currently ongoing cases status conference court took place january discuss scheduling issues including selection early trial pool cases also pending various us courts putative class actions purportedly brought behalf individual purchasers users vioxx claiming either reimbursement alleged economic loss entitlement medical monitoring cases early procedural stages class certified new jersey trial court dismissed complaint case sinclair purported statewide medical monitoring class appellate division reversed dismissal issue appealed new jersey supreme court court heard argument october june new jersey supreme court reversed appellate division dismissed action addition vioxx product liability lawsuits various purported class actions individual lawsuits brought company several current former officers directors company alleging company made false misleading statements regarding vioxx violation federal state securities laws suits referred vioxx securities lawsuits april judge chesler granted defendants motion dismiss complaint prejudice plaintiffs appealed judge cheslers decision united states court appeals third circuit september third circuit issued opinion reversing judge cheslers order remanding case district court september merck filed petition seeking rehearing en banc denied case remanded district court october plaintiffs filed consolidated fifth amended class action complaint addition various putative class actions brought company several current former employees officers directors company alleging violations erisa suits referred vioxx erisa lawsuits addition shareholder derivative suits previously filed dismissed appeal several shareholders filed demands company asserting claims board members company officers suits demands referred vioxx derivative lawsuits together vioxx securities lawsuits vioxx erisa lawsuits vioxx shareholder lawsuits company also named defendant actions various countries outside united states suits referred vioxx foreign lawsuits company also sued ten states five counties new york city respect marketing vioxx company anticipates additional lawsuits relating vioxx may filed andor certain current former officers directors future sec conducting formal investigation company concerning vioxx doj issued subpoena requesting information relating companys research marketing selling activities respect vioxx federal health care investigation criminal statutes investigation includes subpoenas witnesses appear grand jury also ongoing investigations local authorities europe company cooperating authorities investigations investigations referred vioxx investigations company predict outcome investigations however could result potential civil andor criminal liability juries decided favor company twelve times plaintiffs favor five times one merck verdict set aside court retried another merck verdict set aside retried leading one five plaintiffs verdicts two unresolved mistrials respect five plaintiffs verdicts merck filed appeal sought judicial review cases one five table contents intermediate appellate court overturned trial verdict directed judgment entered merck another intermediate appellate court overturned trial verdict entering judgment merck one claim ordering new trial remaining claims vioxx product liability litigation discussed fully item legal proceedings outcomes vioxx product liability trials interpreted indicate trend outcome may likely future vioxx trials trial representative action australia scheduled commence march federal court australia named plaintiff alleges suffered mi seeks represent others australia ingested vioxx suffered mi thrombotic stroke unstable angina transient ischemic attack peripheral vascular disease november company filed motion order proceeding longer continue representative proceeding hearing december court dismissed motion january issued reasons decision february companys motion leave appeal decision denied parties directed prepare proposed lists issues tried company currently anticipates two us vioxx product liability lawsuits tried except respect product liability trial scheduled held australia company predict timing trials related vioxx litigation company believes meritorious defenses vioxx product liability lawsuits vioxx shareholder lawsuits vioxx foreign lawsuits collectively vioxx lawsuits vigorously defend companys insurance coverage respect vioxx lawsuits adequate cover defense costs losses company spent approximately million aggregate legal defense costs worldwide related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation fourth quarter company recorded charge million add reserve solely future legal defense costs related vioxx litigation million december million december addition company recorded pretax charge billion equal aggregate amount paid qualifying claimants settlement program company paid million settlement funds settlement program thus companys total reserve vioxx litigation december billion vioxx reserve amount vioxx reserve allocated defense costs based certain assumptions described legal proceedings best estimate minimum amount company believes incurred connection remaining aspects vioxx litigation however events additional trials vioxx litigation events could arise course vioxx litigation could affect ultimate amount defense costs incurred company company currently able estimate additional amount damages may required pay connection vioxx lawsuits vioxx investigations proceedings still expected continue years company little information course proceedings take view inherent difficulty predicting outcome litigation particularly many claimants claimants seek unspecified damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits included settlement program company established reserves potential liability relating vioxx lawsuits included settlement program vioxx investigations series unfavorable outcomes vioxx lawsuits vioxx investigations resulting payment substantial damages fines resulting criminal penalties excess vioxx reserve could material adverse effect companys business cash flow results operations financial position prospects certain companys major products going lose patent protection near future occurs company expects significant decline sales products company depends upon patents provide exclusive marketing rights products period time product patents several companys products recently expired expire united states countries company faces strong competition lower price generic table contents drugs loss patent protection one companys products typically leads rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss patent protection material adverse effect companys business cash flow results operations financial position prospects fosamax fosamax plus lost marketing exclusivity united states result events company experiencing significant declines fosamax fosamax plus us sales sales fosamax outside united states already adversely affected availability generic alendronate sodium products markets including united kingdom canada germany also trusopt cosopt lost market exclusivity united states october result company experiencing significant decline sales products patent provides us market exclusivity primaxin expires september time company expects significant decline us sales primaxin addition cozaar hyzaar lose patent protection united states april company expects significant declines us sales products time chart listing us patent protection companys major marketed products set forth item business patents trademarks licenses companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lost patent protection like major pharmaceutical companies order remain competitive company must continue launch new products year declines sales products zocor fosamax loss marketing exclusivity mean companys future success dependent pipeline new products including new products develops joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties support research development efforts company must make ongoing substantial expenditures without assurance efforts funding result commercially successful product company must also commit substantial efforts funds resources recruiting retaining high quality scientists personnel pharmaceutical research development expertise description research development process see research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals accordingly company may abandon product invested substantial amounts time money risks encountered research development process include following preclinical testing new compound may yield disappointing results clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved fda intended use may possible obtain patent new drug sales new product may disappointing company state certainty whether products development approved launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications brand extensions existing products sufficient cover substantial research development costs replace sales lost profitable products zocor fosamax lose patent protection displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial position prospects table contents issues concerning vytorin enhance seas clinical trials adverse effect sales vytorin zetia us company scheringplough sell vytorin zetia joint venture company msp partnership january msp partnership announced primary endpoint results enhance trial enhance surrogate endpoint trial conducted patients heterozygous familial hypercholesterolemia rare condition affects approximately population primary endpoint mean change intimamedia thickness measured three sites carotid arteries right left common carotid internal carotid carotid bulb patients treated ezetimibesimvastatin mg versus patients treated simvastatin mg alone two year period statistically significant difference treatment groups primary endpoint also statistically significant difference treatment groups components primary endpoint including common carotid artery previously disclosed company joint venture partner scheringplough received several letters addressed companies house committee energy commerce subcommittee oversight investigations oi ranking minority member senate finance committee collectively seeking combination witness interviews documents information variety issues related enhance clinical trial sale promotion vytorin well sales stock corporate officers addition since august companies received three additional letters oi including one dated february seeking certain information documents related seas clinical trial described detail companies received subpoenas new york new jersey state attorneys general offices letter connecticut attorney general seeking similar information documents addition company received five civil investigative demands cids multistate group state attorneys general jointly investigating whether companies violated state consumer protection laws marketing vytorin finally september company received letter civil division doj informing doj investigating whether companies conduct relating promotion vytorin caused false claims submitted federal health care programs company cooperating investigations working scheringplough respond inquiries addition company become aware served approximately civil class action lawsuits alleging common law state consumer fraud claims connection msp partnerships sale promotion vytorin zetia certain lawsuits allege personal injuries andor seek medical monitoring also previously disclosed april merck shareholder filed putative class action lawsuit federal court eastern district pennsylvania alleging merck chairman president chief executive officer richard clark violated federal securities laws april member merck erisa plan filed putative class action lawsuit company certain officers directors alleging breached fiduciary duties erisa january fda announced completed review final clinical study report enhance fda stated results enhance change position elevated ldl cholesterol risk factor cardiovascular disease lowering ldl cholesterol reduces risk cardiovascular disease fda also stated based current available data patients stop taking vytorin cholesterol lowering medications talk doctor questions vytorin zetia enhance trial july efficacy safety results seas study announced seas designed evaluate whether intensive lipid lowering vytorin would reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patients asymptomatic mild moderate aortic stenosis indication statin therapy vytorin failed meet primary end point reduction major cardiovascular events also significant difference key secondary end point aortic valve events however reduction group patients taking vytorin compared placebo key secondary end point ischemic cardiovascular events study patients group took vytorin higher incidence cancer group took placebo also nonsignificant increase deaths table contents cancer patients group took vytorin versus took placebo cancer cancer deaths distributed across major organ systems august fda announced investigating results seas trial announcement fda also cited interim data two large ongoing cardiovascular trials vytorin study heart renal protection sharp improveit clinical trials increased risk cancer combination simvastatin plus ezetimibe sharp trial expected completed improveit trial scheduled completion around fda determined time findings seas trial plus interim data ongoing trials prompt patients stop taking vytorin cholesterol lowering drug following announcements enhance seas clinical trial results sales vytorin zetia declined us issues concerning enhance seas clinical trials adverse effect msp partnerships sales vytorin zetia could continue adverse effect sales sales products materially adversely affected companys business cash flow results operations financial position prospects could also materially adversely affected addition unfavorable outcomes resulting government investigations litigation concerning sale promotion products could material adverse effect companys business cash flow results operations financial position prospects companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities united states including fda foreign regulatory authorities including european commission united states fda particular importance company administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states regulation outside united states also primarily focused drug safety effectiveness many cases cost reduction fda foreign regulatory authorities substantial discretion require additional testing delay withhold registration marketing approval mandate product withdrawals even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling new products jurisdiction approval obtained ever company would able realize revenues new products jurisdiction approval company dependent patent rights patent rights invalidated circumvented business would adversely affected patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business defend successfully patent rights provide market exclusivity products company often involved patent disputes relating challenges patents infringement similar claims company company aggressively defends important patents within outside united states including filing claims infringement parties see item legal proceedings patent table contents litigation particular manufacturers generic pharmaceutical products time time file abbreviated new drug applications anda fda seeking market generic forms companys products prior expiration relevant patents owned company company normally responds vigorously defending patent including filing lawsuits alleging patent infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases third party patents may prevent company marketing selling product particular geographic area discussed item legal proceedings patent litigation company received notice teva pharmaceuticals inc teva generic company indicating filed anda montelukast challenging us patent listed singulair april company filed patent infringement action teva lawsuit automatically stays fda approval tevas anda august adverse court decision whichever may occur earlier trial matter commenced february one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available companys results operations may adversely affected lost sales unless company successfully launched commercially successful replacement products company faces intense competition lowercost generic products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection significantly weaker united states eu united states political pressure reduce spending prescription drugs led legislation encourages use generic products although companys policy actively protect patent rights generic challenges companys products arise time may able prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time united states countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially business cash flow results operations financial position prospects company faces intense competition new products companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective effectively marketed sold companys products alternatively case generic competition may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business cash flow results operations financial position prospects company faces pricing pressure respect products companys products subject increasing price pressures restrictions worldwide including united states united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act act act included prescription drug benefit individuals first went effect january increased purchasing power entities negotiate behalf medicare beneficiaries could result pricing pressures outside united states numerous major markets pervasive government involvement funding healthcare regard fix pricing reimbursement pharmaceutical vaccine products table contents consequently markets company subject government decision making budgetary actions respect products company expects pricing pressures increase future company experiencing difficulties delays manufacturing certain products previously disclosed company experienced difficulties manufacturing certain vaccines products company working issues assurance issues finally resolved addition difficulties company experiencing currently company may experience difficulties delays inherent manufacturing products failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing ii construction delays related construction new facilities expansion existing facilities including intended support future demand companys products iii manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could impact continuous supply manufacturing difficulties result product shortages leading lost sales pharmaceutical products develop unexpected safety efficacy concerns unexpected safety efficacy concerns arise respect marketed products whether scientifically justified leading product recalls withdrawals declining sales well product liability consumer fraud andor claims company product liability insurance products first sold august result number factors product liability insurance become less available cost increased significantly company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august including liability products first sold date changes laws regulations could adversely affect companys business aspects companys business including research development manufacturing marketing pricing sales litigation intellectual property rights subject extensive legislation regulation changes applicable federal state laws agency regulations could material adverse effect companys business recent financial crisis current uncertainty global economic conditions could negatively affect companys operating results current financial crisis uncertainty global economic conditions resulted substantial volatility credit markets low level liquidity many financial markets conditions may result slowdown global economy could affect companys business reducing prices drug wholesalers retailers hospitals government agencies managed health care providers may able willing pay companys products reducing demand companys products could turn negatively impact companys sales revenue generation result material adverse effect companys business cash flow results operations financial position prospects reliance third party relationships outsourcing arrangements could adversely affect companys business company depends third parties including suppliers alliances pharmaceutical biotechnology companies third party service providers key aspects business including development manufacture commercialization products support information technology systems failure third parties meet contractual regulatory obligations company development factors materially disrupt relationships company third parties could material adverse effect companys business table contents company increasingly dependent sophisticated information technology infrastructure company increasingly dependent sophisticated information technology infrastructure significant breakdown intrusion interruption corruption systems data breaches could material adverse effect business addition company currently proceeding multiyear implementation enterprise wide resource planning system includes modification design operation documentation internal controls financial reporting intends implement resource planning system us material problems implementation could material adverse effect companys business c autionary factors may affect future results cautionary statements private securities litigation reform act report including annual report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following significant litigation related vioxx competition generic products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities table contents increased focus privacy issues countries around world including united states eu legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority us states requiring security breach notification changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties see risk factors tem b unresolved staff comments none tem properties companys corporate headquarters located whitehouse station new jersey companys us commercial operations headquartered upper gwynedd pennsylvania companys us pharmaceutical business conducted divisional headquarters located upper gwynedd whitehouse station new jersey companys vaccines business conducted divisional headquarters located west point pennsylvania principal research facilities human health products located rahway new jersey west point company also production facilities human health products seven locations united states puerto rico outside united states subsidiaries company owns interest manufacturing plants properties australia canada japan singapore south africa countries western europe central south america asia capital expenditures billion compared billion united states amounted million million abroad expenditures amounted million million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company considers properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products tem legal proceedings company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions v ioxx litigation p roduct liability lawsuits previously disclosed individual putative class actions filed company state federal courts alleging personal injury andor economic loss respect purchase use vioxx actions filed federal court coordinated multidistrict litigation us district court eastern district louisiana mdl district judge eldon e fallon number actions filed state court coordinated separate coordinated proceedings state courts new jersey california texas table contents counties philadelphia pennsylvania washoe clark counties nevada december company served aware named defendant approximately lawsuits include approximately plaintiff groups alleging personal injuries resulting use vioxx approximately putative class actions alleging personal injuries andor economic loss actions discussed paragraph lawsuits collectively referred vioxx product liability lawsuits lawsuits approximately lawsuits representing approximately plaintiff groups slated federal mdl approximately lawsuits representing approximately plaintiff groups included coordinated proceeding new jersey superior court judge carol e higbee plaintiff groups described currently vioxx settlement program described december plaintiff groups otherwise eligible settlement program participated claims remained pending merck addition claims plaintiff groups eligible settlement program remained pending merck number plaintiff groups subject motions dismiss failure comply courtordered deadlines since december hundreds plaintiff groups since dismissed addition vioxx product liability lawsuits discussed claims plaintiffs dismissed december plaintiffs whose claims dismissed prejudice ie brought either plaintiffs courts additional plaintiffs claims dismissed without prejudice ie subject applicable statute limitations brought approximately plaintiff groups represent plaintiffs lawsuits pending new jersey superior court time settlement agreement described enrolled program established settlement agreement settlement program judge higbee dismissed cases without prejudice administrative reasons november merck announced entered agreement settlement agreement law firms comprise executive committee plaintiffs steering committee psc federal vioxx mdl well representatives plaintiffs counsel texas new jersey california state coordinated proceedings resolve state federal mi claims filed date united states settlement agreement also applies tolled claims signed parties several meetings three four judges overseeing coordination us vioxx product liability lawsuits settlement agreement applies us legal residents allege mi occurred united states entire settlement agreement including accompanying exhibits may found wwwmerckcom company included website address inactive textual reference intend active link website incorporate reference information contained therein settlement agreement merck pay fixed aggregate amount billion two funds billion mi claims million claims qualifying claims enter settlement program individual claimants examined administrators settlement program determine qualification based objective documented facts provided claimants including records sufficient scientific evaluation independent risk factors conditions settlement agreement also require claimants pass three gates injury gate duration gate proximity gate defined settlement agreement settlement agreement provides merck admit causation fault settlement agreement provided mercks payment obligations would triggered among conditions law firms federal state pscs firms tried cases coordinated proceedings elect recommend enrollment program clients allege either mi june plaintiffs enroll settlement program least currently pending tolled mi claims ii claims iii eligible mi claims together involve death iv eligible mi claims together allege months use terms settlement agreement merck could exercise right walk away settlement agreement thresholds requirements met company waived right august waiver right triggered mercks obligation pay fixed total billion payments made installments settlement funds first payment table contents million made august additional payment million made october interim payments made certain plaintiffs alleged suffered mi company anticipates interim payments claimants begin shortly additional payments made periodic basis going forward needed fund payments claims administrative expenses mercks total payment funds billion fixed amount allocated among qualifying claimants based individual evaluation distribution interim payments qualified claimants began august continue rolling basis claimants qualify interim payment paid final payments made examination eligible claims completed settlement agreement announced november judges federal mdl california texas new jersey state coordinated proceedings entered series orders orders temporarily stayed respective litigations required plaintiffs register claims january required plaintiffs cases pending november preserve produce records serve expert reports required plaintiffs file thereafter make similar productions accelerated schedule clark county nevada washoe county nevada coordinated proceedings also generally stayed october deadline enrollment settlement program approximately individuals eligible settlement program whose claims dismissed expected dismissed near future tolled claims appear abandoned submitted materials required enrollment settlement program represents approximately eligible mi claims previously registered settlement program april june two groups various private insurance companies health plans filed suit browngreer claims administrator settlement program claims administrator us bancorp escrow agent settlement program avmed greater new york benefit fund suits private insurance companies health plans claim paid healthcare costs behalf enrolling claimants seek enjoin claims administrator paying enrolled claimants claims reimbursement enrolled claimants resolved group sought temporary restraining orders preliminary injunctions judge fallon denied requests avmed defendants moved sever claims named plaintiffs greater new york benefit fund strike class allegations judge fallon granted motions avmed appealed decisions fifth circuit heard argument avmeds appeal november november court appeals affirmed district courts ruling denied two motions preliminary injunctive relief greater new york benefit fund served notice appeal january psc counsel certain private insurers announced reached settlement agreement agreement provides program resolution liens asserted private insurers payments received certain claimants enrolled settlement program agreement terminated private insurers fewer eligible claimants participate plaintiffs avmed greater new york benefit fund lawsuits agreed participate settlement two us vioxx product liability lawsuits currently scheduled trial company maintains list trials website wwwmerckcom periodically update appropriate company included website address inactive textual reference intend active link website incorporate reference information contained therein company previously disclosed outcomes several vioxx product liability lawsuits tried prior juries decided favor company twelve times plaintiffs favor five times one merck verdict set aside court retried another merck verdict set aside retried leading one five plaintiffs verdicts two unresolved mistrials respect five plaintiffs verdicts merck filed appeal sought judicial review cases one five intermediate appellate court overturned trial verdict directed judgment entered merck another intermediate appellate court overturned trial verdict entering judgment merck one claim ordering new trial remaining claims table contents following three cases went trial resolved mcdarby v merck ernst v merck garza v merck first mcdarby originally tried along second plaintiff cona april superior court new jersey law division atlantic county jury returned split verdict jury determined vioxx substantially contribute heart attack mr cona substantially contribute heart attack mr mcdarby jury also concluded case merck violated new jerseys consumer fraud statute allows plaintiffs receive expenses purchasing drug trebled well reasonable attorneys fees jury awarded million compensatory damages mr mcdarby wife also plaintiff case well punitive damages million june judge higbee denied mercks motion new trial june judge higbee awarded approximately million aggregate attorneys fees costs company appealed judgments cases appellate division held oral argument cases january may new jersey appellate division vacated consumer fraud awards cases grounds product liability act provides sole remedy personal injury claims appellate division also vacated mcdarby punitive damage award ground federal preemption vacated attorneys fees costs awarded consumer fraud act cases court upheld mcdarby compensatory award company filed supreme court new jersey petition appeal parts trial courts rulings appellate division affirmed plaintiffs filed cross petition appeal parts trial courts rulings appellate division reversed october supreme court new jersey granted mercks petition certification appeal limited solely issue whether federal food drug cosmetic act preempts state law tort claims predicated alleged inadequacy warnings contained vioxx labeling approved fda court denied plaintiffs crosspetition december new jersey supreme court granted mercks motion stay appeal pending issuance decision united states supreme court wyeth v levine previously reported september merck filed notice appeal august jury verdict favor plaintiff texas state court case ernst v merck may texas court appeals reversed trial courts judgment issued judgment favor merck court appeals found evidence legally insufficient issue causation plaintiffs filed motion rehearing en banc court appeals merck filed response october january plaintiffs filed reply support rehearing motion previously reported april garza v merck jury state court rio grande city texas returned verdict favor family decedent leonel garza jury awarded total million compensatory damages mr garzas widow three sons jury also purported award million punitive damages even though texas law case potential punitive damages capped may san antonio court appeals reversed judgment rendered judgment favor merck december court appeals rehearing vacated prior ruling issued replacement new ruling court ordered takenothing judgment merck design defect claim reversed remanded new trial strict liability claim juror misconduct january merck filed petition review texas supreme court merck voluntarily withdrew vioxx market september states statutes limitations product liability claims three years require claims must filed within three years plaintiffs learned could learned potential cause action result may view september significant deadline filing vioxx cases important note however law regarding statutes limitations complex variable depending facts applicable law states longer statutes limitations also arguments statutes limitations began running september new jersey superior court judge higbee federal district court judge fallon issued orders cases new jersey eight jurisdictions ruling statutory period making vioxx personal injury claims passed judge higbees order issued october judge fallons issued november table contents lawsuits previously disclosed july new jersey state trial court certified nationwide class thirdparty payors unions health insurance plans paid whole part vioxx used plan members insureds named plaintiff case sought recovery certain vioxx purchase costs plus penalties based allegations purported class members paid vioxx would known products alleged risks march new jersey superior court appellate division affirmed class certification order september new jersey supreme court reversed certification nationwide class action thirdparty payors finding suit meet requirements class action claims certain individual thirdparty payors remain pending new jersey court counsel purporting represent large number thirdparty payors filed additional actions judge higbee lifted stay cases cases currently discovery phase status conference court took place january discuss scheduling issues cases including selection early trial pool cases new jersey superior court heard argument plaintiffs motion class certification martin kleinman v merck putative consumer class action december also pending various us courts putative class actions purportedly brought behalf individual purchasers users vioxx claiming either reimbursement alleged economic loss entitlement medical monitoring majority cases early procedural stages june missouri state court certified class missouri plaintiffs seeking reimbursement outofpocket costs relating vioxx plaintiffs allege personal injuries taking vioxx company filed petition interlocutory review june granted july briefing complete pendency appeal discovery proceeding lower court february judge fallon dismissed master personal injurywrongful death class action master complaint medical monitoring class action master complaint mdl plaintiffs also filed class action california state court seeking class certification california thirdparty payors endusers parties engaged class certification discovery briefing court heard oral argument class certification issue february company also named defendant eighteen separate lawsuits brought attorneys general ten states five counties city new york private citizens brought qui tam taxpayer derivative suits one lawsuits brought counties class action filed santa clara county california behalf similarly situated california counties actions allege company misrepresented safety vioxx seek recovery cost vioxx purchased reimbursed state agencies ii reimbursement sums paid state agencies medical services treatment persons injured vioxx iii damages various common law theories andor iv remedies various state statutory theories including state consumer fraud andor fair business practices medicaid fraud statutes including civil penalties exception case filed texas attorney general remains texas state court currently scheduled trial november case filed michigan attorney general ordered remanded state court january case recently filed pennsylvania attorney general removed federal court subject pending motion remand one case removed federal court rest actions described paragraph transferred federal mdl discovery phase hareholder lawsuits previously disclosed addition vioxx product liability lawsuits company various current former officers directors defendants various putative class actions individual lawsuits federal securities laws state securities laws vioxx securities lawsuits vioxx securities lawsuits pending federal court transferred judicial panel multidistrict litigation jpml united states district court district new jersey district judge stanley r chesler inclusion nationwide mdl shareholder mdl judge chesler consolidated vioxx table contents securities lawsuits purposes putative class action requested damages behalf purchasers company stock may october alleged defendants made false misleading statements regarding vioxx violation sections b securities exchange act sought unspecified compensatory damages costs suit including attorneys fees complaint also asserted claims section securities exchange act certain defendants relating sales merck stock sections securities act certain defendants based statements registration statement certain prospectuses filed connection merck stock investment plan dividend reinvestment plan april judge chesler granted defendants motion dismiss complaint prejudice plaintiffs appealed judge cheslers decision united states court appeals third circuit september third circuit issued opinion reversing judge cheslers order remanding case district court september merck filed petition seeking rehearing en banc denied case remanded district court october plaintiffs filed consolidated fifth amended class action complaint merck filed petition writ certiorari united states supreme court january merck expects file motion dismiss fifth amended class action complaint october dutch pension fund filed complaint district new jersey alleging violations federal securities laws well violations state law company certain officers pursuant case management order governing shareholder mdl case based allegations vioxx securities lawsuits consolidated vioxx securities lawsuits defendants motion dismiss pension funds complaint filed august september dutch pension fund filed amended complaint rather responding defendants motion dismiss addition six new complaints filed district new jersey behalf various foreign institutional investors also alleging violations federal securities laws well violations state law company certain officers defendants required respond complaints judge chesler resolves motion dismiss consolidated securities action previously disclosed various shareholder derivative actions filed federal court transferred shareholder mdl consolidated purposes judge chesler vioxx derivative lawsuits may judge chesler granted defendants motion dismiss denied plaintiffs request leave amend complaint plaintiffs appealed arguing judge chesler erred denying plaintiffs leave amend complaint materials acquired discovery july united states court appeals third circuit reversed district courts decision grounds judge chesler allowed plaintiffs make use discovery material try establish demand futility remanded case district courts consideration whether even additional materials plaintiffs request amend complaint would still futile plaintiffs filed brief support request leave amend complaint november court denied motion june closed case plaintiffs appealed judge cheslers decision united states court appeals third circuit addition previously disclosed various putative class actions filed federal court employee retirement income security act erisa company certain current former officers directors vioxx erisa lawsuits together vioxx securities lawsuits vioxx derivative lawsuits vioxx shareholder lawsuits transferred shareholder mdl consolidated purposes consolidated complaint asserts claims behalf certain companys current former employees participants certain companys retirement plans breach fiduciary duty lawsuits make similar allegations allegations contained vioxx securities lawsuits july judge chesler granted part denied part defendants motion dismiss erisa complaint october plaintiffs moved certification class individuals participants beneficiaries companys retirement savings plans time october september whose plan accounts included investments merck common stock fund andor merck common stock february court denied motion certification class one count granted motion remaining counts court also limited class individuals participants beneficiaries companys retirement savings plans suffered loss due investments merck stock plans execute settlement releasing claims october defendants filed table contents motion judgment pleadings seeking dismissal complaint december plaintiffs filed motion partial summary judgment certain individual defendants motions pending discovery ongoing litigation previously disclosed october two individual shareholders made demand companys board take legal action mr raymond gilmartin former chairman president chief executive officer individuals allegedly causing damage company respect allegedly improper marketing vioxx december special committee board directors retained honorable john martin jr debevoise plimpton llp conduct independent investigation among things allegations set forth demand judge martins report made public september based special committees recommendation made careful consideration martin report impact derivative litigation would company board rejected demand october shareholders filed lawsuit state court atlantic county new jersey current former executives directors company alleging boards rejection demand unreasonable improper defendants breached various duties company allowing vioxx marketed current former executive director defendants filed motions dismiss complaint june october proceedings case stayed march november pending motions dismiss denied without prejudice nternational lawsuits previously disclosed addition lawsuits discussed company named defendant litigation relating vioxx various countries collectively vioxx foreign lawsuits europe well canada brazil argentina australia turkey israel may provincial court queens bench saskatchewan canada entered order certifying class vioxx users canada except quebec class includes individual purchasers allege inducement purchase unfair marketing practices individuals allege vioxx acceptable quality defective fit purpose managing pain associated approved indications ingestors claim vioxx caused exacerbated cardiovascular gastrointestinal condition june court appeal saskatchewan granted company leave appeal certification order appeal argued court court reserved decision july superior court ontario denied companys motion stay class proceedings ontario based earlier certification order entered saskatchewan decided certify overlapping class vioxx users canada except quebec saskatchewan allege negligence entitlement elect waive tort november ontario divisional court granted companys motion leave appeal superior courts decision denying stay ontario class proceedings denied companys motion appeal certification order companys appeal heard ontario divisional court february february divisional court declined set aside order denying stay company intends seek leave appeal ontario court appeal earlier november superior court quebec authorized institution class action behalf individuals quebec consumed vioxx suffered damages arising ingestion december plaintiffs instituted action based upon authorization trial representative action australia scheduled commence march federal court australia named plaintiff alleges suffered mi seeks represent others australia ingested vioxx suffered mi thrombotic stroke unstable angina transient ischemic attack peripheral vascular disease november company filed motion order proceeding longer continue representative proceeding hearing december court dismissed motion january issued reasons decision february companys motion leave appeal decision denied parties directed prepare proposed lists issues tried table contents additional lawsuits based media reports sources company anticipates additional vioxx product liability lawsuits vioxx shareholder lawsuits vioxx foreign lawsuits collectively vioxx lawsuits may filed andor certain current former officers directors future nsurance previously disclosed company product liability insurance claims brought vioxx product liability lawsuits stated upper limits approximately million deductibles insurance provides coverage legal defense costs potential damage amounts connection vioxx product liability lawsuits arbitration proceeding negotiated settlements company received aggregate approximately million product liability insurance proceeds relating vioxx product liability lawsuits plus approximately million fees interest payments company additional insurance vioxx product liability lawsuits companys insurance coverage respect vioxx lawsuits adequate cover defense costs losses company directors officers insurance coverage applicable vioxx securities lawsuits vioxx derivative lawsuits stated upper limits approximately million company fiduciary insurance vioxx erisa lawsuits stated upper limits approximately million result arbitration additional insurance coverage claims also available needed upperlevel excess policies provide coverage variety risks disputes insurers availability companys insurance coverage claims likely additional disputes amounts actually recovered policies discussed paragraph may less stated upper limits nvestigations previously disclosed november company advised staff sec commencing informal inquiry concerning vioxx january company announced received notice sec issued formal notice investigation also company received subpoenas doj requesting information related companys research marketing selling activities respect vioxx federal health care investigation criminal statutes investigation includes subpoenas witnesses appear grand jury addition previously disclosed investigations conducted local authorities certain cities europe order determine whether criminal charges brought concerning vioxx company cooperating governmental entities respective investigations vioxx investigations company predict outcome inquiries however could result potential civil andor criminal dispositions previously disclosed may company reached civil settlements attorneys general states district columbia fully resolve previously disclosed investigations state consumer protection laws related past activities vioxx part civil resolution investigations merck paid total million divided among states district columbia agreement also includes compliance measures supplement policies procedures previously established company addition company received subpoena september state california attorney general seeking documents information related placement vioxx californias medical formulary company cooperating attorney general responding subpoena r eserves discussed november merck entered settlement agreement law firms comprise executive committee psc federal vioxx mdl well representatives plaintiffs counsel texas new jersey california state coordinated proceedings resolve state federal mi claims filed date united states settlement agreement also applies tolled claims signed parties several meetings three four judges overseeing coordination current claims vioxx litigation settlement agreement applies us legal residents allege mi occurred united states result entering table contents settlement agreement company recorded pretax charge billion represents fixed aggregate amount paid plaintiffs qualifying payment settlement program company currently anticipates two us vioxx product liability lawsuits tried except respect product liability trial scheduled held australia company predict timing trials related vioxx litigation company believes meritorious defenses vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits included settlement program company established reserves potential liability relating vioxx lawsuits included settlement program vioxx investigations cases company believes strong points raise appeal therefore unfavorable outcomes cases probable unfavorable outcomes vioxx litigation could material adverse effect companys financial position liquidity results operations legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable december company aggregate reserve approximately billion vioxx reserve settlement program companys future legal defense costs related vioxx litigation company spent approximately million aggregate legal defense costs worldwide related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation fourth quarter company recorded charge million solely future legal defense costs related vioxx litigation addition fourth quarter company paid additional million settlement funds connection settlement program paid million settlement funds third quarter consequently december aggregate amount vioxx reserve approximately billion adding vioxx reserve solely future legal defense costs company considered factors considered previously established reserves vioxx litigation significant factors considered review vioxx reserve follows actual costs incurred company development companys legal defense strategy structure light scope vioxx litigation including settlement agreement expectation certain lawsuits continue pending number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials vioxx litigation amount vioxx reserve december allocated solely defense costs represents companys best estimate minimum amount defense costs incurred connection remaining aspects vioxx litigation however events additional trials vioxx litigation events could arise course vioxx litigation could affect ultimate amount defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase vioxx reserve time future based upon factors set forth believes would appropriate ther product liability litigation previously disclosed company defendant product liability lawsuits united states involving fosamax fosamax litigation december approximately cases include approximately plaintiff groups filed pending merck either federal state court including one case seeks class action certification well damages andor medical monitoring actions plaintiffs allege among things suffered osteonecrosis jaw generally subsequent invasive dental procedures tooth extraction dental implants andor delayed healing association use fosamax august jpml ordered fosamax product liability cases pending federal courts nationwide transferred consolidated one multidistrict litigation fosamax mdl coordinated pretrial proceedings fosamax mdl transferred judge john keenan table contents united states district court southern district new york result jpml order approximately cases judge keenan judge keenan issued case management order various amendments thereto setting forth schedule governing proceedings focused primarily upon resolving class action certification motions completing fact discovery initial group cases october briefing argument plaintiffs motions certification medical monitoring classes completed judge keenan issued order denying motions january january judge keenan issued order dismissing prejudice class claims asserted first four class action lawsuits filed merck sought personal injury damages andor medical monitoring relief class wide basis october judge keenan issued order requiring daubert motions filed may scheduling trials first three cases mdl august october january respectively trial scheduled alabama state court later addition july application made atlantic county superior court new jersey requesting fosamax cases pending new jersey considered mass tort designation centralized management one judge new jersey october new jersey supreme court ordered pending future actions filed new jersey arising use fosamax seeking damages existing dental jawrelated injuries including osteonecrosis jaw solely seeking medical monitoring designated mass tort centralized management purposes judge higbee atlantic county superior court result new jersey supreme courts order approximately cases coordinated december judge higbee expected begin setting various case management deadlines first quarter discovery ongoing fosamax mdl litigation well various state court cases company intends defend lawsuits december company remaining reserve approximately million solely future legal defense costs fosamax litigation company spent approximately million added million reserve consequently december company reserve approximately million solely future legal defense costs fosamax litigation significant factors considered establishment reserve fosamax litigation legal defense costs follows actual costs incurred company thus far development companys legal defense strategy structure light creation fosamax mdl number cases brought company anticipated timing progression related costs pretrial activities fosamax litigation company continue monitor legal defense costs review adequacy associated reserves due uncertain nature litigation company unable estimate costs beyond completion first three federal trials discussed company established reserves potential liability relating fosamax litigation unfavorable outcomes fosamax litigation could material adverse effect companys financial position liquidity results operations c ommercial litigation previously disclosed company joined ongoing litigation alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used calculations determine public private sector reimbursement levels jpml ordered transfer consolidation pending federal awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions also expanded number manufacturers include like company defendants prior pending case may court granted companys motion dismiss consolidated class action dismissed company class action case subsequent companys dismissal plaintiffs filed amended consolidated class action complaint name company defendant company many pharmaceutical manufacturers defendants similar complaints pending federal state court brought individually number counties state new york fifty county cases consolidated new york state court company dismissed suffolk county case first new york county cases filed addition new york county cases december company defendant state cases brought attorneys general eleven states table contents defended february kansas attorney general filed suit merck several manufacturers additionally attorney general arizona voluntarily dismissed merck case february court awp cases pending hawaii listed merck others set trial mid g overnmental proceedings previously disclosed february company announced entered agreements government settle federal state civil cases alleging violations medicaid rebate statute well federal state false claims acts connection certain nominal pricing programs sales marketing activities connection settlements previously disclosed merck entered corporate integrity agreement cia us department health human services office inspector general hhsoig fiveyear term cia requires among things merck maintain ethics training program policies procedures governing promotional practices medicaid price reporting required cia merck retained independent review organization iro conduct systems review promotional policies procedures conduct sample basis transactional reviews mercks promotional programs certain medicaid pricing calculations merck also required provide regular reports certifications hhsoig regarding compliance cia iro currently conducting required reviews merck scheduled submit first annual report hhsoig may v ytorinzetia litigation previously disclosed company joint venture partner scheringplough received several letters addressed companies house committee energy commerce subcommittee oversight investigations oi ranking minority member senate finance committee collectively seeking combination witness interviews documents information variety issues related enhance clinical trial sale promotion vytorin well sales stock corporate officers addition since august companies received three additional letters oi including one dated february seeking certain information documents related seas clinical trial previously disclosed companies received subpoenas new york new jersey state attorneys general offices letter connecticut attorney general seeking similar information documents addition company received five civil investigative demands cids multistate group state attorneys general jointly investigating whether companies violated state consumer protection laws marketing vytorin finally september company received letter civil division doj informing doj investigating whether companies conduct relating promotion vytorin caused false claims submitted federal health care programs company cooperating investigations working scheringplough respond inquiries addition company become aware served approximately civil class action lawsuits alleging common law state consumer fraud claims connection msp partnerships sale promotion vytorin zetia certain lawsuits allege personal injuries andor seek medical monitoring actions filed transferred federal court coordinated multidistrict litigation us district court district court new jersey district judge dennis cavanaugh parties presently engaged motions practice briefing also previously disclosed april merck shareholder filed putative class action lawsuit federal court eastern district pennsylvania alleging merck chairman president chief executive officer richard clark violated federal securities laws suit since withdrawn refiled district new jersey consolidated another federal securities lawsuit caption merck co inc vytorin securities litigation amended consolidated complaint filed october names defendants merck merckscheringplough pharmaceuticals llc certain companys officers directors specifically complaint alleges merck delayed releasing unfavorable results clinical study regarding efficacy vytorin merck made false misleading statements expected earnings knowing results vytorin study released sales vytorin would decline mercks earnings would suffer april member merck erisa plan filed putative table contents class action lawsuit company certain officers directors alleging breached fiduciary duties erisa since time similar erisa lawsuits filed company district new jersey lawsuits consolidated caption merck co inc vytorin erisa litigation amended consolidated complaint filed february names defendants merck various members mercks board directors members committees mercks board directors plaintiffs allege erisa plans investment company stock imprudent companys earnings dependent commercial success cholesterol drug vytorin defendants knew known results scientific study would cause medical community turn less expensive drugs cholesterol management company intends defend lawsuits referred section vigorously unfavorable outcomes resulting government investigations civil litigation could material adverse effect companys financial position liquidity results operations november individual shareholder previously delivered letter companys board directors demanding board take legal action responsible individuals recover amounts paid company resolve certain governmental investigations delivered another letter board demanding board subcommittee thereof commence investigation matters raised various civil suits governmental investigations relating vytorin v accine litigation previously disclosed company party individual class action product liability lawsuits claims united states involving pediatric vaccines eg hepatitis b vaccine contained thimerosal preservative used vaccines merck distributed thimerosalcontaining pediatric vaccines united states since fall december approximately thimerosal related lawsuits pending company defendant although vast majority lawsuits currently active defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result exposure thimerosal pediatric vaccines cases currently scheduled trial company defend lawsuits however possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations company successful cases type either dismissed stayed ground action prohibited national childhood vaccine injury act vaccine act vaccine act prohibits person filing maintaining civil action state federal court seeking damages vaccine manufacturer vaccinerelated injuries unless petition first filed united states court federal claims hereinafter vaccine court vaccine act filing civil action vaccine manufacturer petitioner must either pursue petition conclusion vaccine court timely file election proceed civil action lieu accepting vaccine courts adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribed time periods company party vaccine court proceedings petitions brought united states department health human services company aware approximately cases pending vaccine court involving allegations thimerosalcontaining vaccines andor mmr ii vaccine cause autism spectrum disorders thimerosalcontaining vaccines involved vaccine court proceeding company vaccines company sole source mmr ii vaccine domestically special masters presiding vaccine court proceedings held hearings three test cases involving theory combination mmr ii vaccine thimerosal vaccines causes autism spectrum disorders february special masters issued decisions cases finding theory unsupported valid scientific evidence petitioners three cases therefore entitled compensation special masters held similar hearings three different test cases involving theory thimerosal vaccines alone causes autism spectrum disorders decisions issued second set test cases special masters previously indicated would hold similar hearings involving theory mmr ii alone causes autism spectrum disorders stated longer intend vaccine court indicated intends table contents use evidence presented test case hearings guide adjudication remaining autism spectrum disorder cases p atent litigation time time generic manufacturers pharmaceutical products file andas fda seeking market generic forms companys products prior expiration relevant patents owned company generic pharmaceutical manufacturers submitted andas fda seeking market united states generic form fosamax nexium singulair primaxin emend prior expiration companys astrazenecas case nexium patents concerning products addition anda submitted fda seeking market united states generic form zetia prior expiration schering ploughs patent concerning product generic companies andas generally include allegations non infringement invalidity unenforceability patents company filed patent infringement suits federal court companies filing andas generic alendronate fosamax montelukast singulair imipenemcilastatin primaxin astrazeneca company filed patent infringement suits federal court companies filing andas generic esomeprazole nexium also company schering plough filed patent infringement suit federal court companies filing andas generic ezetimibe zetia similar patent challenges exist certain foreign jurisdictions company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration dates patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products february scheringplough received notice generic company indicating filed anda zetia challenging us patents listed zetia merck scheringplough market zetia joint venture msp singapore company llc march scheringplough msp singapore company llc filed patent infringement suit glenmark pharmaceuticals inc usa parent corporation glenmark lawsuit automatically stays fda approval glenmarks anda october adverse court decision whichever may occur earlier previously disclosed january company received letter ranbaxy laboratories ltd ranbaxy stating filed anda seeking approval generic version mercks primaxin imipenemcilastatin lawsuit asserted infringement mercks patent due expire september july merck ranbaxy entered agreement pursuant ranbaxy begin market united states generic form imipenemcilastatin september previously disclosed february company received notice teva generic company indicating filed anda montelukast challenging us patent listed singulair april company filed patent infringement action teva lawsuit automatically stays fda approval tevas anda august adverse court decision whichever may occur earlier trial matter commenced february previously disclosed january us court appeals federal circuit washington dc found companys patent claims onceweekly administration fosamax invalid company exhausted options appeal decision based court appeals decision fosamax fosamax plus lost marketing exclusivity united states result events company experiencing significant declines fosamax fosamax plus us sales similarly major foreign markets basic use patent covering alendronate expired generic products sold may federal court canada trial division issued decision refusing bar approval generic alendronate grounds mercks patent weekly alendronate likely invalid decision appealed generic alendronate launched canada june july merck sued federal court canada apotex corp apotex seeking damages lost sales generic weekly alendronate due patent proceeding october federal court canada issued decision awarding apotex lost profits generic alendronate product period time held market due mercks lawsuit company appealed decision table contents previously disclosed september company appealed decision opposition division european patent office epo revoked companys patent europe covers onceweekly administration alendronate march board appeal epo upheld decision opposition division revoking patent march epo issued another patent europe company covers onceweekly administration alendronate terms new patent effective july company sued multiple parties european countries asserting european patent covering onceweekly dosing fosamax oppositions filed epo patent hearing proceeding scheduled march addition previously disclosed japan proceeding filed challenging validity companys japanese patent onceweekly administration alendronate patent office invalidated patent decision appeal october us patent dorzolamide covering trusopt cosopt expired company experienced significant decline us sales products company involved litigation proceedings corresponding patents canada great britain company astrazeneca received notice october ranbaxy filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium november company astrazeneca sued ranbaxy united states district court new jersey previously disclosed astrazeneca merck ranbaxy entered settlement agreement provides ranbaxy bring generic esomeprazole product market united states may company astrazeneca received cid united states federal trade commission ftc july regarding settlement agreement ranbaxy company cooperating ftc responding cid company astrazeneca received notice january ivax pharmaceuticals inc ivax subsequently acquired teva filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium march company astrazeneca sued teva united states district court new jersey january company astrazeneca sued dr reddys laboratories dr reddys district court new jersey based dr reddys filing anda esomeprazole magnesium trial scheduled january respect ivaxs dr reddys andas addition company astrazeneca received notice december sandoz inc sandoz filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium january company astrazeneca sued sandoz district court new jersey based sandozs filing anda esomeprazole magnesium january company received notice anda filed fda aprepitant contained paragraph iv challenge patents emend company evaluating information provided notice determine action taken europe company aware various companies seeking registration generic losartan active ingredient cozaar company patent rights losartan via license ei du pont de nemours company du pont company du pont filed patent infringement proceedings various companies portugal spain norway austria ther litigation february individual shareholder delivered letter companys board directors demanding board take legal action responsible individuals recover amounts paid company resolve certain governmental investigations previously disclosed prior spinoff medco health solutions inc medco health company medco health agreed settle class action basis series lawsuits asserting violations erisa gruer cases company medco health certain plaintiffs counsel filed settlement agreement federal district court new york cases commenced number plaintiffs including participants number pharmaceutical benefit plans medco health pharmacy benefit manager table contents well trustees plans consolidated medco health company agreed proposed settlement order avoid significant cost distraction prolonged litigation proposed class settlement agreed plaintiffs five cases filed medco health company proposed settlement company medco health agreed pay total million medco health agreed modify certain business practices continue certain specified business practices period five years financial compensation intended benefit members settlement class includes erisa plans medco health administered pharmacy benefit time since december district court held hearings hear objections fairness proposed settlement approved settlement yet determined number class member plans properly elected participate settlement settlement becomes final appeals resolved certain class member plans indicated participate settlement cases initiated three plans two individuals remain pending southern district new york plaintiffs cases asserted claims based erisa well federal state laws similar claims asserted settling class members gruer cases company medco health named defendants cases three notices appeal filed appellate court heard oral argument may december appellate court issued decision vacating district courts judgment remanding cases district court allow district court resolve certain jurisdictional issues hearing held address issues february district court issued ruling august resolving jurisdictional issues favor settling plaintiffs class members party previously appealed district courts judgment renewed appeals october renewed appeals affirmed part vacated part federal court appeals appeals court remanded class settlement proceedings district court district court preliminarily approved amended settlement may however plaintiffs initially opted settlement class filed objections settlement district court ordered briefing objections heard argument october district court yet issued ruling objections spinoff medco health medco health assumed substantially liability exposure matters discussed foregoing three paragraphs cases defended medco health various legal proceedings principally product liability intellectual property suits involving company pending feasible predict outcome proceedings proceedings discussed item opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company proceedings separate assessment provided item e nvironmental matters company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company table contents company taken active role identifying providing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties previously disclosed approximately plaintiffs filed amended complaint merck defendants united states district court eastern district california asserting claims clean water act resource conservation recovery act well negligence nuisance suit seeks damages personal injury diminution property value medical monitoring alleged real personal property damage associated groundwater soil contamination found site former merck subsidiary merced california company intends defend claims tem submission matters vote security holders applicable e xecutive officers registrant ages february r ichard clark age april chairman president chief executive officer may chief executive officer president june president merck manufacturing division responsible companys manufacturing information services operational excellence organizations worldwide dele ambrose age december vice president chief communications officer responsible global communications organization april sabbatical prior april ms ambrose executive vice president public relations investor communications att wireless wireless services provider september april j ohn canan age january senior vice president controller responsible corporate controllers group september vice president controller responsible corporate controllers group june vice president corporate audit assurance services c elia colbert age january senior vice president secretary since september assistant general counsel since november responsible corporate secretary function corporate staff legal groups functional responsibility office ethics compliance w illie deese age january executive vice president president merck manufacturing division mmd responsible companys global manufacturing procurement distribuion logistics functions may president mmd responsible companys global manufacturing procurement operational excellence functions table contents january senior vice president global procurement k enneth c frazier age august executive vice president president global human health responsible companys marketing sales organizations worldwide including global pharmaceutical vaccine franchises november executive vice president general counsel responsible legal public affairs functions merck company foundation notforprofit charitable organization affiliated company december senior vice president general counsel responsible legal public affairs functions merck company foundation notforprofit charitable organization affiliated company irian graddickweir age january executive vice president human resources responsible global human resources organization september senior vice president human resources prior september dr graddickweir executive vice president human resources employee communications att communications services provider held several senior human resources leadership positions att years p eter n kellogg age august executive vice president chief financial officer responsible companys worldwide financial organization investor relations corporate development licensing companys joint venture relationships prior august mr kellogg executive vice president finance chief financial officer biogen idec biotechnology company since november merger biogen inc idec pharmaceuticals corporation mr kellogg formerly executive vice president finance chief financial officer biogen inc serving vice president finance chief financial officer since july p eter kim age january executive vice president president merck research laboratories since january responsible companys research development efforts worldwide b ruce n kuhlik age january executive vice president general counsel responsible legal communications public policy functions merck company foundation notforprofit charitable organization affiliated company may vice president associate general counsel primary responsibility companys vioxx litigation defense prior may mr kuhlik senior vice president general counsel pharmaceutical research manufacturers america since october ark e mcdonough age february vice president treasurer responsible companys treasury function table contents january assistant treasurer global capital markets responsible managing companys investment financing portfolios treasury share repurchase program argaret g mcglynn age august president merck vaccines infectious diseases global responsibilities vaccines business infectious diseases franchise including companys sanofipasteur joint venture august president merck vaccines global responsibilities vaccines business including companys sanofipasteur joint venture january president us human health responsible one two prescription drug divisions hospital specialty product franchises comprising us human health ushh managed care group ushh tefan oschmann age september president europe middle east africa canada responsible companys business operations europe middle east africa canada october senior vice president worldwide human health marketing january managing director msd germany subsidiary company j chris scalet age january executive vice president global services chief information officer cio responsible global shared services across human resources finance site services information services function enterprise business process redesign initiative january senior vice president global services cio responsible global shared services across human resources finance site services information services function enterprise business process redesign initiative march senior vice president information services cio responsible areas information technology services including application development technical support voice data communications computer operations worldwide dam h schechter age august president global pharmaceuticals global responsibilities companys atherosclerosiscardiovascular diabetesobesity oncology specialtyneuroscience respiratory bone arthritis analgesia franchises well commercial responsibility united states companys portfolio prescription medicines july president us human health commercial responsibility united states companys portfolio prescription medicines october general manager us human health responsible neuropsychiatry osteoporosis migraine respiratory new products franchises february vice presidentgeneral manager merckscheringplough pharmaceuticals us joint venture officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer board table contents part ii tem market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol mrk common stock market price information set forth table based historical nyse market prices following table also sets forth calendar periods indicated dividend per share information c ash dividends paid per common share ear th q rd q nd q st q c ommon stock market prices th q rd q nd q st q high low h igh low january approximately stockholders record equity compensation plan information following table summarizes information options warrants rights equity compensation companys equity plans close business december table include information tax qualified plans merck co inc employee savings security plan number securities number remaining available securities future issuance issued upon weightedaverage equity exercise exercise price compensation plans outstanding outstanding excluding options warrants options warrants securities rights rights reflected column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following stockholderapproved plans incentive stock plan incentive stock plan incentive stock plan incentive stock plan nonemployee directors stock option plan nonemployee directors stock option plan nonemployee directors stock option plan table contents excludes approximately shares restricted stock units performance share units assuming maximum payouts incentive stock plans also excludes shares phantom stock deferred merck co inc deferral program december additional shares reserved deferral program beginning january onetenth percent outstanding shares merck common stock last business day preceding calendar year plus shares authorized deferral program issued reserved future issuance december actual amount shares issued prospectively equals amount participants elect defer payouts companys various incentive programs executive incentive plan phantom stock increased amount dividends would paid equivalent number shares merck common stock divided market price merck common stock table include information equity compensation plans options warrants rights assumed company connection mergers acquisitions pursuant remain outstanding options warrants rights collectively assumed plans include following medco containment services inc class c nonqualified stock option plan sibia neurosciences inc equity incentive stock option plan provantage health services inc stock incentive plan rosetta inpharmatics inc employee stock option plans total shares merck common stock may purchased assumed plans weighted average exercise price grants may made assumed plans table contents performance graph following graph compares cumulative total stockholder return stock price appreciation plus reinvested dividends companys common stock cumulative total return including reinvested dividends dow jones us pharmaceutical index djuspr formerly referred dow jones pharmaceutical index united states owned companies standard poors index sp index five years ended december amounts rounded nearest dollar percent comparison fiveyear cumulative total return merck co inc dow jones us pharmaceutical index sp index end period value cagr merck djuspr sp merck djuspr sp assumes value investment company common stock index december dividends reinvested compound annual growth rate table contents issuer purchases equity securities three month period ended december follows issuer purchases equity securities total number millions total shares purchased approx dollar value number average part shares may yet shares price paid publicly announced purchased period purchased per share plans programs plans programs october october november november na december december na total share repurchases made part plan announced july purchase billion merck shares table contents item selected financial data following selected financial data read conjunction item managements discussion analysis financial condition results operations consolidated financial statements notes thereto contained item financial statements supplementary data report erck co inc subsidiaries millions except per share amounts results year sales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates us vioxx settlement agreement charge income expense net income taxes taxes income net income basic earnings per common share earnings per common share assuming dilution cash dividends declared cash dividends paid per common share capital expenditures depreciation earend position working capital property plant equipment net total assets longterm debt stockholders equity f inancial ratios income sales net income average total assets earend statistics average common shares outstanding millions average common shares outstanding assuming dilution millions number stockholders record number employees amounts include gain distribution astrazeneca lp gain related sale companys remaining worldwide rights aggrastat favorable impact certain tax items impact restructuring actions additional legal defense costs expense contribution merck company foundation amounts include impact us vioxx settlement agreement charge restructuring actions civil governmental investigations charge insurance arbitration settlement gain acquired research expense resulting acquisition additional vioxx legal defense costs gains sales assets product divestitures well net gain settlements certain patent disputes amounts include impact restructuring actions acquired research expenses resulting acquisitions additional vioxx legal defense costs adoption new accounting standard requiring expensing stock options amounts include impact net tax charge primarily associated american jobs creation act repatriation restructuring actions additional vioxx legal defense costs amounts include impact withdrawal vioxx vioxx legal defense costs restructuring actions table contents tem managements discussion analysis financial condition results operations escription mercks business merck global researchdriven pharmaceutical company discovers develops manufactures markets broad range innovative products improve human animal health companys operations principally managed products basis comprised two reportable segments pharmaceutical segment vaccines infectious diseases segment pharmaceutical segment includes human health pharmaceutical products marketed either directly merck joint ventures products consist therapeutic preventive agents sold prescription treatment human disorders merck sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccines infectious diseases segment includes human health vaccine infectious disease products marketed either directly merck case vaccines also joint venture vaccine products consist preventative pediatric adolescent adult vaccines primarily administered physician offices merck sells human health vaccines primarily physicians wholesalers physician distributors government entities infectious disease products consist therapeutic agents treatment infection sold primarily drug wholesalers retailers hospitals government agencies companys professional representatives communicate effectiveness safety value pharmaceutical vaccine products health care professionals private practice group practices managed care organizations verview company continued address business challenges midst evolving pharmaceutical industry environment revenue declined driven largely lower sales fosamax treatment prevention osteoporosis fosamax fosamax plus lost market exclusivity substantially formulations united states february april respectively result company experiencing significant decline sales united states within fosamax franchise also contributing decline lower sales zocor companys statin modifying cholesterol lost us market exclusivity partially offsetting declines higher sales januvia janumet treatment type diabetes isentress antiretroviral therapy treatment hiv infection address business industry challenges merck faces company remains focused innovation customer value order drive growth business help position merck future success company made significant progress reengineering operations research development initiatives rollout new commercial model continuation mercks supply strategy activities enable company optimize product portfolio invest growth opportunities emerging markets merck bioventures business development merck continues efforts diversify companys scientific portfolio internal programs external research collaborations company focused developing novel bestinclass followon treatments patients primary care specialty care hospital settings additionally merck research laboratories pursuing portfolio treatment modalities includes small molecules vaccines also biologics peptides rna interference rnai merck moving diversify portfolio creating new division merck bioventures leverages unique technology platform followon novel biologics company numerous active clinical programs across companys major research franchises bone respiratory immunology endocrine cardiovascular diabetes obesity infectious diseases neuroscience oncology vaccines company currently nine candidates phase iii clinical development anticipates submitting two new drug applications nda us food drug administration fda respect two candidates mk telcagepant investigational compound treatment migraines mk rolofylline investigational compound treatment acute heart failure addition company anticipates submitting nda mkc ezetimibe combined table contents atorvastatin investigational medication treatment dyslipidemia developed merckschering plough joint venture also company anticipates regulatory action two supplemental filings submitted fda one gardasil mercks hpv vaccine use males one isentress firstinclass integrase inhibitor treatment hiv infection expanded indication use treatment nave patients commercial side company rolling customercentric selling model designed provide competitive advantage help build trust customers improve patient outcomes strategy employs use new marketing technologies complement new customercentered approach moves away traditional frequencybased sales marketing approach also creates efficiencies eliminating redundancies core functions across sales organization manufacturing side merck made significant progress three years since began engineering create lean flexible costeffective capability company continues address manufacturing issues working build additional capacity vaccines biologics well support mercks expansion emerging markets assist goal company shifting investments developed markets emerging markets commensurate size strategic importance opportunity october company announced global restructuring program restructuring program reduce cost structure increase efficiency enhance competitiveness discussed merck rolling new customercentric selling model additionally company make greater use outside technology resources centralize common sales marketing activities consolidate streamline operations mercks manufacturing division focus capabilities core products outsource non core manufacturing also merck expanding access worldwide external science basic research global operating strategy designed provide sustainable pipeline focused translating basic research productivity latestage clinical success increase efficiencies basic research operations consolidate work support given therapeutic area one four locations provide efficient use research facilities result closure three basic research sites located tsukuba japan pomezia italy seattle end part restructuring program company expects eliminate approximately positions active employees vacancies across areas company worldwide end approximately company eliminated total reductions occur united states part restructuring program company streamlining management layers reducing total number senior midlevel executives globally approximately company however continues hire new employees business requires restructuring program expected completed end total pretax costs estimated billion billion company recorded pretax restructuring costs million related restructuring program company estimates twothirds cumulative pretax costs result future cash outlays primarily employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested merck expects restructuring program yield cumulative pretax savings billion billion connection certain transactions astrazeneca lp azlp company recorded aggregate pretax gain billion included income expense net received net proceeds azlp billion see note consolidated financial statements information earnings per common share eps assuming dilution including impact gain distribution azlp per share restructuring costs per share addition eps reflects favorable impact certain tax items items discussed fully notes consolidated financial statements c ompetition health care environment markets company conducts business highly competitive often highly regulated global efforts toward health care cost containment continue exert pressure product pricing access table contents united states government expanded health care access enacting medicare prescription drug improvement modernization act signed law december prescription drug coverage began january legislation supports companys goal improving access medicines expanding insurance coverage preserving marketbased incentives pharmaceutical innovation time legislation ensure prescription drug costs controlled competitive pressures encouraging appropriate use medicines us congress considered may consider proposals increase governments role pharmaceutical pricing medicare program proposals may include removing current legal prohibition secretary health human services intervening price negotiations medicare drug benefit program plans pharmaceutical companies may also include mandating payment rebates pharmaceutical utilization medicare drug benefit plans addition congress may consider proposals allow certain conditions importation medicines countries addressing costcontainment pressure company made continuing effort demonstrate medicines provide value patients pay health care addition pricing flexibility across companys product portfolio encouraged growing use medicines mitigated effects increasing cost pressures outside united states difficult environments encumbered government costcontainment actions company worked partnership payers encourage allocate scarce resources optimize health care outcomes limiting potentially detrimental effects government policies sales growth access innovative medicines vaccines support discovery development innovative products benefit patients company also working governments many emerging markets eastern europe latin america asia encourage increase investments health thereby improve citizens access medicines addition certain countries within eu recognizing economic importance researchbased pharmaceutical industry value innovative medicines society working industry representatives improve competitive climate variety means including market deregulation order advance related policy debate ec launched high level pharmaceutical forum hlpf period initiative aimed improving prospects research based pharmaceutical industry europe thus health prospects patients benefit innovative therapies active dialogue among stakeholders health care system payers patients initiative attempt tackle key policy issues europe promoting greater pricing flexibility medicines ii ensuring health authorities apply best practices evaluation relative effectiveness medicines iii improving greater access information medicines patients europe company actively engaged ec stakeholders broadly agreement recommendations hlpf january ec launched sector inquiry pharmaceutical markets rules eu competition law part inquiry companys offices germany inspected authorities beginning january preliminary report ec issued november ec stated confirmed original hypothesis competition pharmaceutical sector may restricted distorted indicated decline innovation measured number novel medicines reaching market alleged instances delayed market entry generic medicines public consultation period respect preliminary report expired january ec issued inquiries respect subject investigation ec alleged company subsidiaries engaged unlawful practices final report planned later company cooperating ec sector inquiry company committed improving access medicines enhancing quality life people around world african comprehensive hivaids partnerships botswana partnership government botswana bill melinda gates foundation merck company foundationmerck co inc supporting botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support table contents catalyze access hiv medicines developing countries price reduction guidelines company announced merck makes profit sale current hivaids medicines worlds poorest countries hardest hit pandemic offers hivaids medicines significantly reduced prices mediumincome countries february merck announced reduced price stocrin least developed countries world hardest hit pandemic end approximately people living hiv aids developing countries territories estimated treatment antiretroviral regimens containing crixivan stocrin atripla actions merck working independently partners public private sectors alike focus critical barriers access medicines developing world need sustainable financing increased international assistance additional investments education training health infrastructure capacity developing countries october merck announced rotateq awarded prequalification status world health organization prequalification allows expanded access rotateq provides greater opportunity help protect millions infants rotavirus gastroenteritis rotateq prequalified vaccine eligible procurement pan american health organization unicef united nations agencies use national vaccination programs rotateq readytouse oral liquid rotavirus vaccine receive prequalification merck committed providing rotateq global alliance vaccines immunizationeligible countries prices profit company subject number privacy data protection laws regulations globally legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority us states requiring security breach notification although one predict outcome legislative regulatory advocacy initiatives company well positioned respond evolving health care environment market forces company anticipates worldwide trend toward costcontainment continue resulting ongoing pressures health care budgets company continues successfully launch new products contribute health care debates monitor reforms new products policies strategies enable maintain strong position changing economic environment cquisitions september merck completed acquisition novacardia inc novacardia million paid issuance merck common stock novacardia clinicalstage pharmaceutical company focused cardiovascular disease acquisition added rolofylline mk novacardias investigational phase iii compound acute heart failure mercks pipeline connection acquisition company recorded charge million acquired research associated rolofylline acquisition date technological feasibility established alternative future use existed charge deductible tax purposes ongoing activity respect future development rolofylline continues costs expected material companys research development expenses december merck completed acquisition sirna therapeutics inc sirna approximately billion sirna biotechnology company developing new class medicines based rnai technology could significantly alter treatment disease connection acquisition company recorded charge million acquired research associated sirnas compounds currently development related development treatments hepatitis b hepatitis c viruses preclinical development well licensing agreements held sirna charge deductible tax purposes ongoing activity respect compounds development continues costs expected material companys research development expenses acquisition sirna increased mercks ability use rnai technology turn targeted gene human cell potentially rendering inoperative gene responsible triggering specific disease table contents june merck acquired glycofi inc glycofi privatelyheld biotechnology company field yeast glycoengineering addition specific carbohydrate modifications proteins yeast optimization biologic drug molecules million cash million purchase price net million shares already owned net transaction costs company recorded million charge acquired research connection acquisition deductible tax purposes may merck acquired abmaxis inc abmaxis privatelyheld biopharmaceutical company dedicated discovery optimization monoclonal antibody products human therapeutics diagnostics million cash substantially purchase price allocated intangible asset relating abmaxis technology platform acquisitions independent scientific merits combination glycofi abmaxis platforms potentially synergistic giving merck ability operate across entire spectrum therapeutic antibody discovery development commercialization see note consolidated financial statements discussion acquisitions perating results ales worldwide sales totaled billion decline compared primarily attributable volume decrease partially offset favorable effect foreign exchange revenue decline largely reflects lower sales fosamax treatment prevention osteoporosis fosamax fosamax plus lost market exclusivity substantially formulations united states february april respectively also contributing decline lower sales zocor companys statin modifying cholesterol lost us market exclusivity lower sales vasotecvaseretic treatment hypertension andor heart failure lost patent protection certain foreign markets lower sales certain vaccines including hepatitis haemophilus influenzae type b hib vaccines partially offsetting declines higher sales januvia janumet treatment type diabetes isentress antiretroviral therapy treatment hiv infection cozaarhyzaar treatment hypertension rotateq vaccine help protect rotavirus gastroenteritis infants children singulair medicine indicated chronic treatment asthma relief symptoms allergic rhinitis domestic sales declined compared foreign sales rose foreign sales represented total sales domestic sales decline largely driven lower sales fosamax fosamax plus vaccines singulair partially offset higher sales januvia janumet isentress foreign sales growth reflects strong performance januvia janumet singulair cozaarhyzaar isentress partially offset lower sales vasotecvaseretic zocor worldwide sales increased total compared reflecting volume increase favorable effect foreign exchange less favorable effect price changes sales growth primarily driven growth companys vaccines including gardasil vaccine help prevent cervical vulvar vaginal cancers precancerous dysplastic lesions genital warts caused hpv types varivax vaccine help prevent chickenpox rotateq zostavax vaccine help prevent shingles herpes zoster also contributing sales growth period strong performance singulair higher sales januvia sales janumet well increased sales cozaarhyzaar sales growth partially offset lower sales zocor proscar urology product treatment symptomatic benign prostate enlargement mercks us market exclusivity proscar expired june also offsetting sales growth lower revenues companys relationship azlp lower sales fosamax fosamax plus foreign sales represented total sales table contents sales companys products follows millions pharmaceutical singulair cozaarhyzaar fosamax januvia cosopttrusopt zocor maxalt propecia arcoxia vasotecvaseretic janumet proscar emend pharmaceutical vaccine infectious disease product sales included pharmaceutical segment p harmaceutical segment revenues v accines infectious diseases gardasil proquadmmr iivarivax rotateq zostavax hepatitis vaccines vaccines primaxin cancidas isentress crixivanstocrin invanz infectious disease vaccine infectious disease product sales included pharmaceutical segment v accines infectious diseases segment revenues ther segment revenues total segment revenues ther presented net discounts returns pharmaceutical primarily includes sales human pharmaceutical products revenue companys relationship azlp primarily relating sales nexium well prilosec revenue azlp billion billion billion respectively pharmaceutical also reflects certain supply sales including supply sales associated companys arrangement dr reddys laboratories sale generic simvastatin sales vaccine infectious disease products nonus subsidiaries included pharmaceutical segment amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd includes nonreportable human animal health segments revenues primarily comprised miscellaneous corporate revenues sales related divested products businesses supply sales included segment results table contents companys pharmaceutical products include therapeutic preventive agents generally sold prescription treatment human disorders among singulair leukotriene receptor antagonist chronic treatment asthma relief symptoms allergic rhinitis cozaar hyzaar vasotec vaseretic companys significant hypertension andor heart failure products fosamax fosamax plus marketed fosavance throughout european union eu fosamac japan treatment case fosamax prevention osteoporosis januvia janumet treatment type diabetes cosopt trusopt mercks largestselling ophthalmological products zocor mercks statin modifying cholesterol maxalt acute migraine product propecia product treatment male pattern hair loss arcoxia treatment arthritis pain proscar urology product treatment symptomatic benign prostate enlargement emend prevention chemotherapyinduced postoperative nausea vomiting companys vaccine infectious disease products include gardasil vaccine help prevent cervical vulvar vaginal cancers precancerous dysplastic lesions genital warts caused hpv types varivax vaccine help prevent chickenpox proquad pediatric combination vaccine measles mumps rubella varicella mmr ii vaccine measles mumps rubella rotateq vaccine help protect rotavirus gastroenteritis infants children zostavax vaccine help prevent shingles herpes zoster primaxin cancidas antibacterialantifungal products isentress crixivan stocrin antiretroviral therapies treatment hiv infection invanz treatment infection p harmaceutical segment revenues sales pharmaceutical segment declined primarily due declines fosamax zocor vasotecvaseretic partially offset growth januvia janumet cozaarhyzaar sales pharmaceutical segment declined primarily due lower sales zocor proscar post patent expiration partially offset increases singulair cozaarhyzaar januvia sales janumet worldwide sales singulair grew reaching billion rose billion reflecting continued demand asthma seasonal perennial allergic rhinitis medications sales performance benefited higher sales outside united states including volume growth europe japan positive effect foreign exchange sales united states declined reflecting impact switch competing allergic rhinitis product overthecounter status united states early timing public reaction fda early communication regarding limited number postmarketing adverse event reports created uncertainty marketplace smaller spring fall allergy seasons singulair continues number one prescribed product us respiratory market global sales cozaar companion agent hyzaar combination cozaar hydrochlorothiazide increased billion grew billion increase driven strong performance hyzaar japan marketed preminent well positive effect foreign exchange cozaar hyzaar among leading medicines angiotensin receptor blocker class cozaar hyzaar lose patent protection united states april company expects significant declines us sales products time worldwide sales fosamax fosamax plus declined billion decreased billion since substantially formulations medicines lost us market exclusivity company experiencing significant declines sales united states within fosamax franchise company expects declines continue global sales januvia mercks dipeptidyl peptidase dpp inhibitor billion million million januvia approved fda october ec march januvia continues second leading branded oral antidiabetic agent terms new prescription share united states dpp inhibitors represent class prescription medications improve blood sugar control patients type diabetes enhancing natural body system called incretin system helps regulate glucose affecting beta cells alpha cells pancreas november new data presented st annual scientific meeting gerontological society america showed januvia significantly reduced blood sugar levels elderly patients type diabetes associated hypoglycemia low blood sugar study patients aged years table contents reports hypoglycemia either januvia placebo groups advanced age contributes risk hypoglycemia worldwide sales janumet mercks oral antihyperglycemic agent combines sitagliptin mercks dpp inhibitor januvia metformin single tablet target three key defects type diabetes million compared million janumet launched united states april approved adjunct diet exercise improve blood sugar control adult patients type diabetes adequately controlled metformin sitagliptin alone patients already treated combination sitagliptin metformin february merck received fda approval market janumet initial treatment type diabetes treatment sitagliptin metformin appropriate july janumet approved marketing eu iceland norway products experiencing growth include maxalt treat acute migraine pain emend prevention chemotherapyinduced postoperative nausea vomiting arcoxia treatment arthritis pain propecia male pattern hair loss worldwide sales zocor declined zocor lost us market exclusivity june also lost market exclusivity many international markets february company entered agreement dr reddys laboratories dr reddys authorized sale generic simvastatin terms agreement company reimbursed costplus basis dr reddys supplying finished goods received share net profits recorded dr reddys merck recorded million revenue associated dr reddys arrangement simvastatin proscar lost market exclusivity united states june mercks sales proscar declined basic patent proscar also covers propecia however propecia protected additional patents expire october patent provided us market exclusivity cosopt trusopt expired october result company experiencing significant declines us sales products patent provides us market exclusivity primaxin expires september time company expects significant decline us sales product company divested remaining ownership aggrastat foreign markets iroko pharmaceuticals also company azlp entered agreement ranbaxy laboratories ltd ranbaxy settle patent litigation respect esomeprazole nexium provides ranbaxy bring generic esomeprazole product market united states may company faces challenges respect outstanding patent infringement matters esomeprazole see note consolidated financial statements february company formally notified european medicines agency decision withdraw application marketing authorization vorinostat histone deacetylase inhibitor treatment patients advanced stage refratory cutaneous tcell lymphoma ctcl vorinostat marketed zolinza united states granted orphan drug designation ec treatment ctcl v accines infectious diseases segment revenues sales vaccines infectious diseases segment billion billion billion decline primarily due lower sales gardasil hepatitis vaccines viral vaccines include varivax mmr ii proquad hib vaccines lower sales primaxin declines partially offset growth isentress rotateq zostavax increase primarily driven strong performance gardasil well varivax rotateq zostava x following discussion vaccine infectious disease products includes total vaccine infectious disease product sales majority included vaccines infectious diseases segment remainder representing sales products nonus subsidiaries included pharmaceutical table contents segment amounts reflect sales vaccines sold major european markets sanofi pasteur msd spmsd companys joint venture sanofi pasteur results reflected equity income affiliates see selected joint venture affiliate information supply sales spmsd however reflected vaccines infectious diseases segment revenues worldwide sales companys cervical cancer vaccine gardasil recorded merck billion billion million gardasil approved fda june worlds topselling hpv vaccine hpv vaccine available use united states september fda approved gardasil prevention vulvar vaginal cancers caused hpv types gardasil currently indicated girls women years age prevention cervical vulvar vaginal cancers precancerous dysplastic lesions genital warts caused hpv types sales performance reflects lower sales domestically partially offset growth outside united states sales growth outside united states aided adoption schoolbased programs canadian provinces decline united states affected two factors first strong launch uptake significant portion year old eligible population already vaccinated result despite continued strong vaccination rates population number total vaccinations declined secondly number total vaccinations year old age group declined compared sales include initial purchases many states us centers disease control prevention cdc vaccines children program company party certain third party license agreements respect gardasil including crosslicense settlement agreement glaxosmithkline result agreements company pays royalties worldwide gardasil sales approximately aggregate included materials production costs january fda issued second complete response letter regarding supplemental biologics license application sbla use gardasil women ages though agency completed review response merck provided july fdas first complete response letter issued june recommended merck submit additional data month study completed initial sbla included data collected average months enrollment study number prespecified endpoints met following review final results study merck anticipates providing response fda fourth quarter letter affect current indications gardasil females ages letter relate sbla submitted december use gardasil males november data presented european research organization genital infection neoplasia international multidisciplinary conference showed gardasil prevented external genital lesions caused hpv types pivotal phase iii study men aged data evaluating efficacy hpv vaccine preventing disease males initial planned analysis study analysis male study participants aged infected least one four hpv types start study one month receiving third dose vaccine placebo completed analysis predetermined study protocol conducted least cases external genital lesions observed study ongoing additional data submitted global regulatory agencies available merck submitted sbla gardasil december accepted fda use gardasil boys men ages prevention external genital lesions caused hpv types regulatory submissions around world occur planned rotateq achieved worldwide sales recorded merck million million million increases primarily driven continued uptake united states successful launches around world fda approved rotateq february sales included purchases million million support cdc stockpile company anticipates domestic sales impacted recent launch competing product previously disclosed company resolved issue related bulk manufacturing process companys varicella zoster virus vzvcontaining vaccines company manufacturing bulk varicella producing doses varivax zostavax company received regulatory approvals united states certain markets increase manufacturing capacity vzvcontaining vaccines company working ensure adequate market supply continued sufficient inventory varivax clear back orders table contents build stable supply inventory zostavax proquad one vzvcontaining vaccines currently available ordering however orders transitioned appropriate mmr ii varivax total sales recorded merck proquad million million million merck anticipates proquad return us market mercks sales varivax million million million varivax vaccine available united states help protect chickenpox due unavailability proquad varivax benefited advisory committee immunization practices june second dose recommendation mercks sales mmr ii million million million sales varivax mmr ii affected unavailability proquad combined sales proquad mmr ii varivax declined compared sales zostavax recorded merck million million million sales impacted bulk vaccine supply issues caused delays fulfillment customer orders company cleared majority backorders december company expects clear backorders remained end year first quarter return normal shipping times mid backorders resolved company expects adequate supply meet anticipated customer demand remainder company currently anticipates launching zostavax outside united states zostavax approved fda well regulatory authorities australia eu may vaccine first medical option prevention shingles company working resolve manufacturing issues related hibcontaining vaccines pedvaxhib comvax since december company resolved original issue related equipment sterilization identified unrelated manufacturing process changes require regulatory filing merck anticipates pedvaxhib comvax return us market midtolate timing product availability outside united states dependent upon local regulatory requirements pediatric formulation vaqta vaccine hepatitis became available december company anticipates adult formulation may available second half outside united states supply vaqta limited availability vary region addition doses adult dialysis formulations companys hepatitis b vaccine recombivax hb depleted first quarter time unavailable united states remainder year pediatricadolescent formulation recombivax hb expected experience intermittent backorders united states throughout merck expects supplies pediatricadolescent formulation recombivax hb limited throughout company expect return full supply pediatricadolescent formulation recombivax hb time sales isentress million million october fda granted isentress accelerated approval use combination antiretroviral agents treatment hiv infection treatmentexperienced adult patients evidence viral replication hiv strains resistant multiple antiretroviral agents isentress first medicine approved class antiretroviral drugs called integrase inhibitors isentress works inhibiting insertion hiv dna human dna integrase enzyme inhibiting integrase performing essential function limits ability virus replicate infect new cells january fda granted traditional approval isentress following review week data benchmrk clinical trials merck also conducting phase iii clinical trials isentress treatmentnave previously untreated hiv population december merck announced fda accepted supplemental new drug application snda filing isentress tablets standard review company seeking us marketing approval isentress combination hiv medicines treatment adult patients previously untreated nave hiv merck expects fda action july february data several phase iii isentress studies presented th conference retroviruses opportunistic infections montreal canada new subgroup analyses phase iii study startmrk compared isentress efavirenz one leading antiretrovirals prescribed previously untreated treatmentnave hivinfected patients isentress found effective efavirenz table contents suppressing viral load provided improvements immune system function across broad spectrum patient subpopulations weeks use isentress previously untreated hivinfected patients investigational use drug medicines taken combination tenofoviremtricitabine addition results two phase iii studies switchmrk evaluating effect switching patients whose hiv controlled lopinavirritonavirbased regimen regimen containing isentress tablets showed isentress significantly improved total cholesterol triglycerides nonhdlcholesterol study also showed isentress demonstrate noninferior virologic efficacy maintaining viral load suppression result viral load findings trials merck discontinued two studies vaccines infectious diseases segment products experiencing growth include invanz treatment infection cancidas antifungal product fda approved expanded label cancidas makes first echinocandin therapy approved united states treatment pediatric patients aged three months years indicated fungal infections c osts expenses millions c hange c hange materials production marketing administrative research development restructuring costs equity income affiliates us vioxx settlement agreement charge income expense net greater aterials production materials production costs declined compared decline sales primarily reflecting lower restructuring costs included materials production costs million restructuring costs related restructuring programs comprised million accelerated depreciation associated planned sale closure certain companys manufacturing facilities million costs primarily asset writeoffs compares restructuring costs million representing million accelerated depreciation million asset impairments see note consolidated financial statements materials production costs increased primarily due increase sales increase partially offset lower costs related restructuring program million compared million gross margin compared restructuring charges noted unfavorable impact percentage points percentage points percentage points gross margin reflects changes product mix including decline fosamax fosamax plus sales result loss us market exclusivity manufacturing efficiencies gross margin reflects slight unfavorable impact changes product mix positive impact manufacturing efficiencies gross margin reflects unfavorable impact changes product mix including decline zocor sales result loss us market exclusivity june arketing administrative marketing administrative expenses declined marketing administrative expenses included million million million respectively table contents additional reserves solely future vioxx legal defense costs expenses also reflect million million respectively additional reserves solely future legal defense costs fosamax litigation addition marketing administrative expenses included million gain insurance arbitration award related vioxx product liability litigation coverage see note consolidated financial statements information vioxx related fosamax related matters addition lower expenses future legal defense costs decline marketing administrative expenses also reflect companys efforts reduce cost base company incurred separation costs associated sales force reductions reflected restructuring costs discussed r esearch development research development expenses declined compared expenses reflect million costs related closure sale research facilities connection restructuring program substantially represent accelerated depreciation expenses reflect million acquired research expense related novacardia acquisition research development expenses compared reflect increase development spending support continued advancement research pipeline research development expenses increased compared reflecting significant growth number compounds entering clinical trials internal projects well integration late stage acquisitions research development expenses included million acquired research expense related novacardia acquisition compared acquired research expense million related acquisitions sirna glycofi addition research development expenses reflected accelerated depreciation costs million related closure research facilities connection restructuring program company continued advancement drug candidates pipeline companys research pipeline chart included item business research development january fda approved emend fosaprepitant dimeglumine injection mg prevention chemotherapyinduced nausea vomiting emend injection provides new option day one substitute emend mg taken orally part recommended threeday regimen prior fda decision eu january granted marketing approval emend injection known ivemend eu action applies eu member countries well norway iceland company currently nine drug candidates phase iii development anticipates making nda filings respect two candidates noted additionally company anticipates filing nda fda mkc investigational medication combining ezetimibe atorvastatin treatment dyslipidemia developed merckscheringplough joint venture company continues anticipate filing nda fda mk rolofylline potential firstinclass selective adenosine antagonist investigational drug evaluated treatment acute heart failure march results phase iii pilot doseranging study patients hospitalized acute heart failure syndrome renal impairment treated rolofylline presented annual scientific session american college cardiology rolofylline administered intravenous iv loop diuretics associated improved dyspnea shortness breath preserved renal function compared treatment placebo iv diuretics addition posthoc analysis treatment rolofylline associated trend towards reduced day mortality hospital readmission cardiovascular renal causes rolofylline increases renal blood flow urine production blocking adenosinemediated vasoconstriction afferent arterioles kidneys inhibiting salt water reabsorption kidney small pilot study rates adverse events seen across treatment groups similar confirmatory phase iii studies rolofylline mg underway company also continues anticipate filing nda fda mk telcagepant investigational oral calcitonin generelated peptide receptor cgrp antagonist represents new mechanism treatment migraine september merck announced phase iii clinical trial telcagepant significantly relieved moderatetosevere migraine attacks including migraine pain migraine table contents associated symptoms compared placebo data presented london england european headachemigraine trust international congress reported findings worldwide multicenter randomized placebocontrolled clinical trial adult patients acute migraine also june merck presented data american headache society annual meeting phase iii clinical trial showed telcagepant significantly improved relief migraine pain migraineassociated symptoms two hours dosing compared placebo addition efficacy results telcagepant mg similar highest recommended dose zolmitriptan approved migraine therapy lower incidence adverse events associated telcagepant study trial part ongoing phase iii program evaluating telcagepant reports serious adverse events telcagepant zolmitriptan treatment arms telcagepant antagonist receptor cgrp potent neuropeptide thought play central role underlying pathophysiology migraine mk deforolimus novel mtor mammalian target rapamycin inhibitor evaluated treatment cancer drug candidate jointly developed commercialized ariad pharmaceuticals inc agreement reached phase iii study succeed patients metastatic softtissue bone sarcomas underway company continues anticipate filing nda fda mkc combines januvia sitagliptin pioglitazone another type diabetes therapy company anticipates filing nda fda v ninevalent hpv vaccine development expand protection cancercausing hpv types phase iii clinical program underway merck anticipates filing biologics license application bla fda mk odanacatib highly selective inhibitor cathepsin k enzyme evaluated treatment osteoporosis osteoporosis disease reduces bone density strength results increased risk bone fractures cathepsin k enzyme believed play central role osteoclastic bone resorption particularly degradation protein component bone inhibition cathepsin k novel approach treatment osteoporosis differs currently approved treatments september twoyear data phase iib study odanacatib reported th annual meeting american society bone mineral research demonstrated dosedependent increases bone mineral density bmd total hip lumbar spine femoral neck fracture sites decreased indices bone resorption compared placebo postmenopausal women low bmd multicenter doubleblind randomized placebocontrolled study evaluated doses mg odanacatib administered orally onceweekly without regard timing meals patients physical position postmenopausal women low bmd months number patients experiencing drugrelated adverse experience similar mg odanacatib group placebo effect odanacatib mg vertebral hip nonvertebral fractures currently evaluated large global phase iii study merck continues anticipate filing nda fda mka drug candidate combines extendedrelease er niacin novel flushing inhibitor laropiprant mka demonstrated ability lower ldlcholesterol ldlc bad cholesterol raise hdlcholesterol hdlc good cholesterol lower triglycerides significantly less flushing traditional extended release niacin alone high ldlc low hdlc elevated triglycerides risk factors associated heart attacks strokes april merck received nonapprovable action letter fda response nda mka meeting discuss letter fda stated additional efficacy safety data required suggested company wait results treatment hdl reduce incidence vascular events hpsthrive cardiovascular outcomes study expected completed january merck anticipates filing nda fda mka july company announced tredaptive also known mka approved marketing countries eu iceland norway tredaptive approved treatment dyslipidemia particularly patients combined mixed dyslipidemia characterized elevated levels ldlc triglycerides low hdlc patients primary hypercholesterolemia heterozygous familial nonfamilial tredaptive used patients combination statins cholesterol lowering table contents effects statin monotherapy inadequate tredaptive used monotherapy patients statins considered inappropriate tolerated launch tredaptive europe markets delayed due manufacturingrelated issue merck committed quickly resolving issue making tredaptive available europe soon possible countries around world merck continues pursue regulatory approvals mka mkb drug candidate combines novel approach raising hdlc lowering triglycerides er niacin combined laropiprant proven benefits simvastatin one combination product merck seek approval mkb united states files complete response relating mka mk anacetrapib inhibitor cholesteryl ester transfer protein shown promise lipid management raising hdlc reducing ldlc without raising blood pressure phase iii study initiated enrollment cardiovascular outcomes study planned begin company anticipates filing nda fda beyond december company terminated collaboration dynavax technologies corporation dynavax development v investigational hepatitis b vaccine entered october merck dynavax received notification fda regarding two companies response agencys request safety information relating clinical hold two investigational new drug ind applications v issuing clinical hold march fda requested review clinical safety data including available information single case wegeners granulomatosis uncommon disease blood vessels inflamed reported phase iii clinical trial dynavax merck previously provided response fda september october correspondence fda advised companies balance risk versus potential benefit longer favored continued clinical evaluation v healthy adults children october merck announced seek regulatory approval taranabant investigational medicine treat obesity discontinued phase iii clinical development program taranabant obesity available phase iii data showed efficacy adverse events dose related greater efficacy adverse events higher doses therefore careful consideration company determined overall profile taranabant support development obesity merck continues remain focused augmenting internal efforts capitalizing growth opportunities drive near longterm growth company completed transactions across broad range therapeutic categories well earlystage technology transactions merck actively monitoring landscape growth opportunities meet companys strategic criteria highlights activities include february merck entered definitive agreement insmed inc insmed purchase insmeds portfolio followon biologic therapeutic candidates commercial manufacturing facilities located boulder colorado terms agreement merck pay insmed aggregate million cash acquire rights boulder facilities insmeds pipeline followon biologic candidates insmeds followon biologics portfolio includes two clinical candidates ins investigational recombinant granulocyte colony stimulating factor gcsf evaluated ability prevent infections patients cancer receiving chemotherapy ins pegylated recombinant gcsf designed allow less frequent dosing agreement provides initial payments million ins ins merck pay insmed remaining balance upon closing transaction expected end first quarter without milestone royalty obligations september merck japan tobacco inc jt signed worldwide licensing agreement develop commercialize jtt investigational oral osteoanabolic bone growth stimulating agent treatment osteoporosis jtt investigational oral calcium sensing receptor antagonist currently evaluated jt phase ii clinical trials japan effect increasing bone density phase clinical trials outside japan terms agreement merck gained worldwide rights except japan table contents develop commercialize jtt certain related compounds jt received upfront payment million company recorded research development expense eligible receive additional cash payments upon achievement certain milestones associated development approval drug candidate covered agreement jt also eligible receive royalties sales drug candidates receive marketing approval company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development mercks research development model designed increase productivity improve probability success prioritizing companys research development resources disease areas unmet medical needs scientific opportunity commercial opportunity merck managing research development portfolio across diverse approaches discovery development balancing investments appropriately novel innovative targets potential major impact human health developing bestinclass approaches delivering maximum value new medicines vaccines new indications new formulations another important component mercks sciencebased diversification based expanding companys portfolio modalities include small molecules vaccines also biologics peptides rnai merck moving diversify portfolio creating new division merck bioventures leverages unique platform followon novel biologics company continue pursue appropriate external licensing opportunities company began implementing new model basic research global operating strategy new model align franchise function clear roles responsibilities align resources disease area priorities balance capacity across discovery phases allow company act upon programs highest probability success additionally strategy designed expand companys access worldwide external science incorporate external research key component companys early discovery pipeline order translate basic research productivity latestage clinical success companys clinical pipeline includes candidates multiple disease areas including anemia atherosclerosis cancer diabetes heart failure hypertension infectious diseases migraine neurodegenerative diseases psychiatric diseases osteoporosis pain respiratory disease company supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies chart reflecting companys current research pipeline february set forth item business research development harebased compensation company recognizes sharebased compensation expense pursuant financial accounting standards board fasb statement r sharebased payment fas r requires sharebased payments employees expensed requisite service period based grantdate fair value awards total pretax sharebased compensation expense million million million december million total pretax unrecognized compensation expense related nonvested stock option restricted stock unit performance share unit awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses r estructuring costs restructuring costs billion million million respectively restructuring costs recorded million related restructuring program remainder associated restructuring program merck incurred separation costs million million related restructuring program million million respectively associated actual headcount reductions well headcount reductions probable could reasonably estimated company eliminated positions related restructuring program positions positions position eliminations comprised actual headcount reductions elimination contractors vacant positions also included restructuring costs curtailment settlement termination charges table contents companys pension postretirement benefit plans shutdown costs segment reporting restructuring costs unallocated expenses e quity income affiliates equity income affiliates reflects performance companys joint ventures partnerships decline equity income affiliates reflects decreased equity income merckscheringplough partnership lower partnership returns azlp partially offset higher equity income merial limited merial spmsd decrease equity income merckscheringplough joint venture result lower revenues vytorin zetia following announcements enhance seas clinical trial results addition result termination respiratory joint venture company obligated schering plough corporation scheringplough amount million specified joint venture agreements resulted charge million second quarter included equity income affiliates remaining amount amortized remaining patent life zetia lower partnership returns azlp primarily attributable first quarter partial redemption mercks interest certain azlp product rights resulted reduction priority return variable returns based part upon sales certain former astra usa inc products higher equity income merial primarily reflects higher sales biological products increase equity income spmsd largely attributable higher sales gardasil joint venture territories outside united states increase equity income affiliates primarily reflects successful performance vytorin zetia merckscheringplough partnership see selected joint venture affiliate information u vioxx settlement agreement charge november merck entered agreement settlement agreement law firms comprise executive committee plaintiffs steering committee federal multidistrict vioxx litigation well representatives plaintiffs counsel state coordinated proceedings resolve state federal myocardial infarction mi ischemic stroke claims already filed company united states settlement agreement company pay aggregate fixed amount billion two funds qualifying claims consisting billion qualifying mi claims million qualifying claims enter resolution process settlement program million paid funds consequence settlement agreement company recorded pretax charge billion see note consolidated financial statements ther income expense net change income expense net primarily due aggregate gain azlp billion see note consolidated financial statements impact million charge related resolution certain civil governmental investigations gain million related sale companys remaining worldwide rights aggrastat partially offset million expense contribution merck company foundation increase exchange losses million higher recognized losses million net companys investment portfolio million charge related resolution investigation whether company violated consumer protection laws respect sales marketing vioxx see note consolidated financial statements fluctuation exchange losses gains primarily due higher cost foreign currency contracts due lower us interest rates unfavorable impacts periodtoperiod changes foreign currency exchange rates net long net short foreign currency positions considering net monetary assets related foreign currency contracts change income expense net compared primarily reflects million charge related resolution certain civil governmental investigations partially offset table contents favorable impact gains sales assets product divestitures well net gain settlements certain patent disputes egment profits millions pharmaceutical segment profits vaccines infectious diseases segment profits segment profits ncome income taxes segment profits comprised segment revenues less certain elements materials production costs operating expenses including components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker company allocate vast majority indirect production costs research development expenses general administrative expenses well cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits gain distribution azlp us vioxx settlement agreement charge taxes paid joint venture level portion equity income additionally segment profits reflect expenses corporate manufacturing cost centers miscellaneous income expense unallocated items reflected table also included miscellaneous corporate profits operating profits related divested products businesses supply sales adjustments eliminate effect double counting certain items income expense pharmaceutical segment profits decreased largely driven lower sales fosamax fosamax plus zocor decreased equity income merckscheringplough joint venture azlp pharmaceutical segment profits increased reflecting higher equity income primarily driven strong performance merckscheringplough partnership partially offset loss us market exclusivity zocor proscar vaccine infectious diseases segment profits increased primarily driven continued successful rollout isentress strong performance rotateq well higher equity income spmsd vaccine infectious diseases segment profits doubled compared driven launch three new vaccines latter part successful performance varivax axes income companys effective income tax rate effective tax rate reflects net favorable impact compared statutory rate approximately percentage points includes favorable impacts relating tax settlements resulted reduction companys liability unrecognized tax benefits approximately million realization foreign tax credits favorable tax impact foreign exchange rate changes fourth quarter particularly strengthening japanese yen us dollar partially offset unfavorable impact resulting azlp gain fully taxable united states combined federal state tax rate approximately first quarter company decided distribute certain prior years foreign earnings united states result utilization foreign tax credits foreign tax credits arose result tax payments made outside united states prior years became realizable first quarter based change companys decision distribute foreign earnings effective tax rate reflects reduction domestic pretax income primarily resulting us vioxx settlement agreement charge related change mix domestic foreign pretax income table contents net income earnings per share millions except per share amounts c hange c hange net income sales average total assets earnings per common share assuming dilution greater n et income earnings per common share net income billion compared billion billion earnings per common share assuming dilution compared increases net income earnings per share compared primarily attributable gain distribution azlp impacts us vioxx settlement agreement civil governmental investigations charges addition increases reflect positive impact certain tax items lower acquired research costs lower expenses legal defense costs partially offset higher restructuring costs lower equity earnings well recognition insurance arbitration gain declines net income earnings per share compared reflect impact us vioxx settlement agreement charge civil governmental investigations charge partially offset lower expenses legal defense costs gain insurance arbitration award related vioxx product liability litigation coverage lower acquired research costs favorable impact gains sales assets product divestitures well net gain settlements certain patent disputes net income eps compared also reflect revenue growth vaccines singulair januvia well higher equity income affiliates net income percentage sales changes percentage sales ratio reflect factors discussed net income percentage average total assets elected joint venture affiliate information expand research base realize synergies combining capabilities opportunities assets previous years company formed number joint ventures see note consolidated financial statements erckscheringplough partnership company scheringplough collectively partners entered agreements create separate equallyowned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas agreements generally provide equal sharing development costs copromotion approved products company cholesterol management partnership agreements expanded include countries world excluding japan ezetimibe first new class cholesterollowering agents launched united states zetia marketed ezetrol outside united states combination product containing active ingredients zetia zocor approved united states vytorin marketed inegy outside united states vytorin combination tablet cholesterol treatment provide ldl cholesterol lowering dual inhibition cholesterol production absorption cholesterol agreements provide sharing operating income generated merckschering plough cholesterol partnership msp partnership based upon percentages vary product sales level country us market partners share profits zetia vytorin sales equally exception first million annual zetia sales scheringplough receives greater share profits operating income includes expenses partners contractually agreed share portion manufacturing costs specifically identified promotion costs including directtoconsumer advertising direct identifiable outofpocket promotion agreed upon costs specific services ongoing clinical research market support market research market expansion well specialty sales force physician education programs expenses incurred support msp partnership shared table contents partners marketing administrative expenses including certain sales force costs well certain manufacturing costs included equity income affiliates however costs reflected overall results company certain research development expenses generally shared equally partners adjusting earned milestones sales joint venture products follows millions vytorin zetia global sales vytorin declined grew global sales zetia decreased increased following announcements enhance seas clinical trial results discussed sales vytorin zetia declined previously disclosed january company announced results effect combination ezetimibe highdose simvastatin vs simvastatin alone atherosclerotic process patients heterozygous familial hypercholesterolemia enhance clinical trial imaging trial patients heterozygous familial hypercholesterolemia rare genetic condition causes high levels ldl bad cholesterol greatly increases risk premature coronary artery disease previously reported despite fact ezetimibesimvastatin mg vytorin significantly lowered ldl bad cholesterol simvastatin mg alone significant difference treatment ezetimibesimvastatin simvastatin alone prespecified primary endpoint change thickness carotid artery walls two years measured ultrasound also significant differences treatment ezetimibesimvastatin simvastatin four prespecified key secondary endpoints percent patients manifesting regression average carotid artery intimamedia thickness ca imt proportion patients developing new carotid artery plaques mm changes average maximum ca imt changes average ca imt plus average common femoral artery imt enhance compared simvastatin alone ezetimibesimvastatin significantly lowered ldl bad cholesterol well triglycerides creactive protein crp ezetimibesimvastatin indicated reduction crp enhance study overall safety profile ezetimibesimvastatin generally consistent product label enhance study designed powered evaluate cardiovascular clinical events improved reduction highrisk subjects presenting acute coronary syndrome improveit trial underway designed provide cardiovascular outcomes data ezetimibesimvastatin patients acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrated simvastatin established march results enhance reported annual scientific session american college cardiology july efficacy safety results simvastatin ezetimibe aortic stenosis seas study announced seas designed evaluate whether intensive lipid lowering vytorin mg would reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patients asymptomatic mild moderate aortic stenosis indication statin therapy vytorin failed meet primary end point reduction major cardiovascular events also significant difference key secondary end point aortic valve events however reduction group patients taking vytorin compared placebo key secondary end point ischemic cardiovascular events vytorin indicated treatment aortic stenosis incremental benefit vytorin cardiovascular morbidity mortality demonstrated simvastatin established study patients group took vytorin mg higher incidence cancer group took placebo also nonsignificant increase deaths cancer patients group took vytorin versus took placebo cancer cancer deaths distributed across major organ systems company believes cancer finding seas likely anomaly taken light available data support association vytorin august fda announced investigating results seas trial announcement fda also cited interim data two large ongoing table contents cardiovascular trials vytorin study heart renal protection sharp improveit clinical trials increased risk cancer combination simvastatin plus ezetimibe sharp trial expected completed improveit trial scheduled completion around fda determined time findings seas trial plus interim data ongoing trials prompt patients stop taking vytorin cholesterol lowering drug company msp partnership committed working regulatory agencies evaluate available data interpretations data however company believe changes clinical use vytorin warranted see note consolidated financial statements information respect litigation involving partners msp partnership related sale promotion zetia vytorin respiratory therapeutic agreements provided joint development marketing united states partners oncedaily fixedcombination tablet containing active ingredients montelukast sodium loratadine montelukast sodium leukotriene receptor antagonist sold merck singulair loratadine antihistamine sold scheringplough claritin indicated relief symptoms allergic rhinitis partners received notapprovable letter fda proposed fixed combination loratadinemontelukast subsequently announced withdrawal nda combination tablet companies also terminated respiratory joint venture action impact business cholesterol joint venture result termination respiratory joint venture company obligated scheringplough amount million specified joint venture agreements resulted charge million second quarter included equity income affiliates remaining amount amortized remaining patent life zetia results companys interest msp partnership recorded equity income affiliates merck recognized equity income billion billion billion financial statements msp partnership included item financial statement schedules strazeneca lp merck entered agreement astra ab astra develop market astras products royaltybearing license companys total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining merck astra completed restructuring ownership operations joint venture whereby company acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns ongoing revenue based sales current future kbi products revenue billion billion billion respectively primarily relating sales nexium well prilosec addition merck earns certain partnership returns recorded equity income affiliates returns include priority return provided partnership table contents agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings returns aggregated million million million respectively astrazeneca merger triggered partial redemption march mercks interest certain azlp product rights upon redemption merck received billion azlp amount based primarily multiple mercks average annual variable returns derived sales former astra usa inc products three years prior redemption limited partner share agreed value merck recorded billion pretax gain partial redemption partial redemption mercks interest product rights result change mercks limited partner interest conjunction restructuring astra purchased option asset option payment million recorded deferred income buy mercks interest kbi products excluding gastrointestinal medicines nexium prilosec nonppi products asset option exercisable first half exercise price equal net present value march projected future pretax revenue received company nonppi products appraised value merck also right require astra purchase interest appraised value february company advised azlp would exercise asset option thus million remains deferred addition company granted astra option shares option buy mercks common stock interest kbi therefore mercks interest nexium prilosec exercisable two years astras exercise asset option astra also exercise shares option combined annual sales two products fall minimum amount provided case long astrazenecas asset option exercised exercise price shares option based net present value estimated future net sales nexium prilosec determined time exercise subject certain trueup mechanisms astrazeneca merger constituted trigger event kbi restructuring agreements result merger exchange mercks relinquishment rights future astra products existing pending us patents time merger astra paid million advance payment advance payment deferred remained subject trueup calculation trueup amount directly dependent fair market value march astra product rights retained company calculated trueup amount million returned azlp march merck recognized pretax gain million related residual advance payment balance provisions kbi restructuring agreements trigger event occurred sum limited partner share agreed value appraised value trueup amount guaranteed minimum billion distribution limited partner share agreed value less payment trueup amount resulted cash receipts merck billion aggregate pretax gain billion included income expense net astrazenecas purchase mercks interest nonppi products contingent upon exercise asset option astrazeneca therefore payment appraised value may may occur also march billion outstanding loan astra plus interest redemption date settled result transactions company received net proceeds azlp billion erial limited merck rhnepoulenc sa sanofiaventis sa combined animal health businesses form merial limited merial fully integrated animal health company standalone joint venture owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species table contents sales joint venture products follows millions fipronil products biological products avermectin products products anofi pasteur msd merck pasteur merieux connaught sanofi pasteur sa established owned joint venture market vaccines europe collaborate development combination vaccines distribution europe merck launched three new vaccines approved use eu marketed spmsd certain western european countries gardasil help prevent cervical vulvar vaginal cancers precancerous dysplastic lesions genital warts caused hpv types rotateq help protect rotavirus gastroenteritis infants children zostavax help prevent shingles herpes zoster individuals years age older sales joint venture products follows millions gardasil viral vaccines hepatitis vaccines vaccines j ohnson johnsonmerck consumer pharmaceuticals company merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned joint venture subsequently expanded canada significant joint venture products pepcid ac overthecounter form companys ulcer medication pepcid well pepcid complete overthecounter product combines companys ulcer medication antacids sales joint venture products follows millions gastrointestinal products products c apital expenditures capital expenditures billion billion million expenditures united states million million million expenditures included million production facilities million research development facilities million environmental projects million administrative safety general site projects approximately represents capital investments related multiyear initiative standardize companys information systems capital expenditures estimated billion table contents depreciation expense billion billion billion billion billion billion respectively applied locations united states total depreciation expense included accelerated depreciation million million million respectively associated restructuring programs see note consolidated financial statements nalysis liquidity capital resources mercks strong financial profile enables company fully fund research development focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders elected data millions working capital total debt total liabilities equity cash provided operations total debt cash provided operating activities billion billion billion continues companys primary source funds finance capital expenditures treasury stock purchases dividends paid stockholders cash provided operating activities reflects billion received connection partial redemption companys partnership interest azlp discussed representing distribution companys accumulated earnings investment azlp since inception cash provided operating activities also impacted million payment made connection previously disclosed resolution investigations civil claims federal state authorities relating certain past marketing selling activities million payments vioxx settlement funds cash provided operating activities reflects payment made previously disclosed settlement internal revenue service irs cash used investing activities billion compared billion lower use cash investing activities primarily reflects distribution azlp representing return companys investment azlp billion payment connection december acquisition sirna therapeutics inc partially offset higher net purchases securities investments higher capital expenditures increase restricted assets cash used financing activities billion compared billion reflecting higher purchases treasury stock lower proceeds exercise stock options higher payments debt connection settlement note due astra partially offset net increase shortterm borrowings december total worldwide cash investments billion including billion cash cash equivalents shortterm investments billion longterm investments addition company billion cash investments restricted certain collateral arrangements discussed working capital levels adequate meet operating requirements company increase working capital primarily attributable net cash receipts azlp discussed selected joint venture affiliate information ratios total debt total liabilities equity cash provided operations total debt reflect strength companys operating cash flows ability company cover contractual obligations august company executed billion letter credit agreement financial institution satisfied certain conditions set forth us vioxx settlement agreement see note consolidated financial statements company pledged collateral financial institution approximately billion pursuant terms letter credit agreement although amount assets pledged collateral set letter credit agreement assets held custody third party assets table contents managed company company considers assets pledged letter credit agreement restricted result billion billion cash investments respectively classified restricted current assets billion investments classified restricted noncurrent assets letter credit amount required collateral balances decline payments first million settlement agreement made december billion recorded within deferred income taxes current assets billion classified assets additionally company paid million vioxx settlement funds pursuant settlement agreement previously disclosed irs completed examination companys tax returns years result examination company made aggregate payment billion february payment offset tax refund million received amounts previously paid matters ii federal tax benefit approximately million related interest included payment resulting net cash cost company approximately billion impact years subsequent items reviewed part examination included payment although years remain open respects closing irs examination material impact companys results operations amounts previously accrued previously disclosed october cra issued company notice reassessment containing adjustments related certain intercompany pricing matters february merck cra negotiated settlement agreement regard matters settlement calls merck pay additional tax approximately million us dollars interest approximately million us dollars additional amounts penalties due assessment accordance fasb interpretation accounting uncertainty income taxes interpretation fasb statement fin settlement accounted first quarter company previously established reserves matters significant portion taxes paid expected creditable us tax purposes resolution matters material effect companys financial position liquidity respect associated collateral discussed addition july november cra proposed additional adjustments respectively relating intercompany pricing matters adjustments would increase canadian tax due approximately million us dollars plus million us dollars interest possible cra propose similar adjustments later years company disagrees positions taken cra believes without merit company intends contest assessments cra appeals process courts necessary management believes resolution matters material effect companys financial position liquidity connection appeals process company pledged collateral two financial institutions one provided guarantee cra quebec ministry revenue representing portion tax interest assessed collateral included deferred income taxes current assets assets consolidated balance sheet totaled approximately billion billion december respectively guarantees reduced related collateral released following payments cra quebec ministry revenue causing restricted amounts reclassified cash investments appropriate consolidated balance sheet irs examining companys federal income tax returns addition various state foreign tax examinations progress tax years remain subject examination major tax jurisdictions include germany italy japan table contents companys contractual obligations december follows p ayments due period millions total hereafter purchase obligations loans payable current portion longterm debt longterm debt us vioxx settlement agreement unrecognized tax benefits operating leases timing payments us vioxx settlement agreement may vary depending timing claims assessment process december companys consolidated balance sheet reflects liabilities unrecognized tax benefits interest penalties billion including billion reflected current liability largely reflecting amounts related settlement canadian revenue agency discussed due high degree uncertainty regarding timing future cash outflows liabilities unrecognized tax benefits beyond one year reasonable estimate period cash settlement years beyond made purchase obligations consist primarily goods services enforceable legally binding include obligations minimum inventory contracts research development advertising amounts reflected research development obligations include contingent milestone payments loans payable current portion longterm debt also reflects million longdated notes subject repayment option holders annual basis required funding obligations relating companys pension postretirement benefit plans expected material however company currently anticipates contributing million million respectively pension plans postretirement benefit plans december companys existing shelf registration filed securities exchange commission sec expired company intends file new shelf registration april company extended maturity date billion year revolving credit facility april april facility provides backup liquidity companys commercial paper borrowing facility general corporate purposes company drawn funding facility companys longterm credit ratings assigned moodys investors service standard poors aa stable outlook aa stable outlook respectively ratings continue allow access capital markets flexibility obtaining funds competitive terms company continues maintain conservative financial profile total cash investments billion exceed sum loans payable long term debt billion company places cash investments instruments meet high credit quality standards specified investment policy guidelines guidelines also limit amount credit exposure one issuer despite strong financial profile certain contingent events realized discussed note consolidated financial statements could material adverse impact companys liquidity capital resources company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations july board directors approved purchases time billion merck shares total treasury stock purchased program billion december billion remains stock repurchase authorization approved merck board directors table contents financial instruments market risk disclosures f oreign currency risk management us dollar functional currency companys foreign subsidiaries significant portion companys revenues denominated foreign currencies merck relies sustained cash flows generated foreign sources support longterm commitment us dollarbased research development extent dollar value cash flows diminished result strengthening dollar companys ability fund research dollarbased strategic initiatives consistent level may impaired company established revenue hedging balance sheet risk management programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company partially hedge anticipated thirdparty sales expected occur planning cycle typically three years future company layer hedges time increasing portion sales hedged gets closer expected date transaction probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged risk manner merck manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows offset decline expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase value anticipated foreign currency cash flows weaker us dollar would result net benefit market value companys hedges would declined million million respectively uniform weakening us dollar december market value determined using foreign exchange option pricing model holding factors except exchange rates constant merck principally uses purchased local currency put options uniform weakening us dollar yield largest overall potential loss market value options sensitivity measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows primary objective balance sheet risk management program protect us dollar value foreign currency denominated net monetary assets effects volatility foreign exchange might occur prior conversion us dollars merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange amount us dollar cash flows derived net assets merck routinely enters contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level company uses forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly weakened currency exposures company december income taxes would declined million table contents million respectively merck net short position relative major foreign currencies consideration forward contracts uniform weakening us dollar yield largest overall potential net loss earnings due exchange measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows nterest rate risk management addition revenue hedging balance sheet risk management programs company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party two payfloating receivefixed interest rate swap contracts maturing notional amounts million designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes swaps effectively convert fixedrate obligations floating rate instruments company terminated four interest rate swap contracts notional amounts million terminated one interest rate swap contract notional amount million swaps effectively converted billion fixedrate notes due million fixed rate notes due variable rate debt result swap terminations company received million cash excluding accrued interest material corresponding gains related basis adjustment debt associated terminated swap contracts deferred amortized reduction interest expense remaining term notes cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly impacted changes interest rates market value companys medium longterm fixedrate investments modestly impacted changes us interest rates changes medium longterm us interest rates significant impact market value companys fixed rate borrowings generally longer maturities sensitivity analysis measure potential changes market value companys investments debt related swap contracts change interest rates indicated one percentage point increase interest rates december would positively impacted net aggregate market value instruments million million respectively one percentage point decrease december would negatively impacted net aggregate market value million million respectively fair value companys debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair values companys investments determined using combination pricing duration models c ritical accounting policies matters companys consolidated financial statements include certain amounts based managements best estimates judgments estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions amounts recorded connection acquisitions restructuring costs impairments longlived assets investments taxes income uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements r evenue recognition revenues sales products recognized time delivery title risk loss passes customer recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct table contents discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale provision aggregate indirect customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases directly intermediary wholesaler contracted customer generally purchases product contracted price plus markup wholesaler wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision based expected payments driven patient usage contract performance benefit provider customers company assumes firstin firstout movement inventory within supply chain purposes estimating aggregate indirect customer discount accrual addition company uses historical customer segment mix adjusted known events order estimate expected provision amounts accrued aggregate indirect customer discounts evaluated quarterly basis comparison information provided wholesalers customers amounts accrued adjustments recorded trends significant events indicate change estimated provision appropriate company continually monitors provision aggregate indirect customer discounts material adjustments estimates associated aggregate indirect customer discount provision summarized information changes aggregate indirect customer discount accrual follows millions balance january current provision adjustments prior years payments b alance december accruals chargebacks reflected direct reduction accounts receivable accruals rebates current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million million respectively december million million respectively december company maintains returns policy allows customers return product within specified period prior subsequent expiration date generally six months twelve months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market additional generic competition changes formularies launch overthecounter products among others product returns provision well actual returns less net sales distribution program us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories specified levels terms program allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing product returns information provided wholesaler distribution program includes items sales trends inventory onhand onorder quantity product returns table contents wholesalers generally provide mentioned data company regulatory requirement report lot level information manufacturers level information needed determine remaining shelf life original sale date inventory given current wholesaler inventory levels generally less month company believes collection order lot information across wholesale customers would limited use estimating sales discounts returns nventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support initial market demand typically capitalization inventory begin related product candidates phase iii clinical trials considered high probability regulatory approval company monitors status respective product within regulatory approval process however company generally disclose specific timing regulatory approval company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory impacted stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support realization inventory value inventory shelf life sufficient meet initial product launch requirements inventories produced preparation product launches capitalized december significant c ontingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable december company aggregate reserve approximately billion vioxx reserve settlement program companys future legal defense costs worldwide related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation see note consolidated financial statements company spent approximately million aggregate legal defense costs worldwide related vioxx litigation fourth quarter company recorded charge million solely future legal defense costs related vioxx litigation addition fourth quarter company paid additional million settlement funds connection settlement program paid million settlement funds third quarter consequently december aggregate amount vioxx reserve approximately billion adding vioxx reserve solely future legal defense costs company considered factors considered previously established reserves vioxx litigation significant factors considered review vioxx reserve follows actual costs incurred company development companys legal defense strategy structure light scope vioxx litigation including settlement agreement expectation certain lawsuits continue pending number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials vioxx ligation amount vioxx reserve december allocated solely defense costs represents companys best estimate minimum amount defense costs incurred connection remaining aspects vioxx litigation however events additional trials vioxx litigation events could arise course vioxx litigation could affect ultimate amount defense table contents costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase vioxx reserve time future based upon factors set forth believes would appropriate company currently anticipates two us vioxx product liability lawsuits tried except respect product liability trial scheduled held australia company predict timing trials related vioxx litigation company believes meritorious defenses vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits included settlement program company established reserves potential liability relating vioxx lawsuits included settlement program vioxx investigations cases company believes strong points raise appeal therefore unfavorable outcomes cases probable unfavorable outcomes vioxx litigation could material adverse effect companys financial position liquidity results operations december company remaining reserve approximately million solely future legal defense costs fosamax litigation company spent approximately million added million reserve consequently december company reserve approximately million solely future legal defense costs fosamax litigation significant factors considered establishment reserve fosamax litigation legal defense costs follows actual costs incurred company thus far development companys legal defense strategy structure light creation fosamax multidistrict litigation number cases brought company anticipated timing progression related costs pretrial activities fosamax litigation company continue monitor legal defense costs review adequacy associated reserves due uncertain nature litigation company unable estimate costs beyond completion first three federal trials discussed note consolidated financial statements company established reserves potential liability relating fosamax litigation unfavorable outcomes fosamax litigation could material adverse effect companys financial position liquidity results operations company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted site investigations feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying providing costs worldwide survey initially performed assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated estimates extent contamination site initially made preinvestigation stage liabilities potential cost remediation accrued time definitive information became available course investigations andor remedial efforts site estimates refined accruals adjusted accordingly estimates related accruals continue refined annually company believes compliance material respects applicable environmental laws regulations expenditures remediation environmental liabilities million estimated million years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation table contents applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year harebased compensation company recognizes compensation cost accordance fas r requires sharebased payments employees including grants stock options expensed requisite service period based grant date fair value awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options p ensions postretirement benefit plans net pension postretirement benefit cost totaled million million million decrease million primarily due lower amortization actuarial net losses higher expected return plan assets partially offset increase termination benefits attributable companys restructuring actions pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due december discount rates companys us pension plans us postretirement benefit plans ranged compared range december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data well actual returns companys plan assets using reference information company develops forwardlooking return expectations asset category weighted average expected longterm rate return target portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate result analysis companys expected rate return remained unchanged us pension postretirement benefit plans target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligation expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests actual return plan assets pension postretirement benefit plans reflects allocation global equity markets delivered significant negative returns actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact us net pension postretirement benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact us net pension postretirement benefit cost company expect minimum pension funding table contents requirement internal revenue code preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions recorded component accumulated comprehensive income expected returns pension plans based calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns recognized marketrelated value assets ratably fiveyear period also net loss amounts accumulated comprehensive income excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees amortization net losses companys us plans december expected increase net pension postretirement benefit cost approximately million annually cquisitions company accounts acquired businesses using purchase method accounting accordance fas business combinations requires assets acquired liabilities assumed recorded date acquisition respective fair values excess purchase price estimated fair values net assets acquired recorded goodwill company determines acquired company development stage company commenced planned principal operations acquisition accounted acquisition assets rather business combination therefore goodwill would recorded fair value intangible assets including acquired research based significant judgments made management accordingly significant items company typically obtains assistance third party valuation specialists amounts allocated acquired research expensed date acquisition technological feasibility established alternative future use exists projects used immediately research process alternative future uses company capitalizes intangible assets amortizes appropriate useful life valuations useful life assumptions based information available near acquisition date based expectations assumptions deemed reasonable management judgments made determining estimated fair values assigned assets acquired liabilities assumed well asset lives materially impact companys results operations intangible assets including acquired research company typically uses income approach estimates fair value based projects projected cash flows future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent expected revenues adjusted probability technical marketing success resulting cash flows discounted risk adjusted discount rate january company adopted fasb statement r business combinations fas r changes way assets liabilities recognized purchase accounting prospective basis see recently issued accounting standards r estructuring costs company recorded restructuring costs connection global restructuring programs designed reduce companys cost structure increase efficiency enhance competitiveness result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place connection actions management also assesses recoverability longlived assets employed business certain instances asset lives shortened based changes expected useful lives affected assets severance related costs reflected within restructuring costs assetrelated charges reflected within materials production costs research development expenses depending upon nature asset table contents impairments longlived assets company assesses changes economic conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets company periodically evaluates whether current facts circumstances indicate carrying values longlived assets held used recoverable accordance fasb statement accounting impairment disposal longlived assets circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows approach company tests goodwill impairment least annually accordance fasb statement goodwill intangible assets using fair value based test goodwill represents excess acquisition costs fair value net assets businesses purchased assigned reporting units within companys segments acquired intangibles recorded cost events circumstances warrant review company assess recoverability future operations intangibles using undiscounted cash flows derived lowest appropriate asset groupings generally subsidiary level impairments recognized operating results extent carrying values exceed fair value determined based net present value estimated cash flows mpairments investments company reviews investments impairments based determination whether decline market value investment carrying value temporary company considers available evidence evaluating potential impairments investments including duration extent fair value less cost companys ability intent hold investments f air value measurements january company adopted fasb statement fair value measurements fas clarifies definition fair value establishes framework measuring fair value expands disclosures fair value measurements fas establishes fair value hierarchy requires entity maximize use observable inputs minimize use unobservable inputs measuring fair value fas describes three levels inputs may used measure fair value see note consolidated financial statements december companys level assets million primarily include mortgagebacked assetbacked securities well certain corporate notes bonds decrease observability market pricing investments january company million invested shortterm fixed income fund fund due market liquidity conditions cash redemptions fund restricted result restriction cash redemptions company consider fund traded active market observable pricing january amounts categorized level january company elected redeemedinkind fund received share underlying securities fund result million underlying securities transferred level determined securities observable markets december million investment securities associated redemptioninkind remained classified level approximately companys investment securities securities contained least one significant input unobservable pledged certain collateral arrangements see note consolidated financial statements securities account entire balance companys level assets december securities valued primarily using pricing models management understands methodologies models incorporate transaction details contractual terms maturity timing amount future cash inflows well assumptions liquidity credit valuation adjustments marketplace participants december table contents taxes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual onetime item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys tax provision evaluating tax positions recognition measurement tax position based managements best judgment given facts circumstances information available reporting date accordance fin company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements likely threshold met period tax position taken company may subsequently recognize benefit tax position tax matter effectively settled statute limitations expires likely threshold met subsequent period see note consolidated financial statements tax regulations require items included tax return different times items reflected financial statements timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income taxes would payable upon distribution earnings r ecently issued accounting standards december fasb issued fas r expands scope acquisition accounting transactions control business obtained standard requires acquirer recognize assets acquired liabilities assumed acquisition date fair values limited exceptions additionally fas r requires contingent consideration well contingent assets liabilities recorded fair value acquisition date acquired inprocess research development capitalized recorded intangible assets acquisition date also requires transaction costs costs restructure acquired company expensed fas r effective prospective basis january future transactions accounted standard december fasb issued statement noncontrolling interests consolidated financial statements amendment arb fas provides guidance accounting reporting disclosure noncontrolling interests requires among things noncontrolling interests recorded equity consolidated financial statements fas effective prospective basis january exception presentation disclosure requirements fas must applied retrospectively adoption standard result reclassification billion minority interests referred noncontrolling interests separate component stockholders equity consolidated balance sheet additionally net income attributable noncontrolling interests shown separately parent net income consolidated statement income december fasb ratified consensus reached emerging issues task force eitf issue accounting collaborative arrangements eitf eitf effective january applied retrospectively prior periods presented collaborative arrangements existing effective date eitf defines collaborative arrangements establishes reporting requirements table contents transactions participants collaborative arrangement participants arrangement third parties effect adoption eitf expected material companys financial position results operations march fasb issued statement disclosures derivative instruments hedging activities fas effective january fas requires enhanced disclosures derivative instruments hedging activities allow better understanding effects entitys financial position financial performance cash flows among things fas requires disclosure fair values derivative instruments associated gains losses tabular format since fas requires additional disclosures companys derivatives hedging activities adoption fas affect companys financial position results operations june fasb issued staff position eitf determining whether instruments granted sharebased payment transactions participating securities fsp eitf effective january fsp eitf clarifies sharebased payment awards entitle holders receive nonforfeitable dividends vest considered participating securities therefore included basic earnings per share calculation effect adoption fsp eitf expected material companys results operations november fasb issued eitf equity method investment accounting considerations eitf eitf clarifies accounting certain transactions impairment considerations involving equity method investments eitf effective january applied prospective basis future transactions november fasb issued eitf accounting defensive intangible assets eitf clarifies defensive intangible asset accounted separate unit accounting assigned useful life reflects entitys consumption expected benefits related asset eitf effective january applied prospective basis future transactions december fasb issued staff position fas r employers disclosures postretirement benefit plan assets fsp fas r effective december fsp fas r amends fasb statement r employers disclosures pensions postretirement benefits provide guidance employers disclosures plan assets defined pension postretirement plan fsp fas r requires disclosures plan assets including investment allocation decisions made major categories plan assets inputs valuation techniques used measure fair value plan assets effect fair value measurements using significant unobservable inputs level changes plan assets period significant concentrations risk within plan assets since fsp fas r requires additional disclosures companys pension postretirement plan assets adoption fsp fas r affect companys financial position results operations c autionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forward looking statement guaranteed actual future results may vary materially table contents company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms k q k item risk factors annual report company discusses detail various important risk factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties tem quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations table contents tem financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income retained earnings comprehensive income cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows c onsolidated statement income merck co inc subsidiaries years ended december millions except per share amounts ales c osts expenses materials production marketing administrative research development restructuring costs equity income affiliates us vioxx settlement agreement charge income expense net ncome taxes taxes income n et income basic earnings per common share earnings per common share assuming dilution c onsolidated statement retained earnings merck co inc subsidiaries years ended december millions b alance january c umulative effect adoption fin net income dividends declared common stock b alance december c onsolidated statement comprehensive income merck co inc subsidiaries years ended december millions n et income ther comprehensive loss income net unrealized gain loss derivatives net tax net income realization net unrealized loss gain investments net tax net income realization benefit plan net loss gain prior service cost credit net tax amortization minimum pension liability net tax cumulative translation adjustment relating equity investees net tax comprehensive income accompanying notes integral part consolidated financial statements table contents consolidated balance sheet merck co inc subsidiaries december millions ssets current assets cash cash equivalents shortterm investments accounts receivable including nontrade receivables inventories excludes inventories classified assets see note deferred income taxes current assets otal current assets nvestments p roperty plant equipment cost land buildings machinery equipment office furnishings construction progress less allowance depreciation g oodwill ther intangibles net ther assets liabilities stockholders equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable otal current liabilities l ongterm debt eferred income taxes noncurrent liabilities inority interests tockholders equity common stock one cent par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive loss less treasury stock cost shares shares otal stockholders equity accompanying notes integral part consolidated financial statement table contents consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities net income adjustments reconcile net income net cash provided operating activities gain distribution astrazeneca lp equity income affiliates dividends distributions equity affiliates us vioxx settlement agreement charge depreciation amortization deferred income taxes sharebased compensation acquired research taxes paid internal revenue service settlement net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities n et cash provided operating activities c ash flows investing activities capital expenditures purchases securities investments proceeds sales securities investments acquisitions subsidiaries net cash acquired distribution astrazeneca lp increase restricted assets n et cash used investing activities c ash flows financing activities net change shortterm borrowings proceeds issuance debt payments debt purchases treasury stock dividends paid stockholders proceeds exercise stock options n et cash used financing activities e ffect exchange rate changes cash cash equivalents n et decrease cash cash equivalents cash cash equivalents beginning year c ash cash equivalents end year accompanying notes integral part consolidated financial statement table contents notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck global researchdriven pharmaceutical company discovers develops manufactures markets broad range innovative products improve human animal health companys operations principally managed products basis comprised two reportable segments pharmaceutical segment vaccines infectious diseases segment pharmaceutical segment includes human health pharmaceutical products marketed either directly merck joint ventures products consist therapeutic preventive agents sold prescription treatment human disorders merck sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccines infectious diseases segment includes human health vaccine infectious disease products marketed either directly merck case vaccines also joint venture vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices merck sells human health vaccines primarily physicians wholesalers physician distributors government entities infectious disease products consist therapeutic agents treatment infection sold primarily drug wholesalers retailers hospitals government agencies companys professional representatives communicate effectiveness safety value pharmaceutical vaccine products health care professionals private practice group practices managed care organizations summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained intercompany balances transactions eliminated controlling interest determined majority ownership interest absence substantive third party participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside stockholders interests shown minority interests investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis foreign currency translation us dollar functional currency companys foreign subsidiaries cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories inventories valued lower cost market cost substantially domestic inventories determined using lastin firstout lifo method book tax purposes cost inventories determined using firstin firstout fifo method inventories consist currently marketed products certain products awaiting regulatory approval evaluating recoverability inventories produced preparation product launches company considers probability revenue obtained future sale related inventory together status product within regulatory approval process investments investments marketable debt equity securities classified availableforsale reported fair value january company adopted financial accounting standards board fasb statement fair value measurements fas clarifies definition fair value establishes framework measuring fair value expands disclosures fair value measurements fas defines fair value exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date fas also establishes fair value hierarchy requires entity maximize use observable inputs minimize use unobservable inputs measuring fair value table contents fair value companys investments determined using quoted market prices active markets identical assets liabilities quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities declines fair value considered otherthantemporary impairment losses charged income expense net declines fair value considered temporary extent hedged reported net tax accumulated comprehensive income aoci company considers available evidence evaluating potential impairment investments including duration extent fair value less cost companys ability intent hold investment realized gains losses included income expense net revenue recognition revenues sales products recognized time delivery title risk loss passes customer recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale accruals chargebacks reflected direct reduction accounts receivable accruals rebates recorded current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million million respectively december million million respectively december company recognizes revenue sales vaccines federal government placement stockpiles related pediatric vaccine stockpile accordance securities exchange commission sec interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings software capitalization company capitalizes certain costs incurred connection obtaining developing internaluse software including external direct costs material services payroll costs employees directly involved software development accordance statement position accounting costs computer software developed obtained internal use capitalized software costs included property plant equipment amortized beginning asset substantially ready use capitalized software costs associated companys multiyear implementation enterprisewide resource planning system amortized years december company approximately million million respectively remaining unamortized capitalized software costs associated initiative capitalized software costs amortized periods ranging years costs incurred preliminary project stage postimplementation stage well maintenance training costs expensed incurred acquisitions company accounts acquired businesses using purchase method accounting accordance fasb statement business combinations requires assets acquired liabilities assumed recorded date acquisition respective fair values excess purchase price estimated fair values net assets acquired recorded goodwill company determines acquired company development stage company commenced planned principal operations acquisition accounted acquisition assets rather business combination therefore goodwill would recorded accordance fasb interpretation applicability fasb statement business combinations accounted purchase method company allocates amounts acquired research expensed date acquisition technological feasibility established alternative future use exists projects used immediately research process alternative future uses company capitalizes intangible assets amortizes appropriate useful life operating results acquired business reflected companys consolidated financial table contents statements results operations date acquisition january company adopted fasb statement r business combinations changes way assets liabilities recognized purchase accounting prospective basis see recently issued accounting standards goodwill intangibles goodwill represents excess acquisition costs fair value net assets businesses purchased goodwill assigned reporting units within companys segments evaluated impairment least annual basis using fair value based test acquired intangibles recorded cost amortized straightline basis estimated useful lives ranging years see note events circumstances warrant review company assess recoverability future operations intangibles using undiscounted cash flows derived lowest appropriate asset groupings generally subsidiary level impairments recognized operating results extent carrying value exceeds fair value determined based net present value estimated future cash flows research development research development expensed incurred upfront milestone payments due third parties connection research development collaborations prior regulatory approval expensed incurred payments due third parties upon subsequent regulatory approval capitalized amortized shorter remaining license product patent life january company adopted emerging issues task force eitf issue accounting advance payments goods services received use future research development activities requires nonrefundable advance payments goods services used future research development activities expensed activity performed goods received rather payment made see recently issued accounting standards sharebased compensation company expenses sharebased payments employees including grants stock options requisite service period based grantdate fair value awards restructuring costs company records restructuring activities including costs onetime termination benefits accordance fasb statement accounting costs associated exit disposal activities employee termination benefits covered existing benefit arrangements recorded accordance fasb statement employers accounting postemployment benefits amendment fasb statement fasb statement employers accounting settlements curtailments defined benefit pension plans termination benefits employee termination costs recorded actions probable estimable asset impairment costs recorded accordance fasb statement accounting impairment disposal longlived assets contingencies legal defense costs company records accruals contingencies legal defense costs expected incurred connection loss contingency probable liability incurred amount reasonably estimated accordance fasb statement accounting contingencies taxes income deferred taxes recognized future tax effects temporary differences financial income tax reporting based enacted tax laws rates company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions amounts recorded connection acquisitions restructuring costs impairments longlived assets investments table contents taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation recently adopted accounting standards company adopted fasb statement fair value measurements fas statement fair value option financial assets financial liabilities including amendment fasb statement fas statement hierarchy generally accepted accounting principles fas eitf issue accounting advance payments goods services received use future research development activities eitf fasb staff position fas fin r disclosures public entities enterprises transfers financial assets interests variable interest entities fsp fas fin r january company adopted fas clarifies definition fair value establishes framework measuring fair value expands disclosures fair value measurements february fasb issued staff position effective date fasb statement fsp deferred effective date fas one year nonfinancial assets liabilities recorded fair value nonrecurring basis effect adoption fas financial assets liabilities recognized fair value recurring basis material impact companys financial position results operations see note effect adoption fsp companys financial position results operations expected material october fasb issued staff position determining fair value financial asset market asset active fsp clarifies application fas market active fsp effective upon issuance effect adoption companys financial position results operations material january company adopted fas permits companies make irrevocable election measure certain financial assets financial liabilities fair value unrealized gains losses items fair value option elected reported earnings subsequent reporting date company elect fair value option fas financial assets liabilities upon adoption subsequent period fourth quarter company adopted fas identifies sources accounting principles framework selecting principles used order authority preparation financial statements presented conformity generally accepted accounting standards united states effect adoption fas companys financial statements material january company adopted eitf applied prospectively new contracts eitf addresses nonrefundable advance payments goods services used rendered future research development activities eitf requires payments deferred capitalized recognized expense related goods delivered related services performed effect adoption eitf companys financial position results operations material december company adopted fsp fas fin r amends fasb statement accounting transfers servicing financial assets extinguishment liabilities require additional disclosures transfers financial assets fsp fas fin r also amends fasb interpretation r consolidation variable interest entities include additional disclosures public entitys involvement variable interest entities effect adoption fsp fas fin r impact companys disclosures recently issued accounting standards fasb recently issued statement r business combinations fas r statement noncontrolling interests consolidated financial statements amendment arb fas statement disclosures derivative instruments hedging activities fas staff position eitf determining whether instruments granted share based payment transactions participating securities fsp eitf staff position fas r employers disclosures postretirement benefit plan assets fsp fas r ratified consensus reached eitf issue accounting collaborative arrangements eitf issue table contents equity method investment accounting considerations eitf issue accounting defensive intangible assets eitf fas r expands scope acquisition accounting transactions control business obtained standard requires acquirer recognize assets acquired liabilities assumed acquisition date fair values limited exceptions additionally fas r requires contingent consideration well contingent assets liabilities recorded fair value acquisition date acquired inprocess research development capitalized recorded intangible assets acquisition date also requires transaction costs costs restructure acquired company expensed fas r effective prospective basis january future transactions accounted standard fas provides guidance accounting reporting disclosure noncontrolling interests requires among things noncontrolling interests recorded equity consolidated financial statements fas effective prospective basis january exception presentation disclosure requirements fas must applied retrospectively adoption standard result reclassification billion minority interests referred noncontrolling interests separate component stockholders equity consolidated balance sheet additionally net income attributable noncontrolling interests shown separately parent net income consolidated statement income fas effective january requires enhanced disclosures derivative instruments hedging activities allow better understanding effects entitys financial position financial performance cash flows among things fas requires disclosure fair values derivative instruments associated gains losses tabular format since fas requires additional disclosures companys derivatives hedging activities adoption fas affect companys financial position results operations fsp eitf effective january clarifies sharebased payment awards entitle holders receive nonforfeitable dividends vest considered participating securities therefore included basic earnings per share calculation effect adoption fsp eitf expected material companys results operations fsp fas r effective december amends fasb statement r employers disclosures pensions postretirement benefits provide guidance employers disclosures plan assets defined pension postretirement plan fsp fas r requires disclosures plan assets including investment allocation decisions made major categories plan assets inputs valuation techniques used measure fair value plan assets effect fair value measurements using significant unobservable inputs level changes plan assets period significant concentrations risk within plan assets since fsp fas r requires additional disclosures companys pension postretirement plan assets adoption fsp fas r affect companys financial position results operations eitf effective january applied retrospectively prior periods presented collaborative arrangements existing effective date eitf defines collaborative arrangements establishes reporting requirements transactions participants collaborative arrangement participants arrangement third parties effect adoption eitf expected material companys financial position results operations eitf effective january clarifies accounting certain transactions impairment considerations involving equity method investments applied prospective basis future transactions eitf effective january clarifies defensive intangible asset accounted separate unit accounting assigned useful life reflects entitys consumption expected benefits related asset eitf applied prospective basis future transactions table contents restructuring global restructuring program october company announced global restructuring program restructuring program reduce cost structure increase efficiency enhance competitiveness part restructuring program company expects eliminate approximately positions active employees vacancies across areas company worldwide end company eliminated approximately positions connection program comprised employee separations elimination contractors vacant positions total reductions occur united states part restructuring program company streamlining management layers reducing total number senior midlevel executives globally approximately company however continues hire new employees business requires merck rolling new customercentric selling model designed provide merck meaningful competitive advantage help physicians patients payers improve patient outcomes company also make greater use outside technology resources centralize common sales marketing activities consolidate streamline operations mercks manufacturing division focus capabilities core products outsource noncore manufacturing also merck expanding access worldwide external science basic research global operating strategy designed provide sustainable pipeline focused translating basic research productivity latestage clinical success increase efficiencies basic research operations consolidate work support given therapeutic area one four locations provide efficient use research facilities result closure three basic research sites located tsukuba japan pomezia italy seattle end separation costs accounted fas fas connection restructuring program separation costs companys existing severance programs worldwide accounted fas recorded third quarter extent costs probable estimable company commenced accruing costs related onetime termination benefits offered employees restructuring program fourth quarter necessary criteria fas met company recorded pretax restructuring costs million related restructuring program restructuring program expected completed end total pretax costs estimated billion billion company estimates twothirds cumulative pretax costs result future cash outlays primarily employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested global restructuring program november company announced global restructuring program restructuring program designed reduce companys cost structure increase efficiency enhance competitiveness part restructuring program merck sold closed five manufacturing sites two preclinical sites since inception eliminated positions companywide comprised employee separations elimination contractors vacant positions company also sold closed certain facilities sold related assets connection restructuring program since inception december company recorded total pretax accumulated costs billion associated restructuring program substantially complete segment reporting restructuring charges unallocated expenses table contents following table summarizes charges related restructuring activities type cost eparation ccelerated year ended december costs depreciation total restructuring program materials production research development restructuring costs restructuring program materials production research development restructuring costs year ended december aterials production research development restructuring costs year ended december aterials production research development restructuring costs separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated approximately positions positions positions eliminated respectively positions eliminated approximately related restructuring program related restructuring program position eliminations comprised actual headcount reductions elimination contractors vacant positions accelerated depreciation costs primarily relate manufacturing research facilities sold closed part programs sites continue operate respective closure dates since future cash flows sufficient recover respective book values merck required accelerate depreciation site assets rather write immediately site assets include manufacturing research facilities equipment activity includes million million million respectively associated certain fixed assets longer used business result restructuring actions therefore written additionally activity includes million million million respectively related curtailment settlement termination charges companys pension postretirement benefit plans see note activity also includes shutdown costs pretax gains million million respectively resulting sales facilities related assets connection restructuring activities table contents following table summarizes charges spending relating restructuring activities eparation ccelerated costs depreciation total restructuring program restructuring reserves january expense payments receipts net noncash activity r estructuring reserves december restructuring program restructuring reserves january expense payments receipts net noncash activity r estructuring reserves december e xpense payments receipts net noncash activity r estructuring reserves december cash outlays associated restructuring reserve restructuring program expected completed end cash outlays associated remaining restructuring reserve restructuring program expected largely completed end includes proceeds sales facilities connection restructuring program research collaborations acquisitions license agreements merck continues strategy establishing strong external alliances complement substantial internal research capabilities including research collaborations acquisitions licensing preclinical clinical compounds technology transfers drive near longterm growth february merck entered definitive agreement insmed inc insmed purchase insmeds portfolio followon biologic therapeutic candidates commercial manufacturing facilities located boulder colorado terms agreement merck pay insmed aggregate million cash acquire rights boulder facilities insmeds pipeline followon biologic candidates insmeds followon biologics portfolio includes two clinical candidates ins investigational recombinant granulocyte colony stimulating factor gcsf evaluated ability prevent infections patients cancer receiving chemotherapy ins pegylated recombinant gcsf designed allow less frequent dosing agreement provides initial payments million ins ins merck pay insmed remaining balance upon closing transaction expected end first quarter without milestone royalty obligations september merck japan tobacco inc jt signed worldwide licensing agreement develop commercialize jtt investigational oral osteoanabolic bone growth stimulating agent treatment osteoporosis disease reduces bone density strength results increased risk bone fractures jtt investigational oral calcium sensing receptor antagonist currently evaluated jt phase ii clinical trials japan effect increasing bone density phase clinical trials outside japan terms agreement merck gained worldwide rights except japan develop commercialize jtt certain related compounds jt received upfront payment million company recorded research development expense eligible receive additional cash payments table contents upon achievement certain milestones associated development approval drug candidate covered agreement jt also eligible receive royalties sales drug candidates receive marketing approval license agreement merck jt remain effect expiration royalty milestone obligations may terminated event uncured material breach party agreement may also terminated merck without cause initial commercial sale jtt giving six months prior notice jt thereafter giving one year prior notice thereof jt license agreement may also terminated immediately merck merck determines due safety andor efficacy concerns based available scientific evidence cease development jtt andor withdraw jtt market permanent basis september company terminated collaboration foxhollow technologies inc foxhollow atherosclerotic plaque analysis collaboration entered expanded whereby merck acquired equity interest foxhollow december company terminated collaboration dynavax technologies corporation development v investigational hepatitis b vaccine entered september merck completed acquisition novacardia inc novacardia privately held clinicalstage pharmaceutical company focused cardiovascular disease acquisition added rolofylline mk novacardias investigational phase iii compound acute heart failure mercks pipeline merck acquired outstanding equity novacardia total purchase price million including million cash investments hand closing paid issuance million shares merck common stock former novacardia shareholders based mercks average closing stock price five days prior closing acquisition connection acquisition company recorded charge million acquired research associated rolofylline acquisition date technological feasibility established alternative future use existed charge deductible tax purposes recorded research development expense determined based upon present value expected future cash flows resulting technology adjusted probability technical marketing success utilizing income approach reflecting appropriate riskadjusted discount rate ongoing activity respect future development rolofylline continues costs expected material companys research development expenses remaining purchase price allocated cash investments million deferred tax asset relating net operating loss carryforward million net assets million novacardia development stage company commenced planned principal operations transaction accounted acquisition assets rather business combination therefore goodwill recorded novacardias results operations included companys consolidated financial results since acquisition date also merck gtx inc gtx entered agreement providing research development global strategic collaboration selective androgen receptor modulators sarms new class drugs potential treat agerelated muscle loss sarcopenia well musculoskeletal conditions also merck ariad pharmaceuticals inc ariad entered global collaboration jointly develop commercialize deforolimus mk ariads novel mtor inhibitor use cancer collaborations generally continue effect expiration royalty milestone payment obligations collaborations may generally terminated event insolvency material uncured breach either party additionally collaboration agreement merck gtx may terminated merck upon ninety days notice gtx time december collaboration agreement merck ariad may terminated merck upon failure mk meet certain developmental safety requirements event merck concludes advisable continue development mk use cancer indication addition merck may terminate ariad collaboration agreement third anniversary effective date providing least months prior written notice upon termination ariad collaboration agreement depending upon circumstances parties varying rights obligations respect continued development commercialization mk continuing royalty obligations december merck completed acquisition sirna therapeutics inc sirna per share cash total value approximately billion included purchase outstanding sirna table contents shares warrants stock options aggregate purchase price billion paid january sirna publiclyheld biotechnology company developing new class medicines based rna interference rnai technology could significantly alter treatment disease rnaibased therapeutics selectively catalyze destruction rna transcribed individual gene acquisition sirna increased mercks ability use rnai technology turn targeted gene human cell potentially rendering inoperative gene responsible triggering specific disease transaction accounted purchase method accounting assets acquired liabilities assumed sirna date acquisition recorded respective fair values acquisition date companys consolidated financial statements determination fair values requires management make significant estimates assumptions excess purchase price fair value acquired net assets recorded goodwill million goodwill fully allocated pharmaceutical segment deductible tax purposes also company recorded charge million acquired research associated sirnas compounds currently development acquisition date technological feasibility established alternative future use existed acquired research charge related development treatments hepatitis b hepatitis c viruses preclinical development well licensing agreements held sirna charge deductible tax purposes recorded research development expense determined based upon present value expected future cash flows new product candidates resulting technology adjusted probability technical marketing success utilizing income approach reflecting appropriate riskadjusted discount rates ongoing activity respect compounds development continues costs expected material companys research development expenses allocation purchase price also resulted recognition intangible asset million related deferred tax liability million well assets liabilities net million intangible asset relates sirnas developed technology used immediately research development process alternative future uses intangible asset amortized research development expense straightline basis seven year useful life pro forma financial information required sirnas historical financial results significant compared companys financial results transaction closed december accordingly sirnas operating results included companys results operations beginning january june company acquired outstanding equity glycofi inc glycofi approximately million cash million purchase price net million shares already owned net transaction costs glycofi privatelyheld biotechnology company field yeast glycoengineering addition specific carbohydrate modifications proteins yeast optimization biologic drug molecules glycofis technology platform used development glycoproteins well optimization glycoprotein target connection acquisition company recorded charge million acquired research associated glycofis technology platform used research development process acquisition date technological feasibility established alternative future use existed charge deductible tax purposes technology currently utilized mercks pipeline biologics charge recorded research development expense determined based upon present value expected future cash flows new product candidates resulting technology adjusted probability technical marketing success utilizing income approach reflecting appropriate risk adjusted discount rate company also recorded million intangible asset million net deferred taxes related glycofis developed technology used immediately research development process alternative future uses intangible asset amortized research development expense straightline basis five year useful life remaining net assets acquired transaction material glycofi development stage company commenced planned principal operations transaction accounted acquisition assets rather business combination therefore goodwill recorded glycofis results operations included companys consolidated financial results since acquisition date may company acquired equity abmaxis inc abmaxis approximately million cash abmaxis privatelyheld biopharmaceutical company dedicated discovery optimization monoclonal antibody mab products human therapeutics diagnostics abmaxis developed validated breakthrough antibody engineering technology platform abmaxis insilico table contents immunization alternative future uses company significant technological engineering risks date acquisition connection acquisition company allocated substantially purchase price abmaxis technology platform recorded intangible asset million million net deferred taxes intangible asset amortized research development expense straight line basis five year useful life remaining net assets acquired transaction material abmaxis development stage company commenced planned principal operations transaction accounted acquisition assets rather business combination therefore goodwill recorded abmaxis results operations included companys consolidated financial results since acquisition date also merck idera pharmaceuticals idera formed broad collaboration research develop commercialize ideras tolllike receptor agonists use combination mercks therapeutic prophylactic vaccines development oncology infectious diseases alzheimers disease additionally merck ambrilia biopharma inc ambrilia biopharmaceutical company developing innovative therapeutics fields cancer infectious diseases announced entered exclusive licensing agreement granting merck worldwide rights ambrilias hivaids protease inhibitor program also neuromed pharmaceuticals ltd merck signed research collaboration license agreement research develop commercialize novel compounds treatment pain neurological disorders financial instruments fair value f oreign currency risk management us dollar functional currency companys foreign subsidiaries significant portion companys revenues denominated foreign currencies merck relies sustained cash flows generated foreign sources support longterm commitment us dollarbased research development extent dollar value cash flows diminished result strengthening dollar companys ability fund research dollarbased strategic initiatives consistent level may impaired company established revenue hedging balance sheet risk management programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company partially hedge anticipated thirdparty sales expected occur planning cycle typically three years future company layer hedges time increasing portion sales hedged gets closer expected date transaction probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged risk manner merck manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows offset decline expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase value anticipated foreign currency cash flows designated hedge relationship based total changes options cash flows accordingly entire fair value change options deferred aoci reclassified sales hedged anticipated revenue recognized hedge relationship highly effective hedge ineffectiveness de minimis fair values purchased currency options reported accounts receivable assets cash flows contracts reported operating activities consolidated statement cash flows table contents primary objective balance sheet risk management program protect us dollar value foreign currency denominated net monetary assets effects volatility foreign exchange might occur prior conversion us dollars merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange amount us dollar cash flows derived net assets merck routinely enters contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level foreign currency denominated monetary assets liabilities remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year company uses forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates changes fair value hedged securities due fluctuations spot rates offset income expense net fair value changes forward contracts attributable spot rate fluctuations hedge ineffectiveness material changes contracts fair value due spotforward differences excluded designated hedge relationship recognized income expense net amounts significant years ended december fair values forward exchange contracts reported following four balance sheet line items accounts receivable current portion gain position assets noncurrent portion gain position accrued current liabilities current portion loss position deferred income taxes noncurrent liabilities noncurrent portion loss position cash flows contracts reported operating activities consolidated statement cash flows nterest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party two payfloating receivefixed interest rate swap contracts maturing notional amounts million designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes swaps effectively convert fixedrate obligations floatingrate instruments fair value changes notes offset interest expense fair value changes swap contracts fair values contracts reported accounts receivable assets accrued current liabilities deferred income taxes noncurrent liabilities company terminated four interest rate swap contracts notional amounts million terminated one interest rate swap contract notional amount million swaps effectively converted billion fixedrate notes due million fixedrate notes due variable rate debt result swap terminations company received million cash excluding accrued interest material corresponding gains related basis adjustment debt associated terminated swap contracts deferred amortized reduction interest expense remaining term notes cash flows contracts reported operating activities consolidated statement cash flows table contents fair value measurements january company adopted fas clarifies definition fair value establishes framework measuring fair value expands disclosures fair value measurements february fasb issued fsp deferred effective date fas one year nonfinancial assets liabilities recorded fair value nonrecurring basis october fasb issued fsp clarifies application fas market active fas defines fair value exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date fas also establishes fair value hierarchy requires entity maximize use observable inputs minimize use unobservable inputs measuring fair value fas describes three levels inputs may used measure fair value level quoted prices active markets identical assets liabilities companys level assets include equity securities traded active exchange market level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities companys level assets liabilities primarily include debt securities quoted prices traded less frequently exchangetraded instruments corporate notes bonds us foreign government agency securities certain mortgagebacked assetbacked securities municipal securities derivative contracts whose values determined using pricing models inputs observable market derived principally corroborated observable market data level unobservable inputs supported little market activity financial instruments whose values determined using pricing models discounted cash flow methodologies similar techniques well instruments determination fair value requires significant judgment estimation companys level assets mainly include mortgagebacked assetbacked securities well certain corporate notes bonds limited market activity december million approximately companys investment securities categorized level fair value assets pledged certain collateral arrangements see note assets classified level december acquired company elected redeemedinkind shortterm fixed income fund restricted cash redemptions described inputs used measure financial assets liabilities fall within one level described categorization based lowest level input significant fair value measurement instrument table contents financial assets liabilities measured fair value recurring basis financial assets liabilities measured fair value recurring basis summarized fair value measurements using quoted prices significant active significant markets observable unobservable carrying identical assets inputs inputs carrying fair millions value level level level total value value ssets investments corporate notes bonds us government agency securities mortgagebacked securities municipal securities foreign government bonds assetbacked securities equity securities commercial paper debt securities total investments assets derivative assets purchased currency options forward exchange contracts interest rate swaps total deriviative assets liabilities derivative liabilities written currency options forward exchange contracts total derivative liabilities mortgagebacked securities represent aaa rated securities issued unconditionally guaranteed payment principal interest us government agencies substantially assetbacked securities highlyrated standard poors rating aaa moodys investors service rating aaa secured primarily credit card auto loan home equity receivables weightedaverage lives primarily years less assets represent portion pledged collateral discussed note level assets comprised million corporate notes bonds million municipal securities million commercial paper million mortgagebacked securities million us government agency securities million assetbacked securities fair value determination derivatives includes assessment credit risk counterparties derivatives companys credit risk effects significant l evel valuation techniques financial assets considered level fair values determined using pricing models discounted cash flow methodologies similar techniques least one significant model assumption input unobservable level financial assets also include certain investment securities limited market activity determination fair value requires significant judgment estimation companys level investment securities december primarily include mortgagebacked assetbacked securities well certain corporate notes bonds decrease observability market pricing investments securities valued primarily using pricing models management understands methodologies models incorporate transaction details contractual terms maturity timing amount future cash inflows well assumptions liquidity credit valuation adjustments marketplace participants december table contents table provides summary changes fair value including net transfers andor financial assets measured fair value recurring basis using significant unobservable inputs level total l ized losses unrealized losses recorded net purchases included earnings beginning transfers sales compre ending level assets balance settlements hensive balance still held millions january level net earnings income december december assets debt securities total transfers level deemed occur beginning quarter transaction takes place amounts recorded income expense net consolidated statement income january company million invested shortterm fixed income fund fund due market liquidity conditions cash redemptions fund restricted result restriction cash redemptions company consider fund traded active market observable pricing january amounts categorized level january company elected redeemedinkind fund received share underlying securities fund result million underlying securities transferred level determined securities observable markets december million investment securities associated redemptioninkind classified level securities contained least one significant input unobservable securities account entire balance companys level assets december f inancial instruments measured fair value companys financial instruments measured fair value recurring basis recorded amounts approximate fair value due liquid shortterm nature cash cash equivalents receivables payables estimated fair value companys loans payable longterm debt including current portion december million compared carrying value million december estimated fair value million compared carrying amount million fair value estimated using quoted dealer prices summary december gross unrealized gains losses companys availableforsale investments including pledged collateral recorded aoci follows gross unrealized gross unrealized gains losses gains losses corporate notes bonds us government agency securities mortgagebacked securities municipal securities assetbacked securities foreign government bonds debt securities equity securities december gross unrealized gains gross unrealized losses related amounts pledged collateral see note million million respectively table contents amount gross unrealized losses december continuous loss position months de minimis availableforsale debt securities maturing within one year totaled billion december remaining debt securities billion mature within five years l etter credit august company executed billion letter credit agreement financial institution satisfied certain conditions set forth us vioxx settlement agreement see note company pledged collateral financial institution approximately billion pursuant terms letter credit agreement although amount assets pledged collateral set letter credit agreement assets held custody third party assets managed company company considers assets pledged letter credit agreement restricted result billion billion cash investments respectively classified restricted current assets billion investments classified restricted noncurrent assets letter credit amount required collateral balances decline payments first million settlement agreement made december billion recorded within deferred income taxes current assets billion classified assets c oncentrations credit risk ongoing basis company monitors concentrations credit risk associated corporate issuers securities financial institutions conducts business credit exposure limits established limit concentration single issuer institution cash investments placed instruments meet high credit quality standards specified companys investment policy guidelines companys four largest us customers mckesson corporation cardinal health inc amerisourcebergen corporation medco health solutions inc represented aggregate approximately one seventh accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost reduction lifo costs recognized inventories assets inventories valued lifo method comprised approximately inventories december respectively amounts recognized assets comprised entirely raw materials work process inventories majority noncurrent vaccine inventories table contents intangibles intangibles december consisted patents product rights total acquired cost patents product rights total accumulated amortization reflects intangibles primarily technology rights recorded connection acquisitions sirna glycofi abmaxis see note aggregate amortization expense million million million estimated aggregate amortization expense next five years follows million million million million million joint ventures equity method affiliates equity income affiliates reflects performance companys joint ventures equity method affiliates comprised following ears ended december merckscheringplough astrazeneca lp primarily reflects results merial limited sanofi pasteur msd johnson johnsonmerck consumer pharmaceuticals company erckscheringplough company scheringplough corporation scheringplough collectively partners entered agreements create separate equallyowned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas agreements generally provide equal sharing development costs copromotion approved products company cholesterolmanagement partnership agreements expanded include countries world excluding japan ezetimibe first new class cholesterollowering agents launched united states zetia marketed ezetrol outside united states combination product containing active ingredients zetia zocor approved united states vytorin marketed inegy outside united states cholesterol agreements provide sharing operating income generated merckschering plough cholesterol partnership msp partnership based upon percentages vary product sales level country us market partners share profits zetia vytorin sales equally exception first million annual zetia sales scheringplough receives greater share profits operating income includes expenses partners contractually agreed share portion manufacturing costs specifically identified promotion costs including directtoconsumer advertising direct identifiable outofpocket promotion agreed upon costs specific services ongoing clinical research market support market research market expansion well specialty sales force physician education programs expenses incurred support msp partnership shared partners marketing administrative expenses including certain sales force costs well certain manufacturing costs included equity income affiliates however costs reflected table contents overall results company certain research development expenses generally shared equally partners adjusting earned milestones see note information respect litigation involving msp partnership partners related sale promotion zetia vytorin respiratory therapeutic agreements provided joint development marketing united states partners oncedaily fixedcombination tablet containing active ingredients montelukast sodium loratadine montelukast sodium leukotriene receptor antagonist sold merck singulair loratadine antihistamine sold scheringplough claritin indicated relief symptoms allergic rhinitis partners received notapprovable letter us food drug administration fda proposed fixed combination loratadinemontelukast subsequently announced withdrawal new drug application combination tablet companies also terminated respiratory joint venture action impact business cholesterol joint venture result termination respiratory joint venture company obligated scheringplough amount million specified joint venture agreements resulted charge million second quarter included equity income affiliates remaining amount amortized remaining patent life zetia summarized financial information msp partnership follows ears ended december sales vytorin zetia materials production costs expense net income taxes mercks share income taxes ecember otal assets total liabilities mercks share msp partnerships income taxes differs equity income recognized msp partnership primarily due timing recognition certain transactions company msp partnership including million milestone payment discussed milestone payments amounts comprised almost entirely current balances strazeneca lp merck entered agreement astra ab astra develop market astras products royaltybearing license companys total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining merck astra completed restructuring ownership operations joint venture whereby company acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights table contents maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns ongoing revenue based sales current future kbi products revenue billion billion billion respectively primarily relating sales nexium well prilosec addition merck earns certain partnership returns recorded equity income affiliates reflected table returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings astrazeneca merger triggered partial redemption march mercks interest certain azlp product rights upon redemption merck received billion azlp amount based primarily multiple mercks average annual variable returns derived sales former astra usa inc products three years prior redemption limited partner share agreed value merck recorded billion pretax gain partial redemption partial redemption mercks interest product rights result change mercks limited partner interest conjunction restructuring astra purchased option asset option payment million recorded deferred income buy mercks interest kbi products excluding gastrointestinal medicines nexium prilosec nonppi products asset option exercisable first half exercise price equal net present value march projected future pretax revenue received company nonppi products appraised value merck also right require astra purchase interest appraised value february company advised azlp would exercise asset option thus million remains deferred addition company granted astra option shares option buy mercks common stock interest kbi therefore mercks interest nexium prilosec exercisable two years astras exercise asset option astra also exercise shares option combined annual sales two products fall minimum amount provided case long astrazenecas asset option exercised exercise price shares option based net present value estimated future net sales nexium prilosec determined time exercise subject certain trueup mechanisms astrazeneca merger constituted trigger event kbi restructuring agreements result merger exchange mercks relinquishment rights future astra products existing pending us patents time merger astra paid million advance payment advance payment deferred remained subject trueup calculation trueup amount directly dependent fair market value march astra product rights retained company calculated trueup amount million returned azlp march merck recognized pretax gain million related residual advance payment balance provisions kbi restructuring agreements trigger event occurred sum limited partner share agreed value appraised value trueup amount guaranteed minimum billion distribution limited partner share agreed value less payment trueup amount resulted cash receipts merck billion aggregate pretax gain billion included income expense net astrazenecas purchase mercks interest nonppi products contingent upon exercise asset option astrazeneca therefore payment appraised value may may occur also march billion outstanding loan astra plus interest redemption date settled result transactions company received net proceeds azlp billion table contents summarized financial information azlp follows ears ended december sales materials production costs expense net income taxes december current assets noncurrent assets total liabilities current connection restructuring ami company assumed billion par value preferred stock obligation dividend rate per annum carried kbi included minority interests small portion preferred stock carried kbi convertible kbi common shares none preferred securities convertible companys common shares therefore included common shares issuable purposes computing earnings per common share assuming dilution see note erial limited merck rhnepoulenc sa sanofiaventis sa combined animal health businesses form merial limited merial fully integrated animal health company standalone joint venture owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species merial sales billion billion billion anofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe joint venture vaccine sales billion billion million j ohnson johnsonmerck consumer pharmaceuticals company merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned venture subsequently expanded canada significant joint venture products pepcid ac overthecounter form companys ulcer medication pepcid well pepcid complete overthecounter product combines companys ulcer medication antacids sales products marketed joint venture million million million investments affiliates accounted using equity method including joint ventures totaled billion december billion december amounts reported assets amounts due joint ventures included accounts receivable million december million december table contents summarized information affiliates excluding msp partnership azlp disclosed separately follows ears ended december sales materials production costs expense net income taxes ecember current assets noncurrent assets current liabilities noncurrent liabilities loans payable longterm debt commitments loans payable december consisted primarily billion commercial paper borrowings company settled billion astra note due included loans payable current portion longterm debt december see note loans payable december also included million million respectively longdated notes subject repayment option holders annual basis december foreign subsidiary company entered month million line credit financial institution june line credit reduced million maturity extended june december borrowings line credit million million respectively included loans payable weighted average interest rate borrowings included loans payable december respectively longterm debt december consisted notes due notes due debentures due notes due debentures due notes due debentures due company party interest rate swap contracts effectively convert fixedrate notes floatingrate instruments see note presented table december consisted primarily million borrowings variable rates averaging respectively borrowings million subject repayment option holders beginning million subject repayment option holders beginning years also included foreign borrowings varying rates aggregate maturities longterm debt next five years follows million million million million million table contents april company extended maturity date billion year revolving credit facility april april facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility rental expense companys operating leases net sublease income million minimum aggregate rental commitments noncancellable leases follows million million million million million thereafter million company significant capital leases contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made result number factors product liability insurance become less available cost increased significantly company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august including liability products first sold date company continue evaluate insurance needs costs availability benefits product liability insurance future v ioxx litigation p roduct liability lawsuits previously disclosed individual putative class actions filed company state federal courts alleging personal injury andor economic loss respect purchase use vioxx actions filed federal court coordinated multidistrict litigation us district court eastern district louisiana mdl district judge eldon e fallon number actions filed state court coordinated separate coordinated proceedings state courts new jersey california texas counties philadelphia pennsylvania washoe clark counties nevada december company served aware named defendant approximately lawsuits include approximately plaintiff groups alleging personal injuries resulting use vioxx approximately putative class actions alleging personal injuries andor economic loss actions discussed paragraph lawsuits collectively referred vioxx product liability lawsuits lawsuits approximately lawsuits representing approximately plaintiff groups slated federal mdl approximately lawsuits representing approximately plaintiff groups included coordinated proceeding new jersey superior court judge carol e higbee plaintiff groups described currently vioxx settlement program described december plaintiff groups otherwise eligible settlement program participated claims remained pending merck addition claims plaintiff groups eligible settlement program remained pending merck number plaintiff groups subject motions dismiss failure comply courtordered deadlines since december hundreds plaintiff groups since dismissed table contents addition vioxx product liability lawsuits discussed claims plaintiffs dismissed december plaintiffs whose claims dismissed prejudice ie brought either plaintiffs courts additional plaintiffs claims dismissed without prejudice ie subject applicable statute limitations brought approximately plaintiff groups represent plaintiffs lawsuits pending new jersey superior court time settlement agreement described enrolled program established settlement agreement settlement program judge higbee dismissed cases without prejudice administrative reasons november merck announced entered agreement settlement agreement law firms comprise executive committee plaintiffs steering committee psc federal vioxx mdl well representatives plaintiffs counsel texas new jersey california state coordinated proceedings resolve state federal myocardial infarction mi ischemic stroke claims filed date united states settlement agreement also applies tolled claims signed parties several meetings three four judges overseeing coordination us vioxx product liability lawsuits settlement agreement applies us legal residents allege mi occurred united states settlement agreement merck pay fixed aggregate amount billion two funds billion mi claims million claims qualifying claims enter settlement program individual claimants examined administrators settlement program determine qualification based objective documented facts provided claimants including records sufficient scientific evaluation independent risk factors conditions settlement agreement also require claimants pass three gates injury gate duration gate proximity gate defined settlement agreement settlement agreement provides merck admit causation fault settlement agreement provided mercks payment obligations would triggered among conditions law firms federal state pscs firms tried cases coordinated proceedings elect recommend enrollment program clients allege either mi june plaintiffs enroll settlement program least currently pending tolled mi claims ii claims iii eligible mi claims together involve death iv eligible mi claims together allege months use terms settlement agreement merck could exercise right walk away settlement agreement thresholds requirements met company waived right august waiver right triggered mercks obligation pay fixed total billion payments made installments settlement funds first payment million made august additional payment million made october interim payments made certain plaintiffs alleged suffered mi company anticipates interim payments claimants begin shortly additional payments made periodic basis going forward needed fund payments claims administrative expenses mercks total payment funds billion fixed amount allocated among qualifying claimants based individual evaluation distribution interim payments qualified claimants began august continue rolling basis claimants qualify interim payment paid final payments made examination eligible claims completed settlement agreement announced november judges federal mdl california texas new jersey state coordinated proceedings entered series orders orders temporarily stayed respective litigations required plaintiffs register claims january required plaintiffs cases pending november preserve produce records serve expert reports required plaintiffs file thereafter make similar productions accelerated schedule clark county nevada washoe county nevada coordinated proceedings also generally stayed october deadline enrollment settlement program approximately individuals eligible settlement program whose claims dismissed expected dismissed near future tolled claims appear abandoned table contents submitted materials required enrollment settlement program represents approximately eligible mi claims previously registered settlement program april june two groups various private insurance companies health plans filed suit browngreer claims administrator settlement program claims administrator us bancorp escrow agent settlement program avmed greater new york benefit fund suits private insurance companies health plans claim paid healthcare costs behalf enrolling claimants seek enjoin claims administrator paying enrolled claimants claims reimbursement enrolled claimants resolved group sought temporary restraining orders preliminary injunctions judge fallon denied requests avmed defendants moved sever claims named plaintiffs greater new york benefit fund strike class allegations judge fallon granted motions avmed appealed decisions fifth circuit heard argument avmeds appeal november november court appeals affirmed district courts ruling denied two motions preliminary injunctive relief greater new york benefit fund served notice appeal january psc counsel certain private insurers announced reached settlement agreement agreement provides program resolution liens asserted private insurers payments received certain claimants enrolled settlement program agreement terminated private insurers fewer eligible claimants participate plaintiffs avmed greater new york benefit fund lawsuits agreed participate settlement two us vioxx product liability lawsuits currently scheduled trial company previously disclosed outcomes several vioxx product liability lawsuits tried prior juries decided favor company twelve times plaintiffs favor five times one merck verdict set aside court retried another merck verdict set aside retried leading one five plaintiffs verdicts two unresolved mistrials respect five plaintiffs verdicts merck filed appeal sought judicial review cases one five intermediate appellate court overturned trial verdict directed judgment entered merck another intermediate appellate court overturned trial verdict entering judgment merck one claim ordering new trial remaining claims following three cases went trial resolved mcdarby v merck ernst v merck garza v merck first mcdarby originally tried along second plaintiff cona april superior court new jersey law division atlantic county jury returned split verdict jury determined vioxx substantially contribute heart attack mr cona substantially contribute heart attack mr mcdarby jury also concluded case merck violated new jerseys consumer fraud statute allows plaintiffs receive expenses purchasing drug trebled well reasonable attorneys fees jury awarded million compensatory damages mr mcdarby wife also plaintiff case well punitive damages million june judge higbee denied mercks motion new trial june judge higbee awarded approximately million aggregate attorneys fees costs company appealed judgments cases appellate division held oral argument cases january may new jersey appellate division vacated consumer fraud awards cases grounds product liability act provides sole remedy personal injury claims appellate division also vacated mcdarby punitive damage award ground federal preemption vacated attorneys fees costs awarded consumer fraud act cases court upheld mcdarby compensatory award company filed supreme court new jersey petition appeal parts trial courts rulings appellate division affirmed plaintiffs filed cross petition appeal parts trial courts rulings appellate division reversed october supreme court new jersey granted mercks petition certification appeal limited solely issue whether federal food drug cosmetic act preempts state law tort claims predicated alleged inadequacy warnings contained vioxx labeling approved fda court denied plaintiffs crosspetition december new jersey supreme court granted mercks motion stay appeal pending issuance decision united states supreme court wyeth v levine table contents previously reported september merck filed notice appeal august jury verdict favor plaintiff texas state court case ernst v merck may texas court appeals reversed trial courts judgment issued judgment favor merck court appeals found evidence legally insufficient issue causation plaintiffs filed motion rehearing en banc court appeals merck filed response october january plaintiffs filed reply support rehearing motion previously reported april garza v merck jury state court rio grande city texas returned verdict favor family decedent leonel garza jury awarded total million compensatory damages mr garzas widow three sons jury also purported award million punitive damages even though texas law case potential punitive damages capped may san antonio court appeals reversed judgment rendered judgment favor merck december court appeals rehearing vacated prior ruling issued replacement new ruling court ordered takenothing judgment merck design defect claim reversed remanded new trial strict liability claim juror misconduct january merck filed petition review texas supreme court merck voluntarily withdrew vioxx market september states statutes limitations product liability claims three years require claims must filed within three years plaintiffs learned could learned potential cause action result may view september significant deadline filing vioxx cases important note however law regarding statutes limitations complex variable depending facts applicable law states longer statutes limitations also arguments statutes limitations began running september new jersey superior court judge higbee federal district court judge fallon issued orders cases new jersey eight jurisdictions ruling statutory period making vioxx personal injury claims passed judge higbees order issued october judge fallons issued november ther lawsuits previously disclosed july new jersey state trial court certified nationwide class thirdparty payors unions health insurance plans paid whole part vioxx used plan members insureds named plaintiff case sought recovery certain vioxx purchase costs plus penalties based allegations purported class members paid vioxx would known products alleged risks march new jersey superior court appellate division affirmed class certification order september new jersey supreme court reversed certification nationwide class action thirdparty payors finding suit meet requirements class action claims certain individual thirdparty payors remain pending new jersey court counsel purporting represent large number thirdparty payors filed additional actions judge higbee lifted stay cases cases currently discovery phase status conference court took place january discuss scheduling issues cases including selection early trial pool cases new jersey superior court heard argument plaintiffs motion class certification martin kleinman v merck putative consumer class action december also pending various us courts putative class actions purportedly brought behalf individual purchasers users vioxx claiming either reimbursement alleged economic loss entitlement medical monitoring majority cases early procedural stages june missouri state court certified class missouri plaintiffs seeking reimbursement outofpocket costs relating vioxx plaintiffs allege personal injuries taking vioxx company filed petition interlocutory review june granted july briefing complete pendency appeal discovery proceeding lower court february judge fallon dismissed master personal injurywrongful death class action master complaint medical monitoring class action master complaint mdl table contents plaintiffs also filed class action california state court seeking class certification california thirdparty payors endusers parties engaged class certification discovery briefing court heard oral argument class certification issue february company also named defendant eighteen separate lawsuits brought attorneys general ten states five counties city new york private citizens brought qui tam taxpayer derivative suits one lawsuits brought counties class action filed santa clara county california behalf similarly situated california counties actions allege company misrepresented safety vioxx seek recovery cost vioxx purchased reimbursed state agencies ii reimbursement sums paid state agencies medical services treatment persons injured vioxx iii damages various common law theories andor iv remedies various state statutory theories including state consumer fraud andor fair business practices medicaid fraud statutes including civil penalties exception case filed texas attorney general remains texas state court currently scheduled trial november case filed michigan attorney general ordered remanded state court january case recently filed pennsylvania attorney general removed federal court subject pending motion remand one case removed federal court rest actions described paragraph transferred federal mdl discovery phase hareholder lawsuits previously disclosed addition vioxx product liability lawsuits company various current former officers directors defendants various putative class actions individual lawsuits federal securities laws state securities laws vioxx securities lawsuits vioxx securities lawsuits pending federal court transferred judicial panel multidistrict litigation jpml united states district court district new jersey district judge stanley r chesler inclusion nationwide mdl shareholder mdl judge chesler consolidated vioxx securities lawsuits purposes putative class action requested damages behalf purchasers company stock may october alleged defendants made false misleading statements regarding vioxx violation sections b securities exchange act sought unspecified compensatory damages costs suit including attorneys fees complaint also asserted claims section securities exchange act certain defendants relating sales merck stock sections securities act certain defendants based statements registration statement certain prospectuses filed connection merck stock investment plan dividend reinvestment plan april judge chesler granted defendants motion dismiss complaint prejudice plaintiffs appealed judge cheslers decision united states court appeals third circuit september third circuit issued opinion reversing judge cheslers order remanding case district court september merck filed petition seeking rehearing en banc denied case remanded district court october plaintiffs filed consolidated fifth amended class action complaint merck filed petition writ certiorari united states supreme court january merck expects file motion dismiss fifth amended class action complaint october dutch pension fund filed complaint district new jersey alleging violations federal securities laws well violations state law company certain officers pursuant case management order governing shareholder mdl case based allegations vioxx securities lawsuits consolidated vioxx securities lawsuits defendants motion dismiss pension funds complaint filed august september dutch pension fund filed amended complaint rather responding defendants motion dismiss addition six new complaints filed district new jersey behalf various foreign institutional investors also alleging violations federal securities laws well violations state law company certain officers defendants required respond complaints judge chesler resolves motion dismiss consolidated securities action table contents previously disclosed various shareholder derivative actions filed federal court transferred shareholder mdl consolidated purposes judge chesler vioxx derivative lawsuits may judge chesler granted defendants motion dismiss denied plaintiffs request leave amend complaint plaintiffs appealed arguing judge chesler erred denying plaintiffs leave amend complaint materials acquired discovery july united states court appeals third circuit reversed district courts decision grounds judge chesler allowed plaintiffs make use discovery material try establish demand futility remanded case district courts consideration whether even additional materials plaintiffs request amend complaint would still futile plaintiffs filed brief support request leave amend complaint november court denied motion june closed case plaintiffs appealed judge cheslers decision united states court appeals third circuit addition previously disclosed various putative class actions filed federal court employee retirement income security act erisa company certain current former officers directors vioxx erisa lawsuits together vioxx securities lawsuits vioxx derivative lawsuits vioxx shareholder lawsuits transferred shareholder mdl consolidated purposes consolidated complaint asserts claims behalf certain companys current former employees participants certain companys retirement plans breach fiduciary duty lawsuits make similar allegations allegations contained vioxx securities lawsuits july judge chesler granted part denied part defendants motion dismiss erisa complaint october plaintiffs moved certification class individuals participants beneficiaries companys retirement savings plans time october september whose plan accounts included investments merck common stock fund andor merck common stock february court denied motion certification class one count granted motion remaining counts court also limited class individuals participants beneficiaries companys retirement savings plans suffered loss due investments merck stock plans execute settlement releasing claims october defendants filed motion judgment pleadings seeking dismissal complaint december plaintiffs filed motion partial summary judgment certain individual defendants motions pending discovery ongoing litigation previously disclosed october two individual shareholders made demand companys board take legal action mr raymond gilmartin former chairman president chief executive officer individuals allegedly causing damage company respect allegedly improper marketing vioxx december special committee board directors retained honorable john martin jr debevoise plimpton llp conduct independent investigation among things allegations set forth demand judge martins report made public september based special committees recommendation made careful consideration martin report impact derivative litigation would company board rejected demand october shareholders filed lawsuit state court atlantic county new jersey current former executives directors company alleging boards rejection demand unreasonable improper defendants breached various duties company allowing vioxx marketed current former executive director defendants filed motions dismiss complaint june october proceedings case stayed march november pending motions dismiss denied without prejudice nternational lawsuits previously disclosed addition lawsuits discussed company named defendant litigation relating vioxx various countries collectively vioxx foreign lawsuits europe well canada brazil argentina australia turkey israel may provincial court queens bench saskatchewan canada entered order certifying class vioxx users canada except quebec class includes individual purchasers allege inducement purchase unfair marketing practices individuals allege vioxx acceptable table contents quality defective fit purpose managing pain associated approved indications ingestors claim vioxx caused exacerbated cardiovascular gastrointestinal condition june court appeal saskatchewan granted company leave appeal certification order appeal argued court court reserved decision july superior court ontario denied companys motion stay class proceedings ontario based earlier certification order entered saskatchewan decided certify overlapping class vioxx users canada except quebec saskatchewan allege negligence entitlement elect waive tort november ontario divisional court granted companys motion leave appeal superior courts decision denying stay ontario class proceedings denied companys motion appeal certification order companys appeal heard ontario divisional court february february divisional court declined set aside order denying stay company intends seek leave appeal ontario court appeal earlier november superior court quebec authorized institution class action behalf individuals quebec consumed vioxx suffered damages arising ingestion december plaintiffs instituted action based upon authorization trial representative action australia scheduled commence march federal court australia named plaintiff alleges suffered mi seeks represent others australia ingested vioxx suffered mi thrombotic stroke unstable angina transient ischemic attack peripheral vascular disease november company filed motion order proceeding longer continue representative proceeding hearing december court dismissed motion january issued reasons decision february companys motion leave appeal decision denied parties directed prepare proposed lists issues tried dditional lawsuits based media reports sources company anticipates additional vioxx product liability lawsuits vioxx shareholder lawsuits vioxx foreign lawsuits collectively vioxx lawsuits may filed andor certain current former officers directors future nsurance previously disclosed company product liability insurance claims brought vioxx product liability lawsuits stated upper limits approximately million deductibles coinsurance insurance provides coverage legal defense costs potential damage amounts connection vioxx product liability lawsuits arbitration proceeding negotiated settlements company received aggregate approximately million product liability insurance proceeds relating vioxx product liability lawsuits plus approximately million fees interest payments company additional insurance vioxx product liability lawsuits companys insurance coverage respect vioxx lawsuits adequate cover defense costs losses company directors officers insurance coverage applicable vioxx securities lawsuits vioxx derivative lawsuits stated upper limits approximately million company fiduciary insurance vioxx erisa lawsuits stated upper limits approximately million result arbitration additional insurance coverage claims also available needed upperlevel excess policies provide coverage variety risks disputes insurers availability companys insurance coverage claims likely additional disputes amounts actually recovered policies discussed paragraph may less stated upper limits nvestigations previously disclosed november company advised staff sec commencing informal inquiry concerning vioxx january company announced received notice sec issued formal notice investigation also company received subpoenas us department justice doj requesting information related companys research marketing selling activities respect vioxx federal health care investigation criminal statutes investigation includes subpoenas witnesses appear grand jury addition previously disclosed table contents investigations conducted local authorities certain cities europe order determine whether criminal charges brought concerning vioxx company cooperating governmental entities respective investigations vioxx investigations company predict outcome inquiries however could result potential civil andor criminal dispositions previously disclosed may company reached civil settlements attorneys general states district columbia fully resolve previously disclosed investigations state consumer protection laws related past activities vioxx part civil resolution investigations merck paid total million divided among states district columbia agreement also includes compliance measures supplement policies procedures previously established company addition company received subpoena september state california attorney general seeking documents information related placement vioxx californias medical formulary company cooperating attorney general responding subpoena r eserves discussed november merck entered settlement agreement law firms comprise executive committee psc federal vioxx mdl well representatives plaintiffs counsel texas new jersey california state coordinated proceedings resolve state federal mi claims filed date united states settlement agreement also applies tolled claims signed parties several meetings three four judges overseeing coordination current claims vioxx litigation settlement agreement applies us legal residents allege mi occurred united states result entering settlement agreement company recorded pretax charge billion represents fixed aggregate amount paid plaintiffs qualifying payment settlement program company currently anticipates two us vioxx product liability lawsuits tried except respect product liability trial scheduled held australia company predict timing trials related vioxx litigation company believes meritorious defenses vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits included settlement program company established reserves potential liability relating vioxx lawsuits included settlement program vioxx investigations cases company believes strong points raise appeal therefore unfavorable outcomes cases probable unfavorable outcomes vioxx litigation could material adverse effect companys financial position liquidity results operations legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable december company aggregate reserve approximately billion vioxx reserve settlement program companys future legal defense costs related vioxx litigation company spent approximately million aggregate legal defense costs worldwide related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation fourth quarter company recorded charge million solely future legal defense costs related vioxx litigation addition fourth quarter company paid additional million settlement funds connection settlement program paid million settlement funds third quarter consequently december aggregate amount vioxx reserve approximately billion included accrued current liabilities consolidated balance sheet adding vioxx reserve solely future legal defense costs company considered factors considered previously established reserves vioxx litigation significant factors considered review vioxx reserve follows actual costs incurred company development table contents companys legal defense strategy structure light scope vioxx litigation including settlement agreement expectation certain lawsuits continue pending number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials vioxx litigation amount vioxx reserve december allocated solely defense costs represents companys best estimate minimum amount defense costs incurred connection remaining aspects vioxx litigation however events additional trials vioxx litigation events could arise course vioxx litigation could affect ultimate amount defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase vioxx reserve time future based upon factors set forth believes would appropriate ther product liability litigation previously disclosed company defendant product liability lawsuits united states involving fosamax fosamax litigation december approximately cases include approximately plaintiff groups filed pending merck either federal state court including one case seeks class action certification well damages andor medical monitoring actions plaintiffs allege among things suffered osteonecrosis jaw generally subsequent invasive dental procedures tooth extraction dental implants andor delayed healing association use fosamax august jpml ordered fosamax product liability cases pending federal courts nationwide transferred consolidated one multidistrict litigation fosamax mdl coordinated pretrial proceedings fosamax mdl transferred judge john keenan united states district court southern district new york result jpml order approximately cases judge keenan judge keenan issued case management order various amendments thereto setting forth schedule governing proceedings focused primarily upon resolving class action certification motions completing fact discovery initial group cases october briefing argument plaintiffs motions certification medical monitoring classes completed judge keenan issued order denying motions january january judge keenan issued order dismissing prejudice class claims asserted first four class action lawsuits filed merck sought personal injury damages andor medical monitoring relief class wide basis october judge keenan issued order requiring daubert motions filed may scheduling trials first three cases mdl august october january respectively trial scheduled alabama state court later addition july application made atlantic county superior court new jersey requesting fosamax cases pending new jersey considered mass tort designation centralized management one judge new jersey october new jersey supreme court ordered pending future actions filed new jersey arising use fosamax seeking damages existing dental jawrelated injuries including osteonecrosis jaw solely seeking medical monitoring designated mass tort centralized management purposes judge higbee atlantic county superior court result new jersey supreme courts order approximately cases coordinated december judge higbee expected begin setting various case management deadlines first quarter discovery ongoing fosamax mdl litigation well various state court cases company intends defend lawsuits december company remaining reserve approximately million solely future legal defense costs fosamax litigation company spent approximately million added million reserve consequently december company reserve approximately million solely future legal defense costs fosamax litigation significant factors considered establishment reserve fosamax litigation legal defense costs follows actual costs incurred company thus far development companys legal defense table contents strategy structure light creation fosamax mdl number cases brought company anticipated timing progression related costs pretrial activities fosamax litigation company continue monitor legal defense costs review adequacy associated reserves due uncertain nature litigation company unable estimate costs beyond completion first three federal trials discussed company established reserves potential liability relating fosamax litigation unfavorable outcomes fosamax litigation could material adverse effect companys financial position liquidity results operations c ommercial litigation previously disclosed company joined ongoing litigation alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used calculations determine public private sector reimbursement levels jpml ordered transfer consolidation pending federal awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions also expanded number manufacturers include like company defendants prior pending case may court granted companys motion dismiss consolidated class action dismissed company class action case subsequent companys dismissal plaintiffs filed amended consolidated class action complaint name company defendant company many pharmaceutical manufacturers defendants similar complaints pending federal state court brought individually number counties state new york fifty county cases consolidated new york state court company dismissed suffolk county case first new york county cases filed addition new york county cases december company defendant state cases brought attorneys general eleven states defended february kansas attorney general filed suit merck several manufacturers additionally attorney general arizona voluntarily dismissed merck case february court awp cases pending hawaii listed merck others set trial mid g overnmental proceedings previously disclosed february company announced entered agreements government settle federal state civil cases alleging violations medicaid rebate statute well federal state false claims acts connection certain nominal pricing programs sales marketing activities connection settlements previously disclosed merck entered corporate integrity agreement cia us department health human services office inspector general hhsoig fiveyear term cia requires among things merck maintain ethics training program policies procedures governing promotional practices medicaid price reporting required cia merck retained independent review organization iro conduct systems review promotional policies procedures conduct sample basis transactional reviews mercks promotional programs certain medicaid pricing calculations merck also required provide regular reports certifications hhsoig regarding compliance cia iro currently conducting required reviews merck scheduled submit first annual report hhsoig may v ytorinzetia litigation previously disclosed company joint venture partner scheringplough received several letters addressed companies house committee energy commerce subcommittee oversight investigations oi ranking minority member senate finance committee collectively seeking combination witness interviews documents information variety issues related enhance clinical trial sale promotion vytorin well sales stock corporate officers addition since august companies received three additional letters oi including one dated february seeking certain information documents related seas clinical trial previously disclosed companies received subpoenas new york new jersey table contents state attorneys general offices letter connecticut attorney general seeking similar information documents addition company received five civil investigative demands cids multistate group state attorneys general jointly investigating whether companies violated state consumer protection laws marketing vytorin finally september company received letter civil division doj informing doj investigating whether companies conduct relating promotion vytorin caused false claims submitted federal health care programs company cooperating investigations working scheringplough respond inquiries addition company become aware served approximately civil class action lawsuits alleging common law state consumer fraud claims connection msp partnerships sale promotion vytorin zetia certain lawsuits allege personal injuries andor seek medical monitoring actions filed transferred federal court coordinated multidistrict litigation us district court district court new jersey district judge dennis cavanaugh parties presently engaged motions practice briefing also previously disclosed april merck shareholder filed putative class action lawsuit federal court eastern district pennsylvania alleging merck chairman president chief executive officer richard clark violated federal securities laws suit since withdrawn filed district new jersey consolidated another federal securities lawsuit caption merck co inc vytorin securities litigation amended consolidated complaint filed october names defendants merck merckscheringplough pharmaceuticals llc certain companys officers directors specifically complaint alleges merck delayed releasing unfavorable results clinical study regarding efficacy vytorin merck made false misleading statements expected earnings knowing results vytorin study released sales vytorin would decline mercks earnings would suffer april member merck erisa plan filed putative class action lawsuit company certain officers directors alleging breached fiduciary duties erisa since time similar erisa lawsuits filed company district new jersey lawsuits consolidated caption merck co inc vytorin erisa litigation amended consolidated complaint filed february names defendants merck various members mercks board directors members committees mercks board directors plaintiffs allege erisa plans investment company stock imprudent companys earnings dependent commercial success cholesterol drug vytorin defendants knew known results scientific study would cause medical community turn less expensive drugs cholesterol management company intends defend lawsuits referred section vigorously unfavorable outcomes resulting government investigations civil litigation could material adverse effect companys financial position liquidity results operations november individual shareholder previously delivered letter companys board directors demanding board take legal action responsible individuals recover amounts paid company resolve certain governmental investigations delivered another letter board demanding board subcommittee thereof commence investigation matters raised various civil suits governmental investigations relating vytorin v accine litigation previously disclosed company party individual class action product liability lawsuits claims united states involving pediatric vaccines eg hepatitis b vaccine contained thimerosal preservative used vaccines merck distributed thimerosalcontaining pediatric vaccines united states since fall december approximately thimerosal related lawsuits pending company defendant although vast majority lawsuits currently active defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result exposure thimerosal pediatric vaccines cases currently scheduled trial company defend lawsuits however possible table contents unfavorable outcomes could material adverse effect companys financial position liquidity results operations company successful cases type either dismissed stayed ground action prohibited national childhood vaccine injury act vaccine act vaccine act prohibits person filing maintaining civil action state federal court seeking damages vaccine manufacturer vaccinerelated injuries unless petition first filed united states court federal claims hereinafter vaccine court vaccine act filing civil action vaccine manufacturer petitioner must either pursue petition conclusion vaccine court timely file election proceed civil action lieu accepting vaccine courts adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribed time periods company party vaccine court proceedings petitions brought united states department health human services company aware approximately cases pending vaccine court involving allegations thimerosalcontaining vaccines andor mmr ii vaccine cause autism spectrum disorders thimerosalcontaining vaccines involved vaccine court proceeding company vaccines company sole source mmr ii vaccine domestically special masters presiding vaccine court proceedings held hearings three test cases involving theory combination mmr ii vaccine thimerosal vaccines causes autism spectrum disorders february special masters issued decisions cases finding theory unsupported valid scientific evidence petitioners three cases therefore entitled compensation special masters held similar hearings three different test cases involving theory thimerosal vaccines alone causes autism spectrum disorders decisions issued second set test cases special masters previously indicated would hold similar hearings involving theory mmr ii alone causes autism spectrum disorders stated longer intend vaccine court indicated intends use evidence presented test case hearings guide adjudication remaining autism spectrum disorder cases p atent litigation time time generic manufacturers pharmaceutical products file abbreviated new drug applications andas fda seeking market generic forms companys products prior expiration relevant patents owned company generic pharmaceutical manufacturers submitted andas fda seeking market united states generic form fosamax nexium singulair primaxin emend prior expiration companys astrazenecas case nexium patents concerning products addition anda submitted fda seeking market united states generic form zetia prior expiration scheringploughs patent concerning product generic companies andas generally include allegations noninfringement invalidity unenforceability patents company filed patent infringement suits federal court companies filing andas generic alendronate fosamax montelukast singulair imipenemcilastatin primaxin astrazeneca company filed patent infringement suits federal court companies filing andas generic esomeprazole nexium also company scheringplough filed patent infringement suit federal court companies filing andas generic ezetimibe zetia similar patent challenges exist certain foreign jurisdictions company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration dates patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products february scheringplough received notice generic company indicating filed anda zetia challenging us patents listed zetia merck scheringplough market zetia joint venture msp singapore company llc march scheringplough msp singapore company llc filed patent infringement suit glenmark pharmaceuticals inc usa parent corporation glenmark lawsuit automatically stays fda approval glenmarks anda october adverse court decision whichever may occur earlier table contents previously disclosed january company received letter ranbaxy laboratories ltd ranbaxy stating filed anda seeking approval generic version mercks primaxin imipenemcilastatin lawsuit asserted infringement mercks patent due expire september july merck ranbaxy entered agreement pursuant ranbaxy begin market united states generic form imipenemcilastatin september previously disclosed february company received notice teva pharmaceuticals inc teva generic company indicating filed anda montelukast challenging us patent listed singulair april company filed patent infringement action teva lawsuit automatically stays fda approval tevas anda august adverse court decision whichever may occur earlier trial matter commenced february previously disclosed january us court appeals federal circuit washington dc found companys patent claims onceweekly administration fosamax invalid company exhausted options appeal decision based court appeals decision fosamax fosamax plus lost marketing exclusivity united states result events company experiencing significant declines fosamax fosamax plus us sales similarly major foreign markets basic use patent covering alendronate expired generic products sold may federal court canada trial division issued decision refusing bar approval generic alendronate grounds mercks patent weekly alendronate likely invalid decision appealed generic alendronate launched canada june july merck sued federal court canada apotex corp apotex seeking damages lost sales generic weekly alendronate due patent proceeding october federal court canada issued decision awarding apotex lost profits generic alendronate product period time held market due mercks lawsuit company appealed decision previously disclosed september company appealed decision opposition division european patent office epo revoked companys patent europe covers onceweekly administration alendronate march board appeal epo upheld decision opposition division revoking patent march epo issued another patent europe company covers onceweekly administration alendronate terms new patent effective july company sued multiple parties european countries asserting european patent covering onceweekly dosing fosamax oppositions filed epo patent hearing proceeding scheduled march addition previously disclosed japan proceeding filed challenging validity companys japanese patent onceweekly administration alendronate patent office invalidated patent decision appeal october us patent dorzolamide covering trusopt cosopt expired company experienced significant decline us sales products company involved litigation proceedings corresponding patents canada great britain company astrazeneca received notice october ranbaxy filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium november company astrazeneca sued ranbaxy united states district court new jersey previously disclosed astrazeneca merck ranbaxy entered settlement agreement provides ranbaxy bring generic esomeprazole product market united states may company astrazeneca received cid united states federal trade commission ftc july regarding settlement agreement ranbaxy company cooperating ftc responding cid company astrazeneca received notice january ivax pharmaceuticals inc ivax subsequently acquired teva filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium march company astrazeneca sued teva united states district court new jersey january company astrazeneca sued dr reddys table contents laboratories dr reddys district court new jersey based dr reddys filing anda esomeprazole magnesium trial scheduled january respect ivaxs dr reddys andas addition company astrazeneca received notice december sandoz inc sandoz filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium january company astrazeneca sued sandoz district court new jersey based sandozs filing anda esomeprazole magnesium january company received notice anda filed fda aprepitant contained paragraph iv challenge patents emend company evaluating information provided notice determine action taken europe company aware various companies seeking registration generic losartan active ingredient cozaar company patent rights losartan via license ei du pont de nemours company du pont company du pont filed patent infringement proceedings various companies portugal spain norway austria ther litigation february individual shareholder delivered letter companys board directors demanding board take legal action responsible individuals recover amounts paid company resolve certain governmental investigations previously disclosed prior spinoff medco health solutions inc medco health company medco health agreed settle class action basis series lawsuits asserting violations erisa gruer cases company medco health certain plaintiffs counsel filed settlement agreement federal district court new york cases commenced number plaintiffs including participants number pharmaceutical benefit plans medco health pharmacy benefit manager well trustees plans consolidated medco health company agreed proposed settlement order avoid significant cost distraction prolonged litigation proposed class settlement agreed plaintiffs five cases filed medco health company proposed settlement company medco health agreed pay total million medco health agreed modify certain business practices continue certain specified business practices period five years financial compensation intended benefit members settlement class includes erisa plans medco health administered pharmacy benefit time since december district court held hearings hear objections fairness proposed settlement approved settlement yet determined number class member plans properly elected participate settlement settlement becomes final appeals resolved certain class member plans indicated participate settlement cases initiated three plans two individuals remain pending southern district new york plaintiffs cases asserted claims based erisa well federal state laws similar claims asserted settling class members gruer cases company medco health named defendants cases three notices appeal filed appellate court heard oral argument may december appellate court issued decision vacating district courts judgment remanding cases district court allow district court resolve certain jurisdictional issues hearing held address issues february district court issued ruling august resolving jurisdictional issues favor settling plaintiffs class members party previously appealed district courts judgment renewed appeals october renewed appeals affirmed part vacated part federal court appeals appeals court remanded class settlement proceedings district court district court preliminarily approved amended settlement may however plaintiffs initially opted settlement class filed objections settlement district court ordered briefing objections heard argument october district court yet issued ruling objections table contents spinoff medco health medco health assumed substantially liability exposure matters discussed foregoing three paragraphs cases defended medco health various legal proceedings principally product liability intellectual property suits involving company pending feasible predict outcome proceedings proceedings discussed note opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company proceedings separate assessment provided note e nvironmental matters company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying providing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties previously disclosed approximately plaintiffs filed amended complaint merck defendants united states district court eastern district california asserting claims clean water act resource conservation recovery act well negligence nuisance suit seeks damages personal injury diminution property value medical monitoring alleged real personal property damage associated groundwater soil contamination found site former merck subsidiary merced california company intends defend claims managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year stockholders equity paidin capital increased million million million increases periods reflect sharebased compensation activity including recognition sharebased compensation impact shares issued related income tax benefits increase also reflects issuance shares related acquisition novacardia see note table contents summary treasury stock transactions shares millions follows shares cost shares cost shares cost b alance january purchases issuances b alance december issued primarily sharebased compensation plans december million shares preferred stock without par value authorized none issued sharebased compensation plans company sharebased compensation plans employees nonemployee directors employees certain companys equity method investees may granted options purchase shares company common stock fair market value time grant addition stock options company grants performance share units psus restricted stock units rsus certain management level employees plans approved companys shareholders december million shares authorized future grants companys sharebased compensation plans company settles employee sharebased compensation awards primarily treasury shares employee stock options granted purchase shares company stock fair market value time grant awards generally vest onethird year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock awards vest well nonforfeitable dividend equivalents fair value awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized based ultimate number shares issued psu rsu payouts shares company stock end vesting performance period generally three years subject terms applicable awards company recognizes employee sharebased compensation expense pursuant fasb statement r sharebased payment requires recognition fair value sharebased compensation net income company recognizes straightline basis requisite service period addition company applied provisions fasb staff position r transition election related accounting tax effects sharebased payment awards provided company optional shortcut method calculating historical pool windfall tax benefits compensation expense recognized immediately awards granted retirementeligible employees period grant date date retirement eligibility achieved approach known nonsubstantive vesting period approach total pretax sharebased compensation cost recorded consolidated statement income million million million respectively related income tax benefits million million million respectively company uses blackscholes option pricing model determining fair value option grants applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected dividend yield riskfree interest rate volatility term options expected dividend yield based historical patterns dividend payments riskfree rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained table contents market data companys traded options expected life represents expected amount time options granted expected outstanding based historical forecasted exercise behavior weighted average fair value options granted per option respectively determined using following assumptions ears ended december e xpected dividend yield riskfree interest rate expected volatility expected life years summarized information relative companys stock option plans activity options thousands follows weighted weighted average average remaining aggregate number exercise contractual intrinsic options price term value balance january granted exercised forfeited utstanding december exercisable december additional information pertaining companys stock option plans provided table ears ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options summary companys nonvested rsu psu activity shares thousands follows r sus p us weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested january granted vested forfeited n onvested december psu rollforward excludes thousand additional shares ultimately issuedvested connection psus granted exceeded anticipated performance targets december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses table contents pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries pension benefits united states based formula considers final average pay years credited service addition company provides medical dental life insurance benefits principally eligible us retirees similar benefits dependents postretirement benefit plans company uses december yearend measurement date pension plans postretirement benefit plans net cost companys pension postretirement benefit plans consisted following components ot h er po stretir e men pension benefits benefits years ended december service cost interest cost expected return plan assets net amortization termination benefits curtailments settlements n et pension postretirement cost net pension cost attributable us plans included table million million million connection companys restructuring actions see note merck recorded termination charges pension postretirement benefit plans related expanded eligibility certain employees exiting company also connection restructuring activities company recorded net curtailment losses pension plans net curtailment gains postretirement benefit plans amendments changed participant contributions postretirement benefit plans generated curtailment gains addition company recorded settlement losses certain domestic international pension plans table contents summarized information changes plan assets benefit obligation funded status amounts recorded december follows ther po treti rement pension benefits benefits fair value plan assets january actual return plan assets company contributions benefits paid plan assets f air value plan assets december benefit obligation january service cost interest cost actuarial losses gains benefits paid plan amendments curtailments termination benefits b enefit obligation december funded status december recognized assets accrued current liabilities deferred income taxes noncurrent liabilities fair value us pension plan assets included preceding table billion billion pension benefit obligation us plans included table billion billion weighted average asset allocations investment portfolio pension postretirement benefit plans december follows ther pension benefits postretirement benefits target target us equities international equities fixedincome investments real estate investments cash cash equivalents target investment portfolios companys pension plans determined country based nature liabilities considering demographic composition plan participants average age years table contents service active versus retiree status local regulations investments include insurance contracts certain international pension plans target investment portfolio asset allocation companys postretirement benefit plans consistent longterm nature plans benefit obligation well diversified among asset classes portfolio invests actual return plan assets pension postretirement benefit plans reflects portfolios allocation global equity markets delivered significant negative returns result decline plan assets noted company contributed million pension plans postretirement benefit plans fourth quarter contributions pension plans postretirement benefit plans expected million million respectively expected benefit payments follows pension postretirement benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service december accumulated benefit obligation billion billion respectively pension plans december accumulated benefit obligation us pension plans billion billion respectively pension plans benefit obligations excess plan assets december fair value plan assets billion million respectively benefit obligation billion billion respectively plans accumulated benefit obligations excess plan assets december fair value plan assets million million respectively accumulated benefit obligation million million respectively effective december company adopted fasb statement employers accounting defined benefit pension postretirement plans amendment fasb statements r fas except requirement measure plan assets benefit obligations companys fiscal year end effective december fas required company fully recognize funded status benefit plans overfunded plan recognized asset underfunded plan recognized liability previously unrecognized net losses unrecognized plan changes recognized component aoci see note table contents net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees following amounts reflected components comprehensive income pension postretirement year ended december plans benefit plans total net loss arising period prior service credit arising period n et loss amortization included benefit cost prior service cost credit amortization included benefit cost year ended december n et gain loss arising period prior service credit cost arising period n et loss amortization included benefit cost prior service cost credit amortization included benefit cost estimated net loss prior service cost credit amounts amortized aoci net pension postretirement benefit cost million million respectively pension plans million million respectively postretirement benefit plans company reassesses benefit plan assumptions regular basis weighted average assumptions used determining pension plan us pension postretirement benefit plan information follows us p ens ion ther postretirement pension plans benefit plans december net cost iscount rate expected rate return plan assets salary growth rate b enefit obligation iscount rate salary growth rate expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined country basis developing expected rate return within country long term historical returns data considered well actual returns plan assets capital markets experience using reference information longterm return expectations asset category weighted average expected return countrys target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active table contents management appropriate companys expected rate return remain unchanged us pension postretirement benefit plans health care cost trend rate assumptions postretirement benefit plans follows ecember health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate one percentage point change health care cost trend rate would following effects one p ercen tage point increase decrease effect total service interest cost components effect benefit obligation income expense net ears ended december interest income interest expense exchange losses gains minority interests net fluctuation exchange losses gains primarily due higher cost foreign currency contracts due lower us interest rates unfavorable impacts periodtoperiod changes foreign currency exchange rates net long net short foreign currency positions considering net monetary assets related foreign currency contracts change net primarily reflects aggregate gain azlp billion see note impact million charge related resolution certain civil governmental investigations gain million related sale companys remaining worldwide rights aggrastat partially offset million expense contribution merck company foundation higher recognized losses million net companys investment portfolio million charge related resolution investigation whether company violated consumer protection laws respect sales marketing vioxx see note change net primarily reflects charge related resolution certain civil governmental investigations partially offset favorable impact gains sales assets product divestitures well net gain settlements certain patent disputes interest paid million million million table contents taxes income reconciliation companys effective tax rate us statutory rate follows amount tax rate amount tax rate amount tax rate u statutory rate applied income taxes differential arising foreign earnings foreign tax credit utilization state tax settlements tax exemption puerto rico operations state taxes acquired research includes tax effect minority interests contingency reserves research credits export incentives miscellaneous items tax rate reconciliation percentage foreign earnings reflects change mix foreign domestic earnings primarily resulting billion us vioxx settlement agreement charge income loss taxes consisted ears ended december domestic foreign taxes income consisted ears ended december current provision federal foreign state deferred provision federal foreign state table contents deferred income taxes december consisted assets liabilities assets liabilities intangibles inventory related accelerated depreciation advance payment equity investments pensions postretirement benefits compensation related vioxx litigation reserve unrecognized tax benefits net operating losses subtotal valuation allowance otal deferred taxes n et deferred income taxes recognized deferred income taxes current assets assets income taxes payable deferred income taxes noncurrent liabilities company net operating loss nol carryforwards number jurisdictions significant united kingdom nol carryforwards million expiration date valuation allowance years primarily relates certain canadian nol carryforwards resulting legal entity reorganization income taxes paid billion billion billion respectively stock option exercises reduced income taxes paid million stock option exercises significant impact taxes paid january company adopted provisions fasb interpretation accounting uncertainty income taxes interpretation fasb statement fin resulted recognition million decrease companys existing liability unrecognized tax benefits corresponding increase january retained earnings balance implementation fin january companys liability unrecognized tax benefits billion excluding liabilities interest penalties table contents reconciliation beginning ending amount unrecognized tax benefits follows balance january additions related current year positions additions related prior year positions reductions tax positions prior years settlements lapse statute limitations b alance december reflects settlement internal revenue service irs discussed company recognize unrecognized tax benefits billion december income tax provision would reflect favorable net impact billion company recognizes interest penalties exchange gains losses associated uncertain tax positions component taxes income consolidated statement income interest penalties associated uncertain tax positions amounted million million liabilities accrued interest penalties included consolidated balance sheet billion billion billion december december january previously disclosed irs completed examination companys tax returns years result examination company made aggregate payment billion february payment offset tax refund million received amounts previously paid matters ii federal tax benefit approximately million related interest included payment resulting net cash cost company approximately billion impact years subsequent items reviewed part examination included payment although years remain open respects closing irs examination material impact companys results operations amounts previously provided company reported results irs adjustments years various state tax authorities resulted additional tax well interest penalty payments million million respectively million million respectively equivalent reduction balances unrecognized tax benefits accrued interest penalties amount unrecognized tax benefits change next months due anticipated closure various foreign state tax examinations including settlement canada revenue agency cra discussed company estimates change could result reduction unrecognized tax benefits approximately billion previously disclosed october cra issued company notice reassessment containing adjustments related certain intercompany pricing matters february merck cra negotiated settlement agreement regard matters settlement calls merck pay additional tax approximately million us dollars interest approximately million us dollars additional amounts penalties due assessment accordance fin settlement accounted first quarter company previously established reserves matters significant portion taxes paid expected creditable us tax purposes resolution matters material effect companys financial position liquidity respect associated collateral discussed addition july november cra proposed additional adjustments respectively relating intercompany pricing matters adjustments would increase canadian tax due approximately million us dollars plus million us dollars interest possible cra propose similar adjustments later years company disagrees positions taken cra believes without merit company intends contest assessments cra appeals table contents process courts necessary management believes resolution matters material effect companys financial position liquidity connection appeals process company pledged collateral two financial institutions one provided guarantee cra quebec ministry revenue representing portion tax interest assessed collateral included deferred income taxes current assets assets consolidated balance sheet totaled approximately billion billion december respectively guarantees reduced related collateral released following payments cra quebec ministry revenue causing restricted amounts reclassified cash investments appropriate consolidated balance sheet irs examining companys federal income tax returns addition various state foreign tax examinations progress tax years remain subject examination major tax jurisdictions include germany italy japan december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income taxes would payable upon distributions earnings addition company subsidiaries operating puerto rico singapore tax incentive grants expire respectively earnings per share weighted average common shares used computations basic earnings per common share earnings per common share assuming dilution shares millions follows ears ended december verage common shares outstanding common shares issuable verage common shares outstanding assuming dilution issuable primarily sharebased compensation plans million million million respectively common shares issuable companys sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive table contents comprehensive income components comprehensive income follows p retax tax fter tax year ended december n et unrealized gain derivatives net loss realization erivatives n et unrealized loss investments net loss realization nvestments b enefit plan net loss gain prior service cost credit net amortization c umulative translation adjustment related equity investees year ended december n et unrealized loss derivatives net loss realization erivatives n et unrealized gain investments net gain realization nvestments b enefit plan net gain loss prior service cost credit net amortization c umulative translation adjustment related equity investees year ended december n et unrealized loss derivatives net loss realization erivatives n et unrealized gain investments net loss realization nvestments inimum pension liability c umulative translation adjustment related equity investees net applicable minority interest table contents components accumulated comprehensive loss follows ecember net unrealized gain loss derivatives net unrealized gain investments pension plan net loss postretirement benefit plan net loss pension plan prior service cost postretirement benefit plan prior service cost cumulative translation adjustment related equity investees december million net unrealized gain derivatives associated options maturing next months hedge anticipated foreign currency denominated sales period segment reporting companys operations principally managed products basis comprised two reportable segments pharmaceutical segment vaccines infectious diseases segment segment composition reflects certain managerial changes implemented early addition first quarter company revised calculation segment profits include greater allocation costs segments segment disclosures prior periods recast comparable basis pharmaceutical segment includes human health pharmaceutical products marketed either directly merck joint ventures products consist therapeutic preventive agents sold prescription treatment human disorders merck sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccines infectious diseases segment includes human health vaccine infectious disease products marketed either directly merck case vaccines also joint venture vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices merck sells human health vaccines primarily physicians wholesalers physician distributors government entities large component pediatric adolescent vaccines sold us centers disease control prevention vaccines children program funded us government infectious disease products consist therapeutic agents treatment infection sold primarily drug wholesalers retailers hospitals government agencies vaccines infectious diseases segment includes majority companys aggregate vaccine infectious disease product sales excludes sales products nonus subsidiaries included pharmaceutical segment table contents segments include nonreportable human animal health segments accounting policies segments described described note revenues profits segments follows v accines infectious pharmaceutical diseases total year ended december egment revenues segment profits included segment profits equity income affiliates depreciation amortization ear ended december egment revenues segment profits included segment profits equity income affiliates depreciation amortization ear ended december egment revenues segment profits included segment profits equity income affiliates depreciation amortization segment profits comprised segment revenues less certain elements materials production costs operating expenses including components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker company allocate vast majority indirect production costs research development expenses general administrative expenses well cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits table contents sales companys products follows ears ended december p harmaceutical singulair cozaarhyzaar fosamax januvia cosopttrusopt zocor maxalt propecia arcoxia vasotecvaseretic janumet proscar emend pharmaceutical vaccine infectious disease product sales included pharmaceutical segment p harmaceutical segment revenues v accines infectious diseases gardasil proquadmmr iivarivax rotateq zostavax hepatitis vaccines vaccines primaxin cancidas isentress crixivanstocrin invanz infectious disease vaccine infectious disease product sales included pharmaceutical segment v accines infectious diseases segment revenues ther segment revenues total segment revenues ther presented net discounts returns pharmaceutical primarily includes sales human pharmaceutical products revenue companys relationship azlp primarily relating sales nexium well prilosec revenue azlp billion billion billion respectively pharmaceutical also reflects certain supply sales including supply sales associated companys arrangement dr reddys laboratories sale generic simvastatin sales vaccine infectious disease products nonus subsidiaries included pharmaceutical segment amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd includes nonreportable human animal health segments revenues primarily comprised miscellaneous corporate revenues sales related divested products businesses supply sales included segment results table contents consolidated revenues geographic area derived follows ears ended december united states europe middle east africa japan reconciliation total segment profits consolidated income taxes follows ears ended december segment profits profits adjustments unallocated interest income interest expense equity income affiliates depreciation amortization research development gain distribution astrazeneca lp us vioxx settlement agreement charge expenses net profits primarily comprised miscellaneous corporate profits well operating profits related divested products businesses supply sales adjustments represent elimination effect double counting certain items income expense equity income affiliates includes taxes paid joint venture level portion equity income reported segment profits expenses net include expenses corporate manufacturing cost centers miscellaneous income expense net longlived assets geographic area located follows ears ended december united states europe middle east africa japan longlived assets comprised property plant equipment net goodwill intangible assets net company disaggregate assets products services basis internal management reporting therefore information presented table contents r eport independent registered public accounting firm board directors shareholders merck co inc n opinion consolidated balance sheets related consolidated statements income retained earnings comprehensive income cash flows present fairly material respects financial position merck co inc subsidiaries december december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso companys management responsible financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included managements report item responsibility express opinions financial statements companys internal control financial reporting based integrated audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audits obtain reasonable assurance whether financial statements free material misstatement whether effective internal control financial reporting maintained material respects audits financial statements included examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions discussed note consolidated financial statements company changed manner accounts defined benefit pension postretirement plans discussed note consolidated financial statements company changed manner accounts unrecognized tax benefits companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements b ecause inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate p ricewaterhousecoopers llp florham park new jersey february table contents b supplementary data selected quarterly financial data contained condensed interim financial data table c ondensed interim financial data unaudited millions except per share amounts h q r q n q q ales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates income expense net income taxes net income basic earnings per common share earnings per common share assuming dilution ales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates us vioxx settlement agreement charge income expense net loss income taxes net loss income basic loss earnings per common share loss earnings per common share assuming dilution fourth quarter tax provision reflects favorable impact foreign exchange rate changes benefit relating us research development tax credit amounts fourth quarter include impact us vioxx settlement agreement charge civil governmental investigations charge insurance arbitration gain see note fourth quarter tax provision addition items also reflects favorable impacts adjustments relating certain federal state tax items amounts fourth quarter third second quarter include impact additional vioxx legal defense reserves see note amounts first quarter include impact additional fosamax legal defense reserves see note amounts third quarter include acquired research expense associated acquisition see note net gain settlements certain patent disputes amounts reflect favorable impact tax settlements amounts include gain distribution astrazeneca lp see note gain related sale companys remaining worldwide rights aggrastat realization foreign tax credits expense contribution merck company foundation amounts include gains sales assets product divestitures amounts include impact restructuring actions see note table contents item changes disagreements accountants accounting financial disclosure applicable tem controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective management responsible establishing maintaining adequate internal control financial reporting term defined rule af act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission coso based evaluation management concluded internal control financial reporting effective december pricewaterhousecoopers llp independent registered public accounting firm performed assessment effectiveness companys internal control financial reporting attestation report included filing significant changes internal control financial reporting period covered report materially affected reasonably likely materially affect companys internal control financial reporting company previously disclosed process multiyear implementation enterprise wide resource planning system implementation system united states planned include modifications design operation documentation internal controls financial reporting material problem planned implementation subsequent interruption system data contained within could material effect effectiveness internal control financial reporting company plan contingency measures minimize risk disruption anagements report anagements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices company periodically conducts managements stewardship program key management financial personnel program reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows table contents formal certification securities exchange commission included filing addition may company submitted new york stock exchange nyse certificate ceo certifying aware violation company nyse corporate governance listing standards anagements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act companys internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states america management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december inherent limitations internal control financial reporting may prevent detect misstatements projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein richard clark chairman president peter n kellogg chief executive officer executive vice president chief financial officer tem b information none part iii tem directors executive officers corporate governance required information directors nominees incorporated reference discussion item election directors companys proxy statement annual meeting stockholders held april information executive officers set forth part document pages required information compliance section securities exchange act incorporated reference discussion heading section beneficial ownership reporting compliance companys proxy statement annual meeting stockholders held april company adopted code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer code conduct available companys website wwwmerckcomaboutcorporategovernance company intends post website amendments waivers code conduct printed copy sent without charge stockholder requests writing chief ethics officer merck co inc one merck drive whitehouse station nj table contents required information identification audit committee audit committee financial expert incorporated reference discussion heading board committees companys proxy statement annual meeting stockholders held april tem executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table grants planbased awards table outstanding equity awards fiscal yearend table option exercises stock vested table retirement plan benefits related pension benefits table nonqualified deferred compensation related tables potential payments termination change control including discussion subheadings separation separation plan payment benefit estimates table individual agreements change control change control payment benefit estimates table well footnote information various tables companys proxy statement annual meeting stockholders held april required information director compensation incorporated reference discussion heading director compensation related director compensation table schedule director fees table companys proxy statement annual meeting stockholders held april required information headings compensation committee interlocks insider participation compensation benefits committee report incorporated reference companys proxy statement annual meeting stockholders held april tem security ownership certain beneficial owners management related stockholder matters information respect securities authorized issuance equity compensation plans incorporated reference discussion heading equity compensation plan information companys proxy statement annual meeting stockholders held april information respect security ownership certain beneficial owners management incorporated reference discussion heading security ownership certain beneficial owners management companys proxy statement annual meeting stockholders held april tem certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading related person transactions companys proxy statement annual meeting stockholders held april required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting stockholders held april tem principal accountant fees services information required item incorporated reference discussion audit committee beginning caption preapproval policy services independent registered public accounting firm fees companys proxy statement annual meeting stockholders held april table contents part iv tem exhibits financial statement schedules following documents filed part financial statements consolidated statement income years ended december consolidated statement retained earnings years ended december consolidated statement comprehensive income years ended december consolidated balance sheet december consolidated statement cash flows years ended december notes consolidated financial statements report pricewaterhousecoopers llp independent registered public accounting firm table contents financial statement schedules merckscheringplough cholesterol partnership combined financial statements erckscheringplough cholesterol partnership combined statements net sales contractual expenses years ended december millions net sales c ost sales selling general administrative research development ncome operations erckscheringplough cholesterol partnership combined balance sheets december millions assets cash cash equivalents accounts receivable net inventories prepaid expenses assets total assets liabilities partners capital rebates payable payable merck net payable scheringplough net accrued expenses liabilities total liabilities commitments contingent liabilities notes partners capital total liabilities partners capital accompanying notes integral part combined financial statements table contents merckscheringplough cholesterol partnership combined statements cash flows years ended december millions operating activities income operations adjustments reconcile income operations net cash provided operating activities accounts receivable net inventories prepaid expenses assets rebates payable payable merck scheringplough net accrued expenses liabilities noncash charges net cash provided operating activities f inancing activities contributions partners distributions partners net cash used financing activities n et increasedecrease cash cash equivalents cash cash equivalents beginning period c ash cash equivalents end period accompanying notes integral part combined financial statements table contents merckscheringplough cholesterol partnership combined statements partners capital deficit millions chering plough merck total balance january contributions partners income operations distributions partners b alance december contributions partners income operations distributions partners b alance december contributions partners income operations distributions partners b alance december accompanying notes integral part combined financial statements table contents merckscheringplough cholesterol partnership notes combined financial statements description business basis presentation escription business may merck co inc merck scheringplough corporation scheringplough collectively partners entered agreements agreements jointly develop market united states scheringploughs investigational cholesterol absorption inhibitor cai ezetimibe marketed today united states zetia ezetrol countries cholesterol collaboration fixed combination tablet containing active ingredients montelukast sodium loratadine respiratory collaboration montelukast sodium leukotriene receptor antagonist sold merck singulair loratadine antihistamine sold scheringplough claritin indicated relief symptoms allergic rhinitis respiratory collaboration terminated accordance applicable agreements following receipt notapprovable letter us food drug administration fda fixedcombination tablet cholesterol collaboration formally referred merckscheringplough cholesterol partnership partnership december cholesterol collaboration agreements expanded include countries world except japan cholesterol collaboration agreements provide ezetimibe developed marketed following forms ezetimibe daily cai nonstatin cholesterol reducing medicine used alone coadministered statin drug ezetimibe simvastatin mercks existing zocor statin cholesterol modifying medicine combined one tablet marketed today united states vytorin inegy countries vytorin zetia approved fda july october respectively together products whether marketed vytorin zetia trademarks locally referred cholesterol products cholesterol collaboration agreements partners established jointlyowned limited purpose legal entities based canada united states carry contractual activities partnership countries additional jointlyowned limited purpose legal entity based singapore established rights intellectual property fund oversee research development manufacturing activities cholesterol collaboration markets except latin america subsidiaries merck scheringplough perform marketing activities cholesterol products contract partnership legal entity subsidiary operations collectively referred combined companies latin america partnership sells directly scheringplough mercks latin american subsidiaries scheringplough merck compete one another cholesterol market consequently selling promotion distribution activities cholesterol products within latin america included combined companies partnership substantially reliant infrastructures merck scheringplough limited number employees legal entities partnership activities performed employees either merck scheringplough service agreements partnership profits shared partners differing arrangements countries around world generally defined net sales minus agreed upon manufacturing costs expenses incurred partners invoiced partnership direct promotion expenses incurred partners invoiced partnership expenses limited specialty sales force united states incurred partners invoiced partnership certain amounts sales force physician detailing cholesterol products united states puerto rico canada italy administration expenses based percentage cholesterol product net sales invoiced one partners costs expenses incurred partners contemplated cholesterol collaboration agreements entered subsequently agreed partners table contents agreed upon research development expenses incurred partners invoiced partnership shared equally partners adjusting special allocations nature milestones due one partners partnerships future results operations financial position cash flows may differ materially historical results presented herein risks uncertainties related partnerships business partnerships future operating results cash flows dependent cholesterol products events adversely affect market products could significant impact partnerships results operations cash flows events could include loss patent protection increased costs associated manufacturing increased competition introduction new effective treatments exclusion government reimbursement programs discontinuation removal market product safety reason results future clinical outcomes studies note b asis presentation accompanying combined balance sheets combined statements net sales contractual expenses cash flows partners capital deficit include cholesterol respiratory collaboration activities combined companies respiratory collaboration activities primarily pertained clinical development work prelaunch marketing activities spending respiratoryrelated activities ceased following termination collaboration material income operations years presented net sales include net sales cholesterol products sold combined companies expenses include amounts merck scheringplough contractually agreed directly invoice partnership shared contractual profit sharing arrangements partners described accompanying combined financial statements prepared purpose complying certain rules regulations securities exchange commission reflect activities partnership based contractual agreements partners combined financial statements include expenses agreed partners shared included calculation profits contractual agreements partnership intended complete presentation costs expenses would incurred standalone pharmaceutical company discovery development manufacture distribution marketing pharmaceutical products cholesterol collaboration agreements certain activities charged partnership partners based contractually agreed upon allocations partnerincurred expenses described opinion management allocations expenses described made basis reasonably reflects actual level support provided expenses expenses partners reflected separate consolidated financial statements described profit sharing arrangements cholesterol collaboration agreements provide certain partnerincurred costs expenses invoiced partnership partners therefore become part profit sharing calculation following paragraphs list typical categories costs expenses generally incurred discovery development manufacture distribution marketing cholesterol products provide description costs expenses treated accompanying combined statements net sales contractual expenses determining profits contractual agreements manufacturing costs expenses contractually agreed upon manufacturing plant costs expenses incurred partners related manufacture cholesterol products included cost sales accompanying combined statements net sales contractual expenses including direct production costs certain production variances expenses plant services administration warehousing distribution materials management technical services quality control asset utilization manufacturing costs expenses incurred partners agreed included determination profits contractual agreements invoiced partnership therefore excluded accompanying combined financial statements costs expenses include limited yield gains losses excess jointly agreed upon yield rates excessidle capacity manufacturing plant assets table contents direct promotion expenses direct promotion represents direct identifiable outofpocket expenses incurred partners behalf partnership including limited contractually agreed upon expenses related market research detailing aids agency fees directtoconsumer advertising meetings symposia trade programs launch meetings special sales force incentive programs product samples contractually agreed upon expenses included selling general administrative accompanying combined statements net sales contractual expenses promotion expenses incurred partners agreed included determination profits contractual agreements excluded accompanying combined financial statements selling expenses united states canada puerto rico markets outside united states primarily italy general sales forces partners provide majority physician detail activity agreed upon cost included selling general administrative accompanying combined statements net sales contractual expenses addition agreed upon costs limited specialty sales force united states market calls opinion leaders field cholesterol medicine also included selling general administrative selling expenses incurred partners agreed included determination profits contractual agreements excluded accompanying combined financial statements expenses include total costs general sales forces partners detailing cholesterol products countries united states canada puerto rico italy administrative expenses administrative support primarily provided one partners contractually agreed upon expenses support determined based percentage net sales cholesterol products amounts included selling general administrative accompanying combined statements net sales contractual expenses selected contractually agreed upon direct costs employees partners support services outofpocket expenses incurred partners behalf partnership also included selling general administrative expenses incurred partners agreed included determination profits contractual agreements excluded accompanying combined financial statements expenses include limited certain us managed care services partners subsidiary management international markets indirect expenses corporate overhead interest research development rd expenses rd activities performed partners agreed upon costs expenses invoiced partnership agreed upon expenses generally represent allocation partners estimate full time equivalents devoted preclinical postmarketing clinical development regulatory activities include grants thirdparty expenses contractually agreed upon allocated costs included research development accompanying combined statements net sales contractual expenses rd costs incurred partners jointly agreed upon excluded accompanying combined financial statements summary significant accounting policies p rinciples combination accompanying combined balance sheets combined statements net sales contractual expenses cash flows partners capital deficit include cholesterol respiratory collaboration activities combined companies interpartnership balances profits eliminated u se estimates combined financial statements prepared based contractual agreements partners described include certain amounts based managements best estimates judgments estimates used determining items provisions sales discounts returns government managed care rebates uncertainty inherent estimates actual results may differ estimates table contents foreign currency translation net assets partnerships foreign operations translated us dollars current exchange rates us dollar effects arising translating net assets operations included partners capital significant c ash cash equivalents cash cash equivalents primarily consist highly liquid money market instruments original maturities less three months partnership changed certain cash management practices increasing amount cash held partnership partnerships cash primarily invested highly liquid money market instruments used fund trade obligations coming due month distributions partners interest income earned cash cash equivalents reported reduction selling general administrative accompanying combined statements net sales contractual expenses amounted million million million respectively nventories substantially inventories valued lower first first cost market ntangible assets intangible assets consist licenses trademarks trade names owned partnership intangible assets recorded partners historical cost date contribution nominal value r evenue recognition rebates returns allowances revenues sales cholesterol products recognized title risk loss pass customer recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations net sales vytorininegy zetiaezetrol years ended december follows millions vytorininegy zetiaezetrol otal united states sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesale purchaser known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions sales recorded net provisions sales discounts returns reliable estimates made time sale reserves chargebacks discounts returns allowances reflected direct reduction accounts receivable amounted million million december respectively accruals rebates reflected rebates payable shown separately combined balance sheets ncome taxes generally taxable income losses partnership allocated partners included partners income tax return states jurisdictions partnership subject income tax included combined financial statements shared partners except income taxes significant combined financial statements provision made federal foreign state income taxes december partnership million deferred tax assets comprised solely net operating loss carryforwards nols generated branch legal entity partnership nols expire carry full valuation allowance january partnership adopted financial accounting standards board interpretation accounting uncertainty income taxes fin adoption fin impact partnerships financial statements c oncentrations credit risk segment information partnerships concentrations credit risk consist primarily accounts receivable partnership normally require collateral security support credit sales bad debts years ended table contents december minimal december three customers represented accounts receivable net three customers accounted net sales shown table p er cen f n et sa les mckesson drug company cardinal health inc amerisourcebergen corp partnership derived approximately combined net sales united states respectively ermination respiratory collaboration respiratory collaboration terminated accordance applicable agreements following receipt notapprovable letter fda proposed montelukastloratadine combination tablet result termination scheringplough received million incremental allocations partnership profits except allocation certain profits termination impact cholesterol collaboration inventories inventories december consisted millions finished goods raw materials work process otal partnership entered longterm agreements partners supply active pharmaceutical ingredients api formulation packaging cholesterol products agreed upon cost connection supply agreements partnership entered capacity agreements partnership committed take specified annual minimum supply api formulated tablets pay penalty capacity agreements effect period seven years following first full year production one partners expire beginning partnership payment obligation capacity agreements december related party transactions partnership receives substantially goods services including pharmaceutical product manufacturing services sales force services administrative services rd services partners partnership net payable merck scheringplough services million million respectively december million million respectively december selling general administrative expense includes contractually defined costs physician detailing provided scheringplough merck million million respectively million million respectively million million respectively expenses necessarily reflective actual cost partners sales efforts countries amounts contractually defined included amounts million million million respectively relating contractually defined costs physician detailing italy amounts invoiced paid partnership partners component profit sharing calculation cost sales selling general administrative expense also include contractually defined costs distribution administrative services provided merck scheringplough million million million respectively amounts necessarily reflective actual costs distribution administrative services table contents partnership also sells cholesterol products directly partners principally merck schering plough affiliates latin america latin america partners compete one another cholesterol market merck scheringplough purchase cholesterol products partnership sell directly third parties sales partners included net sales invoiced price accompanying combined statements net sales contractual expenses totaled million million million respectively legal matters partnership may become party claims legal proceedings nature considered normal business including product liability intellectual property partnership records liability connection matters probable liability incurred amount reasonably estimated legal costs associated litigation investigation activities expensed incurred partnership maintains insurance coverage deductibles selfinsurance management believes cost beneficial partnership selfinsures risk relates product liability accrues estimate product liability claims incurred reported february scheringplough received notice glenmark pharmaceuticals inc usa glenmark generic pharmaceutical company indicating filed abbreviated new drug application anda generic form zetia challenging us patents listed zetia march scheringplough partnership filed patent infringement suit glenmark parent company lawsuit automatically stays fda approval glenmarks anda earlier october adverse court decision scheringplough partnership intend vigorously defend patents believe valid infringement generic companies attempting market products prior expiration dates patents litigation assurances outcomes adverse could result significantly shortened periods exclusivity january partners announced results effect combination ezetimibe highdose simvastatin vs simvastatin alone atherosclerotic process patients heterozygous familial hypercholesterolemia enhance clinical trial imaging trial patients heterozygous familial hypercholesterolemia rare genetic condition causes high levels ldl bad cholesterol greatly increases risk premature coronary artery disease despite fact ezetimibesimvastatin mg vytorin significantly lowered ldl bad cholesterol simvastatin mg alone significant difference treatment ezetimibesimvastatin simvastatin alone prespecified primary endpoint change thickness carotid artery walls two years measured ultrasound also significant differences treatment ezetimibesimvastatin simvastatin four pre specified key secondary endpoints percent patients manifesting regression average carotid artery intima media thickness ca imt proportion patients developing new carotid artery plaques mm changes average maximum ca imt changes average ca imt plus average common femoral artery imt enhance compared simvastatin alone ezetimibesimvastatin significantly lowered ldl bad cholesterol well triglycerides creactive protein crp ezetimibesimvastatin indicated reduction crp enhance study overall safety profile ezetimibesimvastatin generally consistent product label enhance study designed powered evaluate cardiovascular clinical events improved reduction highrisk subjects presenting acute coronary syndrome improveit trial underway designed provide cardiovascular outcomes data ezetimibesimvastatin patients acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrated simvastatin established march results enhance reported annual scientific session american college cardiology january fda announced completed review final clinical study report enhance fda stated results enhance change position elevated ldl cholesterol risk factor cardiovascular disease lowering ldl cholesterol reduces risk cardiovascular disease fda also stated based current available data patients stop taking vytorin cholesterol lowering medications talk doctor questions vytorin zetia enhance trial table contents july efficacy safety results simvastatin ezetimibe aortic stenosis seas study announced seas designed evaluate whether intensive lipid lowering vytorin mg would reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patients asymptomatic mild moderate aortic stenosis indication statin therapy vytorin failed meet primary end point reduction major cardiovascular events also significant difference key secondary end point aortic valve events however reduction group patients taking vytorin compared placebo key secondary end point ischemic cardiovascular events vytorin indicated treatment aortic stenosis incremental benefit vytorin cardiovascular morbidity mortality demonstrated simvastatin established study patients group took vytorin mg higher incidence cancer group took placebo also nonsignificant increase deaths cancer patients group took vytorin versus took placebo cancer cancer deaths distributed across major organ systems partners partnership believe cancer finding seas likely anomaly taken light available data support association vytorin august fda announced investigating results seas trial announcement fda also cited interim data two large ongoing cardiovascular trials vytorin study heart renal protection sharp improveit clinical trials increased risk cancer combination simvastatin plus ezetimibe sharp trial expected completed improveit trial scheduled completion around fda determined time findings seas trial plus interim data ongoing trials prompt patients stop taking vytorin cholesterol lowering drug partners partnership committed working regulatory agencies evaluate available data interpretations data believe changes clinical use vytorin warranted previously disclosed since december merck scheringplough received several letters addressed companies house committee energy commerce subcommittee oversight investigations oi ranking minority member senate finance committee collectively seeking combination witness interviews documents information variety issues related enhance clinical trial sale promotion vytorin well sales stock corporate officers merck scheringplough addition since august partners received three additional letters oi including one dated february seeking certain information documents related seas clinical trial also previously disclosed partners partnership received subpoenas new york new jersey state attorneys general offices letter connecticut attorney general seeking similar information documents addition partners partnership received five civil investigative demands cids multistate group state attorneys general jointly investigating whether violations state consumer protection laws occurred marketing vytorin finally september merck scheringplough received letter civil division us department justice doj informing doj investigating whether companies conduct relating promotion vytorin caused false claims submitted federal health care programs partners partnership cooperating investigations responding inquiries addition partners partnership become aware served approximately civil class action lawsuits alleging common law state consumer fraud claims connection partnerships sale promotion vytorin zetia certain lawsuits allege personal injuries andor seek medical monitoring actions filed transferred federal court coordinated multidistrict litigation us district court district court new jersey district judge dennis cavanaugh parties presently engaged motions practice briefing feasible predict outcome investigations lawsuits arising enhance seas clinical trials unfavorable outcomes could significant adverse effect partnerships financial position results operations cash flows table contents independent auditors report partners merckscheringplough cholesterol partnership w e audited accompanying combined balance sheets merckscheringplough cholesterol partnership partnership december described note related combined statements net sales contractual expenses partners capital deficit cash flows described note three years period ended december financial statements responsibility management partnership merck co inc scheringplough corporation responsibility express opinion financial statements based audits w e conducted audits accordance generally accepted auditing standards established auditing standards board united states accordance auditing standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement partnership required engaged perform audit internal control financial reporting audits included consideration internal control financial reporting basis designing audit procedures appropriate circumstances purpose expressing opinion effectiveness partnerships internal control financial reporting accordingly express opinion audit also includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion accompanying statements prepared purpose complying certain rules regulations securities exchange commission described note intended complete presentation financial position results operations cash flows activities standalone pharmaceutical company involved discovery development manufacture distribution marketing pharmaceutical products n opinion financial statements referred present fairly material respects combined financial position merckscheringplough cholesterol partnership described note december combined results net sales contractual expenses combined cash flows described note three years period ended december conformity accounting principles generally accepted united states america eloitte touche llp parsippany new jersey february table contents schedules listed omitted either required applicable financial statements affiliates carried equity basis omitted considered individually aggregate affiliates constitute significant subsidiary exhibits ex hib number description master restructuring agreement dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june agreement plan merger among merck co inc spinnaker acquisition corp wholly owned subsidiary merck co inc sirna therapeutics inc dated october incorporated reference current report form k dated october restated certificate incorporation merck co inc may incorporated reference current report form k dated may bylaws merck co inc amended effective may incorporated reference current report form k dated may indenture dated april merck co inc morgan guaranty trust company new york trustee incorporated reference exhibit registration statement form first supplemental indenture merck co inc first trust new york national association trustee incorporated reference exhibit b registration statement form executive incentive plan amended effective february incorporated reference annual report fiscal year ended december base salary deferral plan adopted october effective january incorporated reference annual report fiscal year ended december merck co inc deferral program amended restated january incentive stock plan amended restated december incorporated reference annual report fiscal year ended december incentive stock plan amended restated december incorporated reference annual report fiscal year ended december incentive stock plan amended restated december incorporated reference annual report fiscal year ended december incentive stock plan amended effective december incorporated reference annual report fiscal year ended december merck co inc change control separation benefits plan incorporated reference current report form k dated november merck co inc separation benefits plan nonunion employees amended restated effective july incorporated reference current report form k dated july merck co inc special separation program separated employees effective january merck co inc special separation program bridged employees effective january merck co inc special separation program separated retirement eligible employees effective january table contents ex hib number description nonemployee directors stock option plan amended april incorporated reference form q quarterly report period ended june nonemployee directors stock option plan amended april incorporated reference form q quarterly report period ended june nonemployee directors stock option plan effective april amended restated february incorporated reference annual report fiscal year ended december supplemental retirement plan amended restated effective january retirement plan directors merck co inc amended restated june incorporated reference form q quarterly report period ended june plan deferred payment directors compensation amended restated january offer letter merck co inc peter kim dated december incorporated reference annual report fiscal year ended december offer letter merck co inc peter n kellogg dated june incorporated reference current report form k dated june amended restated license option agreement dated july astra ab astra merck inc incorporated reference form q quarterly report period ended june kbi shares option agreement dated july among astra ab merck co inc merck holdings inc incorporated reference form q quarterly report period ended june kbie asset option agreement dated july among astra ab merck co inc astra merck inc astra merck enterprises inc incorporated reference form q quarterly report period ended june kbi supply agreement dated july astra merck inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june second amended restated manufacturing agreement dated july among merck co inc astra ab astra merck inc astra usa inc incorporated reference form q quarterly report period ended june limited partnership agreement dated july kb usa lp kbi sub inc incorporated reference form q quarterly report period ended june distribution agreement dated july astra merck enterprises inc astra pharmaceuticals lp incorporated reference form q quarterly report period ended june agreement incorporate defined terms dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp incorporated reference form q quarterly report period ended june cholesterol governance agreement dated may among msp distribution servicesc llc msp marketing services c llc msp technology us company llc merck cardiovascular health company merck technology us company inc schering msp corporation schering sales management inc schering sales corporation schering msp pharmaceuticals lp msp cholesterol llc msp singapore company llc msd technology singapore pte ltd msd ventures singapore pte ltd osammor pte ltd renamed schering plough singapore pte ltd citimere pte ltd renamed scheringplough singapore research pte ltd schering corporation scheringplough corporation merck co inc portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june table contents ex hib number description first amendment cholesterol governance agreement dated december among msp distribution services c llc msp marketing services c llc msp technology us company llc merck cardiovascular health company merck technology us company inc schering msp corporation schering sales management inc schering sales corporation schering msp pharmaceuticals lp msp singapore company llc singapore partnership msd technology singapore pte ltd msd ventures singapore pte ltd scheringplough singapore pte ltd scheringplough singapore research pte ltd schering corporation scheringplough corporation merck co inc portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june master agreement dated december among msp technology us company llc msp singapore company llc schering corporation scheringplough corporation merck co inc portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june master merial venture agreement dated may among rhnepoulenc sa institut mrieux sa rhnemrieux sa merck co inc merck sh inc merial limited portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june form voting agreement made entered october merck co inc sirna therapeutics inc incorporated reference current report form k dated october settlement agreement dated november merck co inc counsel listed signature pages hereto including exhibits thereto incorporated reference current report form k dated november computation ratios earnings fixed charges subsidiaries merck co inc consent independent registered public accounting firm contained report independent auditors consent contained report power attorney certified resolution board directors rule aada certification chief executive officer rule aada certification chief financial officer section certification chief executive officer section certification chief financial officer management contract compensatory plan arrangement copies exhibits may obtained stockholders upon written request directed office secretary merck co inc po box ws ab whitehouse station new jersey table contents signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized ated february merck co inc richard clark chairman president chief executive officer celia colbert celia colbert attorneyinfact pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signatures title date richard clark chairman president chief executive february officer principal executive officer director peter n kellogg executive vice president chief financial february officer principal financial officer john canan senior vice president global controller february principal accounting officer leslie brun director february johnnetta b cole director february steven f goldstone director february william b harrison jr director february harry r jacobson director february william n kelley director february carlos e represas director february thomas e shenk director february samuel thier director february wendell p weeks director february peter c wendell director february celia colbert signing name hereto hereby sign document pursuant powers attorney duly executed persons named filed securities exchange commission exhibit document behalf persons capacities date stated persons including majority directors company celia colbert celia colbert attorneyinfact table contents exhibit consent independent registered public accounting firm hereby consent incorporation reference registration statements form form nos merck co inc report dated february relating financial statements effectiveness internal control financial reporting appears p ricewaterhousecoopers llp f lorham park new jersey february table contents exhibit independent auditors consent consent incorporation reference registration statement form registration statement nos form merck co inc report dated february relating combined financial statements merckscheringplough cholesterol partnership appearing annual report merck co inc year ended december eloitte touche llp p arsippany new jersey february table contents exhibit index ex hib number description master restructuring agreement dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june agreement plan merger among merck co inc spinnaker acquisition corp wholly owned subsidiary merck co inc sirna therapeutics inc dated october incorporated reference current report form k dated october restated certificate incorporation merck co inc may incorporated reference current report form k dated may bylaws merck co inc amended effective may incorporated reference current report form k dated may indenture dated april merck co inc morgan guaranty trust company new york trustee incorporated reference exhibit registration statement form first supplemental indenture merck co inc first trust new york national association trustee incorporated reference exhibit b registration statement form executive incentive plan amended effective february incorporated reference annual report fiscal year ended december base salary deferral plan adopted october effective january incorporated reference annual report fiscal year ended december merck co inc deferral program amended restated january incentive stock plan amended restated december incorporated reference annual report fiscal year ended december incentive stock plan amended restated december incorporated reference annual report fiscal year ended december incentive stock plan amended restated december incorporated reference annual report fiscal year ended december incentive stock plan amended effective december incorporated reference annual report fiscal year ended december merck co inc change control separation benefits plan incorporated reference current report form k dated november merck co inc separation benefits plan nonunion employees amended restated effective july incorporated reference current report form k dated july merck co inc special separation program separated employees effective january merck co inc special separation program bridged employees effective january merck co inc special separation program separated retirement eligible employees effective january nonemployee directors stock option plan amended april incorporated reference form q quarterly report period ended june nonemployee directors stock option plan amended april incorporated reference form q quarterly report period ended june nonemployee directors stock option plan effective april amended restated february incorporated reference annual report fiscal year ended december supplemental retirement plan amended restated effective january table contents ex hib number description retirement plan directors merck co inc amended restated june incorporated reference form q quarterly report period ended june plan deferred payment directors compensation amended restated january offer letter merck co inc peter kim dated december incorporated reference annual report fiscal year ended december offer letter merck co inc peter n kellogg dated june incorporated reference current report form k dated june amended restated license option agreement dated july astra ab astra merck inc incorporated reference form q quarterly report period ended june kbi shares option agreement dated july among astra ab merck co inc merck holdings inc incorporated reference form q quarterly report period ended june kbie asset option agreement dated july among astra ab merck co inc astra merck inc astra merck enterprises inc incorporated reference form q quarterly report period ended june kbi supply agreement dated july astra merck inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june second amended restated manufacturing agreement dated july among merck co inc astra ab astra merck inc astra usa inc incorporated reference form q quarterly report period ended june limited partnership agreement dated july kb usa lp kbi sub inc incorporated reference form q quarterly report period ended june distribution agreement dated july astra merck enterprises inc astra pharmaceuticals lp incorporated reference form q quarterly report period ended june agreement incorporate defined terms dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp incorporated reference form q quarterly report period ended june cholesterol governance agreement dated may among msp distribution servicesc llc msp marketing servicesc llc msp technology us company llc merck cardiovascular health company merck technology us company inc schering msp corporation schering sales management inc schering sales corporation schering msp pharmaceuticals lp msp cholesterol llc msp singapore company llc msd technology singapore pte ltd msd ventures singapore pte ltd osammor pte ltd renamed scheringplough singapore pte ltd citimere pte ltd renamed scheringplough singapore research pte ltd schering corporation scheringplough corporation merck co inc portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june first amendment cholesterol governance agreement dated december among msp distribution servicesc llc msp marketing servicesc llc msp technology us company llc merck cardiovascular health company merck technology us company inc schering msp corporation schering sales management inc schering sales corporation schering msp pharmaceuticals lp msp singapore company llc singapore partnership msd technology singapore pte ltd msd ventures singapore pte ltd scheringplough singapore pte ltd scheringplough singapore research pte ltd schering corporation scheringplough corporation merck co inc portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june table contents ex hib number description master agreement dated december among msp technology us company llc msp singapore company llc schering corporation scheringplough corporation merck co inc portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june master merial venture agreement dated may among rhnepoulenc sa institut mrieux sa rhnemrieux sa merck co inc merck sh inc merial limited portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june form voting agreement made entered october merck co inc sirna therapeutics inc incorporated reference current report form k dated october settlement agreement dated november merck co inc counsel listed signature pages hereto including exhibits thereto incorporated reference current report form k dated november computation ratios earnings fixed charges subsidiaries merck co inc consent independent registered public accounting firm contained xxx report independent auditors consent contained xxx report power attorney certified resolution board directors rule aada certification chief executive officer rule aada certification chief financial officer section certification chief executive officer section certification chief financial officer management contract compensatory plan arrangementexhibit merck co inc deferral program amended restated january table contents article administration article ii eligibility article iii deferral deferred compensation account article iv valuation deferred compensation accounts article v redesignation within deferred compensation account article vi distribution deferred compensation accounts article vii deductions distributions article viii beneficiary designations article ix amendments article x claims appeal procedures article xi domestic relations orders schedule deferral program investment alternatives schedule ii special provisions applicable medco health employees imerck co inc deferral program deferral program program unfunded arrangement intended permit select group management defer income would otherwise immediately payable annual base salary various incentive plans merck co inc merck company program nonqualified deferred compensation plan within meaning section code section anything program contrary notwithstanding program shall interpreted operated compliance requirements section successor thereto effect time time including limited applicable regulations us department treasury internal revenue service treas reg secs successor thereto payment called program designated date shall made later date within tax year participant march following year later dates specified treas reg sec successor thereto provided participant permitted designate taxable year payment programs obligation pay unclear company including dispute proper beneficiary participant dies payment shall made soon adminstratively feasible programs obligation becomes clear time permitted treas reg sec ag successor thereto administration program administered compensation benefits committee committee companys board directors committee composed nonemployee directors committee shall responsibility determining investments available program investments shall listed schedule hereto committee shall make decisions affecting timing price amount deferred compensation officers defined rule af securities exchange act amended section officers rules general application participants may otherwise delegate authority program ii eligibility salaried employees merck co inc based subject us income taxes eligible make election defer program bands successor level according mercks assignment effect time time according mercks payroll system date initial elections must made year otherwise eligibility defer program determined accordance terms companys base salary deferral plan various incentive plans committee may refuse permit employee class employees participate program b anything program contrary notwithstanding following eligible make election person independent contractor company affiliates agrees agreed independent contractor company agreement understanding company affiliates person employee even person previously employee employed temporary employment agency regardless amount control supervision ortraining provided company affiliates foregoing exclusion applies even court agency authority rules person happens common law employee company affiliates also excluded individuals included unit employees covered collective bargaining agreement employee representatives one employers provided however employee may eligible employee period covered covered collective bargaining agreement otherwise eligible participate according article ii section c person made election program pursuant section shall participant long account balance make another election defer unless eligible pursuant article ii section person made election defer thereafter becomes ineligible defer example band employee becomes band employee election nonetheless given effect iii deferral deferred compensation account initial election defer defer participant must irrevocably elect defer program earlier time specified treas reg sec successor thereto base salary deferral plan prior end year preceding year base salary earned amount may deferred less percent annual base salary defined base salary deferral plan b lesser percent annual base salary portion participants annual base salary exceeds amount determined section internal revenue code code provided however amounts may expressed relation amounts may deducted company section code annual incentive plans annual incentive plan executive incentive plan prior commencement performance year bonus monies deferred earned provided participant hired company performance year may make election later th day participants date hire defer bonus monies earned performance year b minimum may deferred year section iva annual grants restricted stock units rsus performance share units psus may deferred prior commencement last year award period earned rsus psus may deferred rsus psus deferral election made grant must deferred compliance rules applicable deferral opposed initial elections section described article vi section f deferrals rsus psus must made initially merck common stock fund may thereafter reallocated investment alternative provided pursuant schedule mutual fund amounts deferred known deferred compensation credited participants deferred compensation account deferred compensation shall accounted one account regardless plan eg base salary deferral incentive plan deferred separate election defer applies year base salary annual incentive grant rsus psus records shall show separate election purposes modifications distribution schedule separate election shall eligible modification amounts described may deferred stock option gains may deferred notwithstanding foregoing participants deferral election cancelled receives hardship distribution merck co inc employee savings security plan qualified savings plan k feature maintained company affiliates cancellation required applicable regulation internal revenue service participant terminates employment transfers class employees ineligible make deferral election made deferral election election nevertheless effected company pays amount reasonably believes may held substitute payment within meaning treas reg sec ab amount would deferred pursuant foregoing substitute payment also deferred according participants election b initial election distribution schedule timing election participant must elect initial distribution schedule making initial election pursuant iiia distribution schedule participant may elect payments begin particular year whether employment ended b year following participants separation service defined c years subsequent participants separation service separation service means separation service defined treas reg sec ah successor thereto includes limited retirement separation due lack work voluntary resignation involuntary termination employment include termination service due death commencement employment joint venture described participant may elect lump sum schedule annual installments maximum annual installments manner elections elections program shall made programs designated recordkeeper recordkeeper manner accordance process approved companys head human resources department time time default designation participants initial election distribution schedule reason unclear company including limited participant failed elect amounts distributed participant shall deemed elected receive distributions year following year occurs separation service c election investment alternatives participant shall designate accordance procedures established company designation portion multiples percent deferred compensation allocated investment alternative available program iv valuation deferred compensation accounts deferral program shall offer investment alternatives fund merck common stock b mutual funds merck common stock initial crediting amount allocated merck common stock shall used determine number full partial shares merck common stock amount would purchase closing price merck common stock new york stock exchange nyse date cash payments base salary amounts deferred base salary deferral plan incentive awards amounts deferred various incentive plans would otherwise paid participant deferral date company shall credit participants deferred compensation account number full partial shares merck common stock determined however time prior delivery shares shall actual shares purchased earmarked account participant shall rights shareholder respect shares credited hisher deferred compensation account dividends company shall credit participants deferred compensation account number full partial shares merck common stock purchasable closing price merck common stock nyse date dividend paid common stock dividends would paid number shares credited account including pro rata dividends partial share shares credited issued outstanding redesignations value merck common stock purposes redesignation shall closing price merck common stock nyse first day nyse open request received recordkeeper distributions distributions merck common stock valued closing price merck common stock nyse distribution date limitations shares merck common stock delivered provisions program may delivered company authorized unissued shares common stock common stock held treasury company also may sole nonreviewable discretion purchase shares public markets order make distributions program adjustments event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares company number kind shares merck common stock available program credited participants deferred compensation accounts shall adjusted accordingly fair market value merck common stock purposes valuation merck common stock merck common stock longer traded nyse publicly traded exchange references nyse shall mean exchange merck common stock publicly traded committee determines measurement merck common stock applicable date would constitute fair market value committee shall decide date method determine fair market value shall accord requirements set forth section successor thereto b mutual funds initial crediting amount allocated mutual fund shall used determine number full partial mutual fund shares amount would purchase closing net asset value mutual fund shares deferral date company shall credit participants deferred compensation account number full partial mutual fund shares determined however actual mutual fund shares shall purchased earmarked account shall participant rights shareholder respect mutual fund shares dividends company shall credit participants deferred compensation account number full partial mutual fund shares purchasable closing net asset value mutual fund shares date dividend paid mutual fund shares dividends would paid number shares credited account including pro rata dividends partial share shares owned participant purposes computation redesignations value mutual fund shares purposes redesignation shall net asset value mutual fund close business first day nyse open request received recordkeeper distributions mutual fund distributions valued based closing net asset value mutual fund shares distribution date defined adjustments event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares mutual fund number kind shares mutual fund credited participants deferred compensation accounts shall adjusted accordingly default designation participants designation investment alternatives reason clear including limited participant failed make election participant shall deemed designated deferrals life cycle target similar mutual fund target date closest participants attainment age v redesignation within deferred compensation account basic redesignation rules participant beneficiary legal representative deceased participant may redesignate amounts credited deferred compensation account among investments available program accordance following rules eligible participants participants beneficiaries may redesignate frequency timing redesignation shall effective pm et first day nyse open request received recordkeeper amount extent redesignation redesignation must multiples investment redesignation made beneficiaries legal representatives beneficiary legal representative deceased participant may redesignate subject rules participants b special rules redesignation merck common stock frequency timing section officers redesignations may made merck common stock window period established company timetotime redesignation merck common stock restricted amounts held merck common stock longer six months redesignation shall permitted extent company aware transaction company reasonably believes may cause violation section securities exchange act amended material nonpublic information committee sole discretion advice counsel time may rescind redesignation merck common stock redesignation made participant time redesignation possession material nonpublic information respect company b committees estimation benefited information timing hisher redesignation committees determination shall final binding event rescission participants deferred compensation account shall returned status though redesignation occurred notwithstanding committee shall rescind redesignation facts reviewed participant general counsel company designee prior redesignation general counsel designee concluded participant possession adverse material nonpublic information c conversion common stock accounts committee may sole discretion convert shares merck common stock allocated participants deferred compensation account manner provided position participant taken wishes take opinion committee would make uncertain propriety participants continued interest merck common stock date conversion shall date commencement employment date committees action whichever later conversion shall expression value shares merck common stock participants deferred compensation account expression value united states dollars another available investment value merck common stock shall based upon closing price nyse date conversion trading took place day next business day trading took place conversion paragraph shall irrevocable absolute vi distribution deferred compensation accounts distribution deferred compensation accounts shall made accordance participants distribution schedule pro rata investment distributions merck common stock made shares cash payable partial share subject limitations set forth article iv section section officers distribution amounts merck common stock also restricted amounts held merck common stock longer six months distributions mutual funds cash distributions valued distribution date ie th day distribution month day business day next business day paid soon thereafter practicable distribution months shall mean january april july october separation service distribution commences upon participants separation service deferred compensation accounts commence accordance participants previously elected schedule participant incurs separation service thereafter rehired company rehire shall ignored distributions shall commence notwithstanding rehire provided however participant eligible elects make additional deferrals additional deferrals may payable relation subsequent separation service specified employee anything program contrary notwithstanding extent required section distributions account separation service specified employee term defined section may made date months date separation service earlier date death employee payment would made specified employee within month period payment one series annual payments first payment shall delayed necessary remaining payments shall made according elected schedule notwithstanding delay two otherwise annual payments may made single year b death event participants death whether distributions commenced pursuant participants election deferred compensation accounts program distributed participants beneficiary estate lump sum soon administratively feasible event march year following death except otherwise permitted treas reg sec ag successor thereto c automatic distribution except provided schedule ii participant incurs separation service deferred compensation account valued less first distribution date thereafter deferred compensation account shall distributed lump sum soon administratively feasible following termination event march year following death except otherwise permitted treas reg sec ag successor thereto joint venture service participants termination employment order take position joint venture business entity company shall directly indirectly percent outstanding voting ownership interest shall considered separation service e hardship distributions committee shall distribute participants deferred compensation account extent participant applies receive distribution due unforeseeable emergency defined treas reg sec ai participant wishing hardship distribution must provide committee delegate sufficient evidence prove compliance treas reg sec ai f modifications distribution schedule making initial election participant may elect change distribution schedule time time provided however changes shall permitted might reasonably expected cause plan failure term used section code example except otherwise permitted section election may permit acceleration distribution may become effective earlier one year date made may permit additional deferral initial election unless results deferral least five additional years previously schedule distribution date purposes provision participant elected receive distribution series payments series shall considered single distribution purposes section elections shall made recordkeeper manner accordance process approved companys head human resources department time time vii deductions distributions company deduct distribution amounts required withheld income social security tax purposes withholding done pro rata basis per investment company may also deduct amounts participant owes company reason viii beneficiary designations participant may designate beneficiary receive hisher deferred compensation account upon participants death beneficiary predeceases participant participant name beneficiary participants deferred compensation account distributed participants estate designation shall format designated companys head human resources department time time must received companys human resources department prior participants death valid ix amendments committee may amend terminate program time however amendment may retroactively reduce participants deferred compensation account two years following change control company term defined change control separation benefits plan material terms program including terms relating eligibility benefit calculation benefit accrual cost participants subsidies rates employee contributions may modified manner materially adverse individuals participated immediately change control company pay legal fees expenses participant prevails claim relief action regarding impermissible amendment program ordinary claims benefits applicable action regarding restrictive covenants applicable participant x claims appeals procedure determination claim employee hisher authorized representative may present claim benefits global benefits leader successor thereto director person committee may determine handle claims appeals program director make determinations employees claim benefits program director grants claim benefits payable program paid employee soon feasible thereafter director denies whole part claim benefit program heshe furnish claimant notice decision later days receipt claim special circumstances require extension time processing claim director provide written notice extension initial day period case decision rendered days receipt claim written notice director provide every claimant denied claim benefits set forth manner calculated understood claimant specific reason reasons denial b specific reference pertinent program provisions denial based c description additional material information necessary claimant perfect claim explanation material information necessary appropriate information steps taken claimant wishes submit hisher claim review appeal denied claim claimant hisher authorized representative may request review denied claim committee request made writing presented committee days receipt claimant written notification denial claim committee render decision review later days receipt claimants request review unless special circumstances require extension time case decision rendered soon possible later days receipt request review decision review writing include specific reasons decision erisa section intended claims procedure program administered accordance regulations department labor issued erisa section limitation action action law equity action shall maintained participant beneficiary individual entity party including limited person determined participant beneficiary claimant program company affiliates agents fiduciaries officers directors employees successors assigns plans collectively program group unless claimant presented every basis argument support action claim strict accordance sections claim denied whole part b unless action commenced later one year date company provides notice adverse decision pursuant section company puts claimant notice companys programs intention respect basis argument support action claimant must commence process described section within one year notice claim includes limited claim benefits purported actual fiduciary breach member program group limitation action may tolled writing executed director xi domestic relations orders notwithstanding provision program contrary creation assignment recognition right benefit payable respect participant pursuant domestic relations order hereinafter defined prohibited event right benefit hereunder established pursuant domestic relations order benefit otherwise payable participant hisher beneficiary hereunder shall appropriately reduced reflect effect qualified domestic relations order purposes program alternate payee means person would alternate payee section p code program subject section code domestic relations order shall mean judgment decree order including approval property settlement agreement provided order relates provision child support alimony marital property rights made pursuant state domestic relations community property laws b order creates recognizes existence alternate payees right receive portion participants account balance c order specifies name last known mailing address participant alternate payee covered order order precisely unambiguously specifies amount percentage participants account balance paid alternate payee manner amount percentage determined e order clearly specifies applies program f order require program provide type benefits form benefits otherwise provided program g order provides alternate payee shall receive interest program lump sum soon administratively feasible following determination companys legal department delegate order satisfies requirements article schedule deferral program investment alternatives mutual funds shall mean investment alternatives offered merck co inc employee savings security plan effect time time excluding participant loans merck common stock merck common stock fund offered deferral program shall measured invested merck common stock dividends reinvested additional shares merck common stock schedule ii special provisions applicable medco health employees approved july definitions medco health medco health solutions inc medco health employee participant employed medco health prior spinoff ii employed merck prior spinoff expected employed medco health prior spinoff separated medco health employee participant deferral program employed medco health date spinoff considered terminated employment company result spinoff spinoff distribution merck shareholders equity securities medco health spinoff divestiture purposes deferral program special provisions notwithstanding anything contrary article vi section c deferral program deferred compensation account separated medco health employee shall paid accordance article vi section without regard threshold set forth section c exhibit merck co inc special separation program separated employees eligible employees employees merck co inc subject collective bargaining agreement experience separation service defined separation benefits plan january december separation date less age least age yet age less years credited service effective date january document summarizes benefits separated employee may eligible special separation program merck employee benefit plans programs unless otherwise noted terms conditions mercks employee benefit plans programs applicable employees termination employment merck described applicable sections current merck benefits book applicable summaries material modification previously provided provided brochure plans programs applicable sections merck benefits book may amended time time copy applicable sections merck benefits book applicable summaries material modification obtained line httphumresmerckcombenefitaboutbenefitsbookhtml wwwmerckcombenefits calling merck benefits service center however extent terms differ described applicable sections current merck benefits book applicable summaries material modification communication constitutes summary material modifications kept book separated employees certain nonunionized merck co inc employees experience separation service term defined separation benefits plan january december separation date less age least age yet age less nine years credited service separated employees employees designated merck separated employees separated employees include employees terminate employment way constitute separation service determined merck including employees resign reason benefits described brochure apply separated employees apply merck employees designated separated employee company provide separation letter separation letter describe special separation program benefits eligible include release legal claims company may also include terms nonsolicitation noncompetition provisions company sole discretion decides include order receive benefits special separation program must sign return separation letter date stated letter separation letter return date revocation period applicable revoke letter within revocation period special separation program benefits special separation program contingent upon separated employee signing revocation period applicable revoking separation letter consist separation pay outplacement services eligibility continued medical dental life insurance benefits eligibility special payment lieu aipeip bonus performance year separation date occurs separation date occurs june december performance year eligibility extended use day care center separation pay outplacement benefits continued medical dental life insurance benefits described separation plan spd distributed brochure brochure describes following eligibility extended use day care center applicable special separation program exchange signing revoking separation letter benefits separated employees sign sign revocation period applicable later revoke separation letter terms conditions certain merck benefit plans programs apply separated employee without regard whether sign separation letter medical including prescription drug dental medical including prescription drug dental sign separation letter sign separation letter revocation period applicable revoke separation letter medical dental coverage options effect separation date continue mercks medical dental plans may amended time time end month following calendar month separation date occurred end period eligible elect continue coverage accordance cobra months separation date medical andor dental coverage mercks medical dental plans separation date medical andor dental coverage applicable separation date eligible elect coverage cobra special separation program medical including prescription drug dental sign separation letter special separation program sign separation letter revocation period applicable revoke separation letter eligible continue medical dental coverage mercks plans may amended time time separation pay period fully described separation plan spd separation pay period less six months may continue medical dental coverage six months contributions continue coverage contributions active employees may change time time payable merck designee time manner specified merck time time pay required contributions merck designee time manner specified merck time time coverage terminated reinstated provided paid required contributions continue coverage end separation pay period separation pay period less months end month period medical dental coverages provided may elect continue coverage accordance cobra additional months continuation medical dental coverages special separation program subject early forfeiture provisions described separation plan spd life insurance life insurance sign separation letter sign separation letter revocation period applicable revoke separation letter employee group term life dependent life survivor income protection continue days separation date day period may elect continue coverages level effect separation date mercks life insurance plan may amended time time may continue coverages cost earlier months separation date age wish continue survivor income protection andor dependent life coverage must continue employee group term life basic optional continue life insurance coverages must contact merck benefits service center within days separation letter return date must pay applicable premium time manner specified merck fail pay premium time manner specified merck coverages terminated reinstated interested continuing coverages contact merck benefits service center information accidental death dismemberment coverage ends separation date full months premium may deducted paycheck month separation date occurs special separation program life insurance sign separation letter special separation program sign separation letter revocation period applicable revoke separation letter basic employee group term life insurance coverage continue mercks life insurance plan may amended time time earlier last day month separation pay period ends separation pay period less months months beginning first month coincident following separation date fully described separation plan spd ii age basic employee group term life coverage old format equal x base pay contributions continue coverage contributions active employees may change time time payable merck designee time manner specified merck time time pay required contributions merck designee time manner specified merck time time coverage default new format x base pay contributions required basic employee group term life coverage new format x base pay continuation basic life insurance special separation program subject early forfeiture provisions described separation plan spd sign separation letter revocation period applicable revoke separation letter basic life insurance continues may also continue optional term life dependent life survivor income protection cost earlier months separation date age wish continue survivor income protection andor dependent life coverage must continue optional employee group term life continue optional life insurance coverages must contact merck benefits service center within days separation letter return date must pay applicable premium time manner specified merck fail pay premium time manner specified merck optional coverages terminated reinstated interested continuing optional coverages contact merck benefits service center information separation pay period may continue basic employee group term life coverage cost remainder period ending earlier expiration month period separation date age time interested continuing basic life coverage must contact merck benefits service center basic life insurance ends result early forfeiture provisions separation benefits plan allowed continue optional coverages month continuation provisions see life insurance section merck benefits book applicable summaries material modification description conversion rights chart provided convenience compare medical dental life insurance benefits offered special separation program normal plan provisions regular plan special separation provisions program sign letter medical dental benefits continue end benefits continue end prescription drug month following month month separation pay separation date period ends minimum occurs eligible cobra months provided pay afterward applicable employee contributions time manner specified merck designee eligible cobra afterward basic employee term life coverage level effect coverage continues end insurance new formatmaximum separation date continues month separation pay x base pay old format x base days may elect period ends minimum pay continue coverage months beyond age months beyond age provided pay applicable separation date employee contributions time cost manner specified merck designee may elect continue coverage balance months beyond age separation date cost optional employee coverage level effect coverage level effect group term life separation date continues separation date continues days dependent life days may elect may elect continue coverage survivor income continue coverage months beyond age months beyond age separation date separation date cost cost add coverage coverage merck onsite day care centers child enrolled merck onsite day care center child remain enrolled center separation letter return date sign separation letter child infant toddler preschool room separation date heshe may continue day care center third month anniversary separation date child kindergarten separation date may continue end calendar week kindergarten graduation occurs provided continued enrollment subject continuing abide rules regulations day care center terms separation letter continuation first three months shall regular tuition rate kindergarten children continuing first three months may additional charge annual incentive programexecutive incentive program aipeip described detail payment bonuses special payment lieu bonus depends separated employees separation date occurs performance year actual aipeip bonuses respect performance year immediately preceding separated employees separation date may paid employees whose employment terminates january time aipeip bonuses paid year employees aipeip special payment lieu bonus respect performance year separation date occurs payable employee separated january june inclusive special payment lieu bonus payable program respect performance year separation date occurs employees whose separation dates occur july december performance year executives listed summary compensation table recent proxy materials issued company connection annual meeting shareholders amount payment lieu eip award guided following principles company retains complete discretion pay less amounts company reserves right treat payment aipeip bonuses andor special payments lieu aipeip bonuses supplemental wages subject flatrate withholding taking account exemptions separation date occurs january prior time aipeip bonuses paid prior performance year separation date occurs january prior day aipeip bonuses prior performance year paid merck employees eligible consideration aipeip bonus respect prior complete performance year terms conditions merck employees provided class employees eligible aipeip aipeip bonus paid time aipeip bonuses paid merck employees deferred accordance applicable deferral election aipeip performance year applicable eligibility consideration aipeip bonus contingent upon signing separation letter eligible aipeip payment lieu aipeip performance year separation date occurs separation date occurs time aipeip bonuses prior performance year paid june separation date occurs aipeip bonuses prior performance year paid merck employees june eligible consideration aipeip bonus special lieu bonus payment described whether sign separation letter separation date occurs june december separation date occurs june december special payment lieu aipeip respect performance year separation date occurs may paid sign revocation period applicable revoke separation letter special payment calculated based target bonus applicable annual incentive programexecutive incentive program respect current performance year number full partial months worked current performance year subject adjustment company sole discretion based variety factors including limited documented poor extraordinary performance current performance year receive special payment lieu aipeip bonus paid less applicable withholding soon administratively feasible following separation date however elected defer aipeip bonus election apply payments made lieu aipeip bonus benefits programs stock options restricted stock units performance stock units employees may receive incentives mercks incentive stock plans including stock options restricted stock units rsus performance stock units psus therefore eligible receive grants separation date outstanding stock options rsus psus whether sign separation letter separation provisions applicable stock options rsus psus apply outstanding incentives hold separation date separation provisions may differ based grants responsibility familiarize terms individual grants stock options separation terms generally outstanding annual quarterly stock option grants made prior terms vested options expire upon earlier day oneyear anniversary separation date ii original year expiration date generally outstanding annual quarterly stock option grants made thereafter unvested options vest separation date two years exercise previously vested grants outstanding vested optionsincluding previously vestedwill expire day second anniversary separation date original expiration date earlier key rd mrl mmd new hire stock option grants stock option grants may different terms see term sheets applicable stock option grants later rehired stock options unexercised outstanding rehire date reinstated active status employment interrupted rsus separation terms separation provisions rsus pro rata portion annual grants restricted stock units generally vest become distributable time employment continued see term sheets applicable rsus granted psus separation terms separation provisions psus pro rata portion annual grant performance share units payable distribution respect applicable performance year made active employees see term sheets applicable psus granted question stock options rsus psus call hr service center mrkhru following describes terms conditions certain merck benefit plans programs apply employees whose employment merck terminates reason additional information see applicable sections current merck benefits book applicable summaries material modification dependent care reimbursement account participation dependent care reimbursement account dcra ends separation date eligible expenses incurred throughout calendar year separation date occurs even merck employment ends reimbursed amount actually contributed account claims expenses must submitted horizon blue cross blue shield april th year following year separation date occurs amounts remaining account eligible expenses paid forfeited financial engines eligibility use financial engines financial planning tool end separation date financial planning elected financial planning continue benefit remainder calendar year separation date occurs remaining cost benefit deducted final pay check necessary separation pay paid pursuant separation benefits plan financial planning election irrevocable changed flexible benefits program flexible benefits program consists following merck plans programs medical dental vision health care dependent care reimbursement accounts financial planning life insurance including basic optional term life dependent term life survivor income accidental death dismemberment long term care long term disability participation plans ends described elsewhere communication however full month contributionpremium coverage plans effect separation date may deducted paycheck month separation date occurs health care reimbursement account participation health care reimbursement account hcra ends separation date unless elect continue participate accordance cobra remainder calendar year separation date occurs elect continue participation hcra cobra must make required contributions aftertax basis eligible expenses incurred participate hcra calendar year separation date occurs reimbursed entire elected amount claims incurred participation hcra ends reimbursed matter much money left account claims expenses incurred calendar year separation date occurs participant hcra must submitted horizon blue cross blue shield april year following year separation date occurs amounts remaining account eligible expenses paid forfeited long term care elected coverage mercks long term care plan spouse samesex domestic partner coverage end separation date however want continue coverage without interruption must contact cna insurer pay first quarterly premium cna within days last day month separation date occurs information request necessary forms contact cna directly long term disability participation long term disability plan end last day month separation date occurs words must satisfied week eligibility period end month includes separation date eligible ltd benefits disabled receiving income replacement benefits long term disability plan separation date benefits continue accordance terms long term disability plan however separation pay paid company special separation program act offset benefits payable long term disability plan meaning ltd benefits reduced separation pay pension least years vesting service term defined retirement plan separation date terminated vested participant retirement plan means employment terminated eligible retire active service company generally age least years credited service term defined retirement plan vested pension retirement plan terminated vested participant benefits retirement plan must begin later first day month following age employment terminates however start receiving reduced benefit first day month reach age early payment reduction terminated vested participant actuarial reduction life expectancy certain actuarial assumptions used calculating reduction amount expect reduce benefits substantially commencing benefit early receive benefits earlier longer period table illustrating examples actuarial reductions age benefit detailed explanation benefits terminated vested participants found salaried retirement plan section current merck benefits book applicable summaries material modification least years vesting service separation date eligible benefit retirement plan leave company entitled vested benefit retirement plan youll receive statement tell life income age sent within approximately one year separation date portion benefit different plan retirement plan hourly employees merck co inc offset reduces benefit retirement plan aggregate lump sum benefit payable two different plans generally differs slightly lump sum payable one plan especially different interest rate methodologies apply payments compensation retirement plan separation pay compensation retirement plan purposes bonus special payment lieu aipeip bonus paid separation date also compensation retirement plan purposes savings plan separation pay receive special separation program base pay may contributed savings plan prorata deduction made savings plan based percentage monthly base pay receive month separation date occurs plan loan repay within days separation date loan declared default reported taxable distribution internal revenue service generally may receive final distribution savings plan time separation date however account balance less account balance automatically distributed soon separation date upon reaching age previously elected receive benefits account balance distributed without regard amount review information salaried savings plan section current merck benefits book applicable summaries material modification additional information receiving final distribution short term disability subject applicable state law participation short term disability plan ends separation date disabled receiving income replacement benefits short term disability plan separation date benefits continue accordance terms plan however subject state law separation pay paid company special separation program act offset benefits payable short term disability plan meaning std benefits reduced separation pay state law permit offsets made std benefits company sole absolute discretion determines easier company administer std benefits instead act offset separation pay paid payable company special separation program meaning separation pay reduced std benefits travel accident coverage travel accident insurance plan ends separation date vacation pay paid amount vacation accrued used separation date conversely must reimburse merck vacation used prior separation date earned separation date amounts reimbursed may deducted separation pay paid pursuant separation benefits plan vision coverage vision plan ends last day month separation date occurs given opportunity continue benefit accordance cobra months separation date paying required premiums special separation program described currently scheduled effect separations service occur january december merck retains right extent permitted law amend terminate special separation program benefit plan described brochure otherwise time however following change control merck defined change control separation benefits plan certain limitations apply mercks ability amend terminate benefit plans current intention merck also may extend decrease enhance special separation program future sign return separation letter separation letter return date later amendment termination decrease increase amount separation pay eligible receive special separation program notwithstanding anything special separation program contrary benefits program subject section internal revenue code amended adjusted avoid excise tax section merck take steps determines necessary sole absolute discretion adjust benefits special separation program avoid excise tax section including limited reducing eliminating benefits changing time form payment benefits etc payments made account separation service limited six months following termination employment specified employee defined treas reg sec successor thereto general includes top employees company ranked compensation notwithstanding anything contained special separation program contrary covered employee specified employee separation date extent required section internal revenue code amended payments made sixmonth period following termination employment instead amounts would otherwise paid sixmonth period accumulated paid without interest soon administratively feasible following end sixmonth period termination employment glossary definitions used document following terms following meanings basic employee group term life coverage lesser amount separated employees group term life coverage effect separation date x base pay considered new format x base pay considered old format company merck means merck co inc credited service defined retirement plan retirement plan means retirement plan salaried employees merck co inc separation benefits plan means merck co inc separation benefits plan nonunion employees separation date means separated employees last day employment merck separated employees certain nonunionized merck co inc employees experience separation service term defined separation benefits plan january december separation date less age least age yet age less nine years credited service separated employees employees designated merck separated employees separated employees include employees terminate employment way constitute separation service determined merck including employees resign reason separation letter means companyprovided letter describe special separation program benefits include release claims company may include terms nonsolicitation noncompetition provisions company determines separation letter return date date stated separation letter separated employees must sign return company separation pay period number full partial workweeks separated employee paid separation pay special separation program means separation benefits separated employees receive sign revocation period applicable revoke separation letter exhibit merck co inc special separation program bridged employees eligible employees employees merck co inc subject collective bargaining agreement experience separation service defined separation benefits plan january december last day employment separation date least years age yet age least years credited service least years age yet age least years credited service years credited service least years age yet age less years credited service least age least less years credited service see brochure applicable separated retirement eligible employees effective date january document summarizes benefits bridgeeligible employee may eligible special separation program merck employee benefit plans programs unless otherwise noted terms conditions mercks employee benefit plans programs applicable employees termination employment merck described applicable sections current merck benefits book applicable summaries material modification previously provided provided brochure plans programs applicable sections merck benefits book may amended time time copy applicable sections merck benefits book applicable summaries material modification obtained line httphumresmerckcombenefitaboutbenefitsbookhtml wwwmerckcombenefits calling merck benefits service center however extent terms differ described applicable sections current merck benefits book applicable summaries material modification communication constitutes summary material modifications kept book bridgeeligible employees certain nonunionized merck co inc employees experience separation service defined separation benefits plan january december last day employment merck separation date least years age yet age least years credited service least years age yet age least years credited service years credited service least years age yet age less years credited service defined retirement plan bridgeeligible employees employees designated merck bridgeeligible employees bridge eligible employees include employees terminate employment way constitute separation service defined separation benefits plan determined merck including employees resign reason benefits described brochure apply bridgeeligible employees apply merck employees designated bridgeeligible employee company provide separation letter separation letter describe special separation program benefits eligible include release legal claims company may also include terms nonsolicitation noncompetition provisions company sole discretion decides include order retire retirement plan separation date receive benefits special separation program must sign return separation letter date stated letter separation letter return date revocation period applicable revoke letter within revocation period bridgeeligible employees sign return revocation period applicable revoke separation letter shall treated retired retirement plan referred bridged employees special separation program benefits special separation program contingent upon bridgeeligible employee signing revocation period applicable revoking separation letter consist separation pay outplacement services prorata portion certain early retirement subsidies retirement plan pension bridge treatment retiree retirement plan medical dental benefits bridgeeligible employees least years credited service defined retirement plan separation datestreatment retiree purposes medical dental benefits bridgeeligible employees less years credited service separation dates eligibility continued medical dental benefits period treatment retiree purposes life insurance benefits treatment retiree purposes unexercised stock options restricted stock units performance stock units eligibility special payment lieu aipeip bonus performance year separation date occurs separation date occurs june december performance year eligibility extended use day care center separation pay outplacement benefits described separation plan spd distributed brochure brochure describes additional benefits offered special separation program described separation plan spd pension bridge treatment retiree purposes medical dental life insurance benefits provided retiree healthcare benefits bridgeeligible employees would least years credited service defined retirement plan separation dates treatment retiree purposes stock options restricted stock units performance stock units eligibility special payment lieu aipeip bonus performance year separation date occurs eligibility extended use day care center benefits bridgeeligible employees sign revocation period applicable sign later revoke separation letter terms conditions certain merck benefit plans programs apply separated employee without regard whether sign separation letter retirement plan pension bridge terminated vested sign separation letter definition separation date bridgeeligible employees eligible early normal retirement terms retirement plan salaried employees separation date bridged employee one signed revocation period applicable revoked separation letter least years vesting service term defined retirement plan terminated vested participant retirement plan purposes stop accruing additional credited service term defined retirement plan means employment terminated vested eligible early normal retirement retirement plan generally least age least years credited service least age without regard years service less employment terminates least years vesting service vested entitlement retirement plan considered terminated vested terminated vested participant benefits retirement plan must begin later first day month following age however start receiving reduced benefit first day month reach age benefit reduced reflect early payment benefits early payment reduction terminated vested participant actuarial reduction life expectancy certain actuarial assumptions used calculating reduction amount year prior age benefits begin expect reduce benefits substantially commencing benefit early receive benefits earlier longer period table illustrating examples actuarial reductions age benefit detailed explanation benefits terminated vested participants found salaried retirement plan section current merck benefits book applicable summaries material modification leave company entitled vested benefit retirement plan youll receive statement tell life income age sent within approximately one year separation date portion benefit different plan retirement plan hourly employees merck co inc offset reduces benefit retirement plan aggregate lump sum benefit payable two different plans generally differs slightly lump sum payable one plan especially different interest rate methodologies apply payments compensation retirement plan separation pay compensation retirement plan purposes bonus special payment lieu aipeip bonus paid separation date also compensation retirement plan purposes special separation program pension bridge sign separation letter retirement plan purposes bridged employee one signed revocation period applicable revoked separation letter considered retired active service merck separation date entitled prorata portion early retirement subsidies yet considered deferred pension terms described deferred pension benefit payable earlier first month following participants th birthday early retirement subsidy benefit retirement plan based credited service accrued separation date payable age however begin receive benefits first day month reach age commence benefit age age benefit still reduced amount reduction less actuarial reduction applies terminated vested participants reduction applies early retirees bridged employees retirement plan provides benefits early retirees reduced month ie year begin age bridged employees receive prorata portion prorata fraction enhancement provided early retirement subsidies prorata fraction equals percentage employees credited service hisher separation date divided credited service employee would employment continued heshe first eligible treated early retiree purposes fraction credited service limited years credited service separation credited service employment continued hisher first day eligibility treatment early retiree example assume employee years old years credited service separation date would first eligible treated early retiree attained age would years credited service prorata fraction example would another example assume bridged employee years credited service separation date employee would first eligible treated early retiree years credited service prorata portion would calculate benefit paid formula prorata fraction times participants accrued benefit separation date payable early retirement subsidies plus minus prorata fraction times participants accrued benefit separation date actuarially reduced early commencement heres example formula work assume employee years old separation years credited service earliest retirement age time would years credited service prorata fraction assume accrued benefitthat age annuity paid every month rest lifeis receives pension age early retiree would receive terminated vested participant would receive formula would receive times equals plus times equals equals annuity payable age annuity value could converted forms benefit available retirement plan rule transition benefit bridged employees employment merck continued would qualified rule transition benefit within two years separation date receive rule transition benefit benefits retirement plan begin words enhancement applies separation date least years old sum age credited service least rule transition benefit payable upon commencement pension benefits even date commencement pension benefits earlier date would otherwise qualified rule transition benefit included early retirement subsidies subject prorata fraction described rule transition benefit fully described salaried retirement plan section current merck benefits book applicable summaries material modification general rule phased july provided employee whose employment terminated age age service equaled least would eligible unreduced age benefit instead normal early retirement subsidy ie per year reduction year benefit payments begin prior age rule transition benefit preserved rule employee older july preserved year old employees year old employees etc benefit preserved employees younger example assume bridged employee born june july employee rule benefit preserved assume separation date january shell years months old years credited service employment continued attained age would entitled rule transition benefit july age service date would exceeded employee may begin receive benefits including rule transition benefit ie rule benefit retirement plan july first day month reaches age bridged employee early retirement subsidies described subject prorata fraction would include rule transition benefit hand assume instead bridged employee would separation date matter many years credited service eligible rule transition benefit special separation program would entitled rule transition benefit within two years separation date remained merck employee words would reached age points within years separation date employment continued social security bridge transition benefit bridged employees also eligible social security bridge transition benefit special separation program social security bridge transition benefit fully described salaried retirement plan section current merck benefits book applicable summaries material modification general social security bridge transition benefit reduces offset social security benefits retirement plan providing temporary monthly supplement prior age benefit eliminated july preserved employees least age preserved employees employees etc benefit preserved employees younger benefit require particular number points may eligible social security transition benefit even eligible rule transition benefit death bridged employee die sign separation letter begin receive benefits retirement plan spouse estate case unmarried participant receive annuity lump sum die age eligible social security bridge transition benefit eligible rule transition benefit separation date eligible benefit die reach age pro rata fraction described would applied described benefit calculated though elected joint survivor annuity spouse youre unmarried though spouse age day died lump sum actuarial equivalent survivor portion benefitthat taking account death annuity lump sum payable spouse administrator estate applies benefit bridged employees special separation program charged qualified preretirement spousal annuity fully described salaried retirement plan section current merck benefits book applicable summaries material modification information except described treated terminated vested participant retirement plan purposes example may receive disability retirement discussed salaried retirement plan section current merck benefits book applicable summaries material modification special provisions retirement plan regarding bridged employees subject certain discrimination tests tax laws actuaries reviewed data preliminary basis concluded special provisions satisfy tests scenarios however provisions practice happen fail tests benefits described paid extent necessary company assets outside retirement plan benefits retirement plan tax advantages payments outside notified soon possible provision affects leave company entitled vested benefit retirement plan youll receive statement tell life income age sent within approximately one year separation date portion benefit different plan retirement plan hourly employees merck co inc offset reduces benefit retirement plan aggregate lump sum benefit payable two different plans generally differs slightly lump sum payable one plan especially different interest rate methodologies apply payments compensation retirement plan separation pay compensation retirement plan purposes bonus special payment lieu aipeip bonus paid separation date also compensation retirement plan purposes split election bridged employees whose pension benefits payable part supplemental retirement plan wish make election respect retirement benefits plan may accordance plan contacting hr service center mrkhru request appropriate paperwork eligible medical including prescription drug dental medical including prescription drug dental sign separation letter dont sign separation letter revocation period applicable revoke separation letter medical dental coverage options effect separation date continue mercks medical dental plans may amended time time end month following calendar month separation date occurred end period eligible elect continue coverage accordance cobra months separation date medical andor dental coverage mercks plans separation date medical andor dental coverage applicable separation date eligible elect coverage cobra special separation program retiree medical including prescription drug dental least nine years credited service separation date sign separation letter special separation program least nine years credited service separation date sign revocation period applicable revoke separation letter eligible participate retiree medical dental coverage mercks plans may amended time time first day month separation date even separation date first day month active employee coverage continue end month separation date occurs retiree healthcare benefits commence first month following separation date retiree healthcare commencement date automatically enrolled retiree dental comprehensive coverage option retiree medical coverage coverage option enrolled active employee day retiree healthcare commencement date provided coverage option available retiree medical coverage option available automatically enrolled plans default option currently merck ppo option address within network coverage area otherwise merck area option coverage retiree medical dental coverage also automatically continue eligible dependents covered dependents applicable plans day retiree healthcare commencement date permitted add eligible dependents drop covered dependents andor change medical coverage options retroactive date retiree healthcare commencement date notify merck benefits service center changes within days retiree healthcare commencement date thereafter permitted changes made prospectively note eligible dependents dependents record retiree healthcare commencement date eligible dependent coverage retiree healthcare coverage sure register eligible dependents dependents record merck benefit service center within days retiree healthcare commencement date eligible dependent timely registered dependent record heshe never eligible dependent coverage merck retiree healthcare coverage eligible dependents covered dependents retiree healthcare commencement date automatically registered dependents record optout retiree coverage note ability reenroll coverage generally limited annual open enrollment following january reenrollment effective date midyear enrollment available covered lose coverage contact merck benefit service center reenroll merck retiree coverage within days loss coverage must pay applicable retiree premiums retiree healthcare coverage beginning retiree healthcare commencement date receive invoice fidelity indicates premium due retiree coverage fail pay premium required retiree medical dental coverage time manner specified invoice deemed opted coverage ability reenroll limited described purposes determining retiree medical dental premiums bridged employee number points sum hisher age years adjusted service recorded companys records age subject rule adjusted service subject rule hisher separation date provided however sum less bridged employee deemed points pay premiums medical coverage accordance premium schedule rule rule applicable effect hisher retiree healthcare commencement date premium schedule may amended time time determine whether rule rule applies see premiums applicable schedules see reference library fidelitys netbenefits website continuation retiree medical dental coverages bridged employees special separation program subject early forfeiture provisions applicable separated employees described separation plan spd forfeiture provisions apply separation pay period special separation program would less years credited service separation date sign separation letter less nine years credited service separation date b sign separation letter revocation period applicable revoke separation letter special separation program eligible continued medical dental coverage retiree coverage mercks medical dental plans may amended time time separation pay period fully described separation plan spd separation pay period less six months may continue medical dental coverage six months contributions continue coverage contributions active employees may change time time payable merck designee time manner specified merck time time pay required contributions merck designee time manner specified merck time time coverage terminated reinstated provided paid required contributions continue coverage end separation pay period separation pay period less months end month period medical dental coverages provided may elect continue coverage accordance cobra additional months continuation medical dental coverages special separation program bridgeeligible employees paragraph subject early forfeiture provisions applicable separated employees described separation plan spd life insurance life insurance sign separation letter sign separation letter revocation period applicable revoke separation letter employee group term life dependent life survivor income protection continue days separation date day period may elect continue coverages level effect separation date mercks life insurance plan may amended time time may continue coverages cost earlier months separation date age wish continue survivor income protection andor dependent life coverage must continue employee group term life basic optional continue life insurance coverages must contact merck benefits service center within days separation letter return date must pay applicable premium time manner specified merck fail pay premium time manner specified merck coverages terminated reinstated interested continuing coverages contact merck benefits service center information accidental death dismemberment coverage ends separation date full months premium may deducted paycheck month separation date occurs special separation program life insurance sign separation letter special separation program sign separation letter revocation period applicable revoke separation letter considered retiree life insurance purposes mercks life insurance plan may amended time time separation date retiree coverage begin first day month separation date retiree employee group term life insurance coverage equal x base pay x base pay old format continue cost amount reduce amount coverage starting first day month following separation date equal dollar amount anniversary date third anniversary date balance remains right convert amount reduction individual policy see life insurance plan section current merck benefits book applicable summaries material modification information conversion retiree may continue employee group term life insurance excess x base pay x old format dependent life andor survivor income protection collectively optional coverages effect separation date age paying applicable premiums time manner required merck fail pay premium required continue coverage time manner specified merck coverages terminated reinstated continuation basic life insurance retiree special separation program subject early forfeiture provisions applicable separated employees described separation plan spd basic life insurance ends result forfeiture optional coverages also cease see life insurance section merck benefits book applicable summaries material modification description conversion rights accidental death dismemberment coverage ends separation date chart provided convenience compare medical dental life insurance benefits offered special separation program normal plan provisions regular plan special separation provisions program medical dental prescription drug benefits continue end treated retiree month following month applicable contributions separation date occurs eligible would least years cobra afterward credited service separation date less years credited service separation date benefits continue end month separation pay period ends minimum months provided pay applicable employee contributions time manner specified merck designee thereafter eligible cobra basic employee term life insurance coverage level effect treated retiree coverage new formatmaximum x base pay separation date continues level effect separation date old format x base pay days may elect continue reduced first day coverage months month following beyond age separation separation date reduced date cost anniversary date coverage amount reaches zero optional employee group term life coverage level effect treated retiree dependent life survivor income separation date continues continue coverage cost days may elect continue age coverage months beyond age separation date cost add coverage coverage stock options restricted stock units performance stock units employees may receive incentives mercks incentive stock plans including stock options restricted stock units rsus performance stock units psus therefore eligible receive grants separation date outstanding stock options rsus psus sign separation letter separated purposes stock options rsus psus mercks incentive stock plans stock options rsus psus held us employee whose employment ends treated provisions grants applicable retirement employee considered retiree retirement plan bridgeeligible employees sign separation letter revocation period applicable revoke separation letter considered retirees retirement plan therefore sign separation letter revocation period applicable revoke separation letter separation provisions retirement provisions applicable stock options rsus psus apply outstanding incentives hold separation date separation provisions may differ based grants responsibility familiarize terms individual grants stock options separation terms generally outstanding annual quarterly stock option grants made prior separation terms vested options expire upon earlier day oneyear anniversary separation date ii original year expiration date generally outstanding annual quarterly stock option grants made thereafter separation terms unvested options vest separation date two years exercise previously vested grants outstanding vested optionsincluding previously vestedwill expire day second anniversary separation date original expiration date earlier key rd mrl mmd new hire stock option grants stock option grants may different terms see term sheets applicable stock option grants treated separated later rehired stock options unexercised outstanding rehire date reinstated active status employment interrupted rsus separation terms treated separated pro rata portion annual grants restricted stock units generally vest become distributable time employment continued see term sheets applicable rsus granted psus separation terms treated separated pro rata portion annual grant performance share units payable distribution respect applicable performance year made active employees see term sheets applicable psus granted question stock options restricted stock units performance stock units call hr service center mrkhru special separation program sign separation letter retired purposes stock options rsus psus mercks incentive stock plans stock options rsus psus held us employee whose employment ends treated provisions grants applicable retirement employee considered retiree retirement plan sign revocation period applicable revoke separation letter considered retiree retirement plan therefore sign revocation period applicable revoke separation letter retirement provisions separation provisions applicable stock options rsus psus apply outstanding incentive hold separation date retirement provisions may differ based grants responsibility familiarize terms individual grants stock options retirement terms generally outstanding annual quarterly stock option grants made prior retirement provisions vested options may exercised earlier day th anniversary separation date considered retirement date ii original expiration date generally outstanding annual quarterly stock option grants made thereafter retirement provisions unvested options vest original vesting date exercisable full term option expiring original expiration date vested options exercisable remaining term option expiring original expiration date key rd mrl mmd new hire stock option grants stock option grants may different terms see term sheets applicable stock option grants treated retired later rehired stock options unexercised outstanding rehire date continue retirement terms rsus retirement terms treated retired annual grants restricted stock units granted least months prior separation date generally vest become distributable employment merck continued rsus granted within months separation date forfeited see term sheets applicable rsus granted psus retirement terms treated retired pro rata portion annual grant performance share units granted least months prior separation date payable distribution respect applicable performance year made active employees performance share units granted within months separation date lapse separation date see term sheets applicable psus granted question stock options rsus psus call hr service center mrkhru annual incentive programexecutive incentive program aipeip described detail payment bonuses special payment lieu bonus depends bridged employees separation date occurs performance year actual aipeip bonuses respect performance year immediately preceding bridged employees separation date may paid employees whose employment terminates january time aipeip bonuses paid year employees aipeip special payment lieu bonus respect performance year separation date occurs payable employee separated january june inclusive special payment lieu bonus payable program respect performance year separation date occurs employees whose separation dates occur july december performance year executives listed summary compensation table recent proxy materials issued company connection annual meeting shareholders amount payment lieu eip award guided following principles company retains complete discretion pay less amounts company reserves right treat payment aipeip bonuses andor special payments lieu aipeip bonuses supplemental wages subject flatrate withholding taking account exemptions separation date occurs january prior time aipeip bonuses paid prior performance year separation date occurs january prior day aipeip bonuses prior performance year paid merck employees eligible consideration aipeip bonus respect prior complete performance year terms conditions merck employees provided class employees eligible aipeip aipeip bonus paid time aipeip bonuses paid merck employees deferred accordance applicable deferral election aipeip performance year applicable eligibility consideration aipeip bonus contingent upon signing separation letter eligible aipeip payment lieu aipeip performance year separation date occurs separation date occurs time aipeip bonuses paid prior performance year june separation date occurs aipeip bonuses paid merck employees june eligible consideration aipeip bonus special lieu bonus payment described whether sign separation letter separation date occurs june december separation date occurs june december special payment lieu aipeip respect performance year separation date occurs may paid sign revocation period applicable revoke separation letter special payment calculated based target bonus applicable annual incentive programexecutive incentive program respect current performance year number full partial months worked current performance year subject adjustment company sole discretion based variety factors including limited documented poor extraordinary performance current performance year receive special payment lieu aipeip bonus paid less applicable withholding soon administratively feasible following separation date however elected defer aipeip bonus election apply payments made lieu aipeip bonus merck onsite day care centers child enrolled merck onsite day care center child remain enrolled center separation letter return date sign separation letter child infant toddler preschool room separation date heshe may continue day care center third month anniversary separation date child kindergarten separation date may continue end calendar week kindergarten graduation occurs provided continued enrollment subject continuing abide rules regulations day care center terms separation letter continuation first three months shall regular tuition rate kindergarten children continuing first three months may additional charge following describes terms conditions certain merck benefit plans programs apply employees whose employment merck terminates reason additional information see applicable sections current merck benefits book applicable summaries material modification dependent care reimbursement account participation dependent care reimbursement account dcra ends separation date eligible expenses incurred throughout calendar year separation date occurs even merck employment ends reimbursed amount actually contributed account claims expenses must submitted horizon blue cross blue shield april th year following year separation date occurs amounts remaining account eligible expenses paid forfeited financial engines eligibility use financial engines financial planning tool end separation date financial planning elected financial planning continue benefit remainder calendar year separation date occurs remaining cost benefit deducted final pay check necessary separation pay paid pursuant separation benefits plan financial planning election irrevocable changed flexible benefits program flexible benefits program consists following merck plans programs medical dental vision health care dependent care reimbursement accounts financial planning life insurance including basic optional term life dependent term life survivor income accidental death dismemberment long term care long term disability participation plans ends described elsewhere communication however full month contributionpremium coverage plans effect separation date may deducted paycheck month separation date occurs health care reimbursement account participation health care reimbursement account hcra ends separation date unless elect continue participate accordance cobra remainder calendar year separation date occurs elect continue participation hcra cobra must make required contributions aftertax basis eligible expenses incurred participate hcra calendar year separation date occurs reimbursed entire elected amount claims incurred participation hcra ends reimbursed matter much money left account claims expenses incurred calendar year separation date occurs participant hcra must submitted horizon blue cross blue shield april year following year separation date occurs amounts remaining account eligible expenses paid forfeited long term care elected coverage mercks long term care plan spouse samesex domestic partner coverage end separation date however want continue coverage without interruption must contact cna insurer pay first quarterly premium cna within days last day month separation date occurs information request necessary forms contact cna directly long term disability participation long term disability plan end last day month separation date occurs words must satisfied week eligibility period end month includes separation date eligible ltd benefits disabled receiving income replacement benefits long term disability plan separation date benefits continue accordance terms long term disability plan however separation pay paid company special separation program act offset benefits payable long term disability plan meaning ltd benefits reduced separation pay savings plan separation pay receive special separation program base pay may contributed savings plan prorata deduction made savings plan based percentage monthly base pay receive month separation date occurs plan loan repay within days separation date loan declared default reported taxable distribution internal revenue service generally may receive final distribution savings plan time separation date however account balance less account balance automatically distributed soon separation date upon reaching age previously elected receive benefits account balance distributed without regard amount review information salaried savings plan section current merck benefits book applicable summaries material modification additional information receiving final distribution short term disability subject applicable state law participation short term disability plan ends separation date disabled receiving income replacement benefits short term disability plan separation date benefits continue accordance terms plan however subject state law separation pay paid company special separation program act offset benefits payable short term disability plan meaning std benefits reduced separation pay state law permit offsets made std benefits company sole absolute discretion determines easier company administer std benefits instead act offset separation pay paid payable company special separation program meaning separation pay reduced std benefits travel accident coverage travel accident insurance plan ends separation date vacation pay paid amount vacation accrued used separation date conversely must reimburse merck vacation used prior separation date earned separation date amounts reimbursed may deducted separation pay paid pursuant separation benefits plan vision coverage vision plan ends last day month separation date occurs given opportunity continue benefit accordance cobra months separation date paying required premiums special separation program described currently scheduled effect separations service occur january december merck retains right extent permitted law amend terminate special separation program benefit plan described brochure otherwise time however following change control merck defined change control separation benefits plan certain limitations apply mercks ability amend terminate benefit plans addition employee whose employment terminated without cause within two years following change control also entitled receive retirement bridge provided change control separation benefits plan current intention merck also may extend decrease enhance special separation program future sign return separation letter separation letter return date later amendment termination decrease increase amount separation pay eligible receive special separation program notwithstanding anything special separation program contrary benefits program subject section internal revenue code amended adjusted avoid excise tax section merck take steps determines necessary sole absolute discretion adjust benefits special separation program avoid excise tax section including limited reducing eliminating benefits changing time form payment benefits etc payments generally may made account separation service limited six months following termination employment specified employee defined treas reg sec successor thereto general includes top employees company ranked compensation notwithstanding anything contained special separation program contrary covered employee specified employee separation date extent required section internal revenue code amended payments made sixmonth period following termination employment instead amounts would otherwise paid sixmonth period accumulated paid without interest soon administratively feasible following end sixmonth period termination employment glossary definitions used document following terms following meanings bridgeeligible employees employees merck co inc subject collective bargaining agreement experience separation service defined separation benefits plan january december last day employment merck separation date least years age yet age least years credited service least years age yet age least years credited service years credited service least years age yet age less years credited service bridgeeligible employees employees designated merck bridgeeligible employees brochure applies bridgeeligible employees bridged employees bridgeeligible employees sign revocation period applicable revoke separation letter bridged employees considered retired retirement plan bridged employees include employees terminate employment way constitute separation determined merck including employees resign reason company merck means merck co inc credited service defined retirement plan retirement plan means retirement plan salaried employees merck co inc separation benefits plan means merck co inc separation benefits plan nonunion employees separation date means bridgeeligible employees last day employment merck separation letter means companyprovided letter describe special separation program benefits include release claims company may include terms nonsolicitation noncompetition provisions company determines separation letter return date date stated separation letter bridgeeligible employees must sign return company sign return revocation period applicable revoke separation letter become bridged employees separation pay period number full partial work weeks bridged employee paid separation pay special separation program means separation benefits bridged employees receive sign revocation period applicable revoke separation letter exhibit merck co inc special separation program separated retirement eligible employees eligible employees employees merck co inc subject collective bargaining agreement experience separation service defined separation benefits plan january december separation date least age least years credited service least age effective date january document summarizes benefits separated retirement eligible employee may eligible special separation program merck employee benefit plans programs unless otherwise noted terms conditions mercks employee benefit plans programs applicable employees termination employment merck described applicable sections current merck benefits book applicable summaries material modification previously provided provided brochure plans programs applicable sections merck benefits book may amended time time copy applicable sections merck benefits book applicable summaries material modification obtained line httphumresmerckcombenefitaboutbenefitsbookhtml wwwmerckcombenefits calling merck benefits service center however extent terms differ described applicable sections current merck benefits book applicable summaries material modification communication constitutes summary material modifications kept book separated retirement eligible employees certain nonunionized merck co inc employees experience separation service defined separation benefits plan january december last day employment merck separation date least age least years credited service defined retirement plan least age separated retirement eligible employees employees designated merck separated retirement eligible employees separated retirement eligible employees include employees terminate employment way constitute separation service defined separation benefits plan determined merck including employees resign reason benefits described brochure apply separated retirement eligible employees apply merck employees designated separated retirement eligible employee company provide separation letter separation letter describe special separation program benefits eligible include release legal claims company may also include terms nonsolicitation noncompetition provisions company sole discretion decides include order receive benefits special separation program must sign return separation letter date stated letter separation letter return date revocation period applicable revoke letter within revocation period special separation program benefits special separation program contingent upon separated retirement eligible employee signing revocation period applicable revoking separation letter consist separation pay outplacement services eligibility continued medical dental benefits employees otherwise eligible retiree medical dental benefits rule transition benefit retirement plan would attained within two years separation dates eligibility special payment lieu aipeip bonus performance year separation date occurs eligibility extended use day care center separation pay outplacement benefits described separation plan spd distributed brochure brochure describes additional benefits offered special separation program described separation plan spd eligibility rule transition benefit retirement plan eligibility continued medical dental benefits employees otherwise eligible retiree medical dental benefits eligibility extended use day care center applicable benefits separated retirement eligible employees sign revocation period applicable sign later revoke separation letter terms conditions certain merck benefit plans programs apply separated employee without regard whether sign separation letter retirement plan rule transition benefit sign separation letter eligible retire terms retirement plan separated retirement eligible employee considered retired active service retirement plan purposes separation date even separation date first day month benefit retirement plan based credited service accrued separation date payable first day month following age least separation date first day month following separation date however begin receive benefits first day month reach age commence benefit age age benefit reduced reduction reflects payments made earlier longer period time reduction retirees month ie year benefit payments begin age reduction much less actuarial reduction applies terminated vested participants receive rule transition benefit unless eligible rule transition benefit described death die separation date begin receive benefits retirement plan spouse estate case unmarried participant receive annuity lump sum lump sum according plan factors effect change time time based age accrued benefit reduced per month age death occurs benefit calculated though elected joint survivor annuity spouse youre unmarried though spouse age day died lump sum actuarial equivalent survivor portion benefitthat taking account death annuity lump sum payable spouse administrator estate applies benefit payments compensation retirement plan separation pay compensation retirement plan purposes bonus special payment lieu aipeip bonus paid separation date also compensation retirement plan purposes portion benefit different plan retirement plan hourly employees merck co inc offset reduces benefit retirement plan aggregate lump sum benefit payable two different plans generally differs slightly lump sum payable one plan especially different interest rate methodologies apply special separation program rule transition benefit sign separation letter described paragraph sign separation letter eligible retire terms retirement plan special separation program would qualified rule transition benefit within two years separation date rule transition benefit paid special provisions retirement plan rule transition benefit payable upon commencement pension benefits even date commencement pension benefits earlier date would otherwise qualified rule transition benefit rule transition benefit fully described salaried retirement plan section current merck benefits book applicable summaries material modification general rule phased july provided employee whose employment terminated age whose age service equaled least would eligible unreduced age benefit instead normal early retirement subsidy ie per year reduction every year benefit begins prior age rule transition benefit preserved rule employee older july preserved year old employees etc benefit preserved employees younger eligible rule transition benefit special separation program would reached rule transition benefit within two years separation date words enhancement applies separation date sum age credited service least example assume separated retirement eligible employee born june july employee rule transition benefit preserved assume separation date january exactly years credited service employment continued would entitled rule transition benefit october age service date would equaled therefore employee would receive rule transition benefit ie rule transition benefit benefits retirement plan begin october less two years separation date january hand assume instead separated retirement eligible employees age credited service separation date add less eligible rule transition benefit special separation program would entitled rule transition benefit within two years separation date special provisions retirement plan subject certain discrimination tests tax laws actuaries reviewed data preliminary basis concluded special provisions satisfy tests scenarios however provisions practice happen fail tests benefits described made extent necessary company assets outside retirement plan benefits retirement plan tax advantages payments outside notified soon possible provision affects split election separated retirement eligible employees whose pension benefits payable part supplemental retirement plan wish make election respect retirement benefits plan may accordance plan contacting hr service center mrkhru request appropriate paperwork eligible medical including prescription drug dental eligible retiree healthcare benefits current terms merck medical dental plans separation date eligible retiree healthcare medical dental benefits terms mercks medical dental plans whether sign separation letter eligible select retiree healthcare coverage mercks plans may amended time time first day month separation date even separation date first day month active employee coverage continue end month separation date occurs retiree healthcare benefits commence first month following separation date retiree healthcare commencement date automatically enrolled retiree dental comprehensive coverage option retiree medical coverage coverage option enrolled active employee day retiree healthcare commencement date provided coverage option available retiree medical coverage option available automatically enrolled plans default option currently merck ppo option address within network coverage area otherwise merck area option coverage retiree medical dental coverage also automatically continue eligible dependents covered dependents applicable plans day retiree healthcare commencement date permitted add eligible dependents drop covered dependents andor change medical coverage options retroactive date retiree healthcare commencement date notify merck benefits service center changes within days retiree healthcare commencement date thereafter permitted changes made prospectively note eligible dependents dependents record retiree healthcare commencement date eligible dependent coverage retiree healthcare coverage sure register eligible dependents dependents record merck benefit service center within days retiree healthcare commencement date eligible dependent timely registered dependent record heshe never eligible dependent coverage merck retiree healthcare coverage eligible dependents covered dependents retiree healthcare commencement date automatically registered dependents record optout retiree coverage note ability reenroll coverage generally limited annual open enrollment following january reenrollment effective date midyear enrollment available covered lose coverage contact merck benefit service center reenroll merck retiree coverage within days loss coverage must pay applicable premiums retiree healthcare coverage beginning retiree healthcare commencement date receive invoice fidelity indicates premium due retiree coverage fail pay premium required retiree healthcare coverage time manner specified invoice deemed opted coverage ability reenroll limited described purposes determining retiree medical dental premiums separated retirement eligible employee number points sum hisher age years adjusted service recorded companys records age subject rule adjusted service subject rule hisher separation date pay premiums medical coverage accordance premium schedule rule rule applicable effect hisher retiree healthcare commencement date premium schedule may amended time time determine whether rule rule applies see premiums applicable schedules see reference library fidelitys netbenefits website eligible retiree healthcare benefits separation date least age least years service company age employee company january ii break service since january iii least years credited service defined retirement plan break service company age april ii returned work april employed date iii break service since april iv years credited service defined retirement plan eligible retiree healthcare benefits eligible retiree healthcare benefits sign separation letter eligible retiree healthcare benefits sign separation letter revocation period applicable revoke separation letter medical dental coverage options effect separation date continue normal provisions mercks medical dental plans may amended time time end month following calendar month separation date occurred end period eligible elect continue coverage accordance cobra months separation date medical andor dental coverage mercks medical dental plans separation date medical andor dental coverage applicable separation date eligible elect coverage cobra special separation program eligible retiree healthcare benefits least years credited service sign separation letter separation date least age ii least years credited service defined retirement plan iii eligible retiree healthcare benefits see section eligible retiree healthcare benefits current terms mercks medical dental plans iv sign separation letter revocation period applicable revoke separation letter special separation program eligible select retiree healthcare coverage mercks plans may amended time time first day month separation date even separation date first day month active employee coverage continue end month separation date occurs retiree healthcare benefits commence first month following separation date retiree healthcare commencement date automatically enrolled retiree dental comprehensive coverage option retiree medical coverage coverage option enrolled active employee day retiree healthcare commencement date provided coverage option available retiree medical coverage option available automatically enrolled plans default option currently merck ppo option address within network coverage area otherwise merck area option coverage retiree medical dental coverage also automatically continue eligible dependents covered dependents applicable plans day retiree healthcare commencement date permitted add eligible dependents drop covered dependents andor change medical coverage options retroactive date retiree healthcare commencement date notify merck benefits service center changes within days retiree healthcare commencement date thereafter permitted changes made prospectively note eligible dependents dependents record retiree healthcare commencement date eligible dependent coverage retiree healthcare coverage sure register eligible dependents dependents record merck benefit service center within days retiree healthcare commencement date eligible dependent timely registered dependent record heshe never eligible dependent coverage merck retiree healthcare coverage eligible dependents covered dependents retiree healthcare commencement date automatically registered dependents record optout retiree coverage note ability reenroll coverage generally limited annual open enrollment following january reenrollment effective date midyear enrollment available covered lose coverage contact merck benefit service center reenroll merck retiree coverage within days loss coverage must pay applicable premiums retiree healthcare coverage beginning retiree healthcare commencement date receive invoice fidelity indicates premium due retiree coverage fail pay premium required retiree healthcare coverage time manner specified invoice deemed opted coverage ability reenroll limited described purposes determining retiree medical dental premiums separated retirement eligible employee number points sum hisher age years adjusted service recorded companys records age subject rule adjusted service subject rule hisher separation date provided however sum less separated retirement eligible employee deemed points pay premiums medical coverage accordance premium schedule rule rule applicable effect hisher retiree healthcare commencement date premium schedule may amended time time determine whether rule rule applies see premiums applicable schedules see reference library fidelitys netbenefits website continuation retiree medical dental coverages special separation program separated retirement eligible employees otherwise eligible retiree healthcare benefits subject early forfeiture provisions applicable separated employees described separation plan spd forfeiture provisions apply separation pay period special separation program eligible retiree healthcare benefits less years credited service sign separation letter separation date separated retirement eligible employee otherwise eligible retiree healthcare benefits terms mercks medical dental plans ii less nine years credited service iii sign separation letter revocation period applicable revoke separation letter special separation program eligible continued medical dental coverage retiree coverage mercks medical dental plans may amended time time separation pay period fully described separation plan spd separation pay period less six months may continue medical dental coverage six months contributions continue coverage contributions active employees may change time time payable merck designee time manner specified merck time time pay required contributions merck designee time manner specified merck time time coverage terminated reinstated provided paid required contributions continue coverage end separation pay period separation pay period less months end month period medical dental coverages provided may elect continue coverage accordance cobra additional months continuation medical dental coverages special separation program separated retirement eligible employees otherwise eligible retiree healthcare benefits subject early forfeiture provisions applicable separated employees described separation plan spd life insurance whether sign separation letter considered retiree life insurance purposes mercks life insurance plan may amended time time separation date retiree coverage begin first day month separation date retiree employee group term life insurance coverage equal x base pay x base pay old format continue cost amount reduce amount coverage starting first day month separation date equal dollar amount anniversary date third anniversary date balance remains right convert amount insurance reduced individual policy see life insurance plan section current merck benefits book applicable summaries material modification information conversion retiree yet age separation date may continue employee group term life insurance excess x base pay x old format dependent life andor survivor income protection collectively optional coverages effect separation date age paying applicable premiums time manner required merck fail pay premium required continue coverage time manner specified merck coverages terminated reinstated age older separation date optional coverages continue days separation date period may convert coverages individual policy see life insurance plan section current merck benefits book applicable summaries material modification information conversion event accidental death dismemberment coverage ends separation date chart provided convenience compare medical dental life insurance benefits offered regular plan provisions special separation program regular plan special separation provisions program medical dental eligible retiree healthcare eligible retiree healthcare prescription drug benefits treated benefits treated retiree retiree w applicable contributions wapplicable contributions paid retiree eligible retiree healthcare eligible retiree healthcare benefits benefits continue benefits medical dental end month following benefits continue separation month separation pay period minimum months date occurred eligible cobra provided pay applicable afterward employee contributions time manner specified merck designee eligible cobra afterward basic employee term life treated retiree treated retiree coverage level insurance new formatmaximum effect separation date reduced x base pay old format x base first day month pay following separation date reduced anniversary date coverage amount reaches zero optional employee treated retiree treated retiree group term life continue coverage cost continue coverage cost dependent life age age survivor income add coverage coverage annual incentive programexecutive incentive program aipeip described detail payment bonuses special payment lieu bonus depends separated retirement eligible employees separation date occurs performance year whether employee signs separation letter performance year prior separation date actual aipeip bonuses respect performance year immediately preceding separated retirement eligible employees separation date may paid employees whose employment terminates january prior time aipeip bonuses prior performance year paid year employees performance year separation date occurs employees sign separation letter prorated actual aipeip bonuses respect performance year separated retirement eligible employees separation date occurs may paid employees time aipeip bonuses paid performance year employees employees sign separation letter special payment lieu actual aipeip bonus performance year separated retirement eligible employees separation date occurs payable program executives listed summary compensation table recent proxy materials issued company connection annual meeting shareholders amount payment lieu eip award guided following principles company retains complete discretion pay less amounts company reserves right treat payment aipeip bonuses andor special payments lieu aipeip bonuses supplemental wages subject flatrate withholding taking account exemptions aipeip performance year prior separation date separation date occurs january prior day aipeip bonuses prior performance year paid merck employees eligible consideration aipeip bonus respect prior complete performance year terms conditions merck employees provided class employees eligible aipeip aipeip bonus paid time aipeip bonuses paid merck employees deferred accordance applicable deferral election aipeip performance year applicable eligibility consideration aipeip bonus prior performance year contingent upon signing separation letter aipeip performance year separation date occursif sign separation letter sign separation letter eligible consideration aipeip bonus respect performance year separation date occurs terms conditions merck employees retired performance year provided class employees eligible aipeip aipeip bonus paid time aipeip bonuses paid merck employees deferred accordance applicable deferral election aipeip performance year applicable aipeip performance year separation date occursif sign separation letter special payment lieu aipeip respect performance year separation date occurs may paid sign revocation period applicable revoke separation letter special payment calculated based target bonus applicable annual incentive programexecutive incentive program respect current performance year number full partial months worked current performance year subject adjustment company sole discretion based variety factors including limited documented poor extraordinary performance current performance year receive special payment lieu aipeip bonus paid less applicable withholding soon administratively feasible following separation date however elected defer aipeip bonus election apply payments made lieu aipeip bonus merck onsite day care centers child enrolled merck onsite day care center child remain enrolled center separation letter return date sign separation letter child infant toddler preschool room separation date heshe may continue day care center third month anniversary separation date child kindergarten separation date may continue end calendar week kindergarten graduation occurs provided continued enrollment subject continuing abide rules regulations day care center terms separation letter continuation first three months shall regular tuition rate kindergarten children continuing first three months may additional charge benefits programs stock options restricted stock units performance stock units employees may receive incentives mercks incentive stock plans including stock options restricted stock units rsus performance stock units psus therefore eligible receive grants separation date outstanding stock options rsus psus mercks incentive stock plans stock options rsus psus held us employee whose employment ends treated provisions grants applicable retirement employee considered retiree retirement plan whether sign separation letter considered retiree retirement plan retirement provisions applicable stock options restricted stock units performance stock units apply outstanding incentive hold separation date retirement provisions may differ based grants responsibilty familiarize terms individual grants retirement provisions stock options generally outstanding annual quarterly stock option grants made prior retirement provisions vested options may exercised earlier day th anniversary separation date considered retirement date ii original expiration date generally outstanding annual quarterly stock option grants made thereafter retirement provisions unvested options vest original vesting date exercisable full term option expiring original expiration date vested options exercisable remaining term option expiring original expiration date key rd mrl mmd new hire stock option grants stock option grants may different terms see term sheets applicable stock option grants treated retired later rehired stock options unexercised outstanding rehire date continue retirement terms rsus retirement provisions rsus annual grants restricted stock units granted least months prior separation date generally vest become distributable employment merck continued rsus granted within months separation date forfeited see term sheets applicable rsus granted psus retirement provisions psus pro rata portion annual grant performance share units granted least months prior separation date payable distribution respect applicable performance year made active employees performance share units granted within months separation date lapse separation date see term sheets applicable psus granted question stock options restricted stock units performance stock units call hr service center mrkhru following describes terms conditions certain merck benefit plans programs apply employees whose employment merck terminates reason additional information see applicable sections current merck benefits book applicable summaries material modification dependent care reimbursement account participation dependent care reimbursement account dcra ends separation date eligible expenses incurred throughout calendar year separation date occurs even merck employment ends reimbursed amount actually contributed account claims expenses must submitted horizon blue cross blue shield april th year following year separation date occurs amounts remaining account eligible expenses paid forfeited financial engines eligibility use financial engines financial planning tool end separation date financial planning elected financial planning continue benefit remainder calendar year separation date occurs remaining cost benefit deducted final pay check necessary separation pay paid pursuant separation benefits plan financial planning election irrevocable changed flexible benefits program flexible benefits program consists following merck plans programs medical dental vision health care dependent care reimbursement accounts financial planning life insurance including basic optional term life dependent term life survivor income accidental death dismemberment long term care long term disability participation plans ends described elsewhere communication however full month contributionpremium coverage plans effect separation date may deducted paycheck month separation date occurs health care reimbursement account participation health care reimbursement account hcra ends separation date unless elect continue participate accordance cobra remainder calendar year separation date occurs elect continue participation hcra cobra must make required contributions aftertax basis eligible expenses incurred participate hcra calendar year separation date occurs reimbursed entire elected amount claims incurred participation hcra ends reimbursed matter much money left account claims expenses incurred calendar year separation date occurs participant hcra must submitted horizon blue cross blue shield april year following year separation date occurs amounts remaining account eligible expenses paid forfeited long term care elected coverage mercks long term care plan spouse samesex domestic partner coverage end separation date however want continue coverage without interruption must contact cna insurer pay first quarterly premium cna within days last day month separation date occurs information request necessary forms contact cna directly long term disability participation long term disability plan end last day month separation date occurs words must satisfied week eligibility period end month includes separation date eligible ltd benefits disabled receiving income replacement benefits long term disability plan separation date benefits continue accordance terms long term disability plan however separation pay paid company special separation program act offset benefits payable long term disability plan meaning ltd benefits reduced separation pay savings plan separation pay receive special separation program base pay may contributed savings plan prorata deduction made savings plan based percentage monthly base pay receive month separation date occurs plan loan repay within days separation date loan declared default reported taxable distribution internal revenue service generally may receive final distribution savings plan time separation date however account balance less account balance automatically distributed soon separation date upon reaching age previously elected receive benefits account balance distributed without regard amount review information salaried savings plan section current merck benefits book applicable summaries material modification additional information receiving final distribution short term disability subject applicable state law participation short term disability plan ends separation date disabled receiving income replacement benefits short term disability plan separation date benefits continue accordance terms plan however subject state law separation pay paid company special separation program act offset benefits payable short term disability plan meaning std benefits reduced separation pay state law permit offsets made std benefits company sole absolute discretion determines easier company administer std benefits instead act offset separation pay paid payable company special separation program meaning separation pay reduced std benefits travel accident coverage travel accident insurance plan ends separation date vacation pay paid amount vacation accrued used separation date conversely must reimburse merck vacation used prior separation date earned separation date amounts reimbursed may deducted separation pay paid pursuant separation benefits plan vision coverage vision plan ends last day month separation date occurs given opportunity continue benefit accordance cobra months separation date paying required premiums special separation program described currently scheduled effect separations service occur january december merck retains right extent permitted law amend terminate special separation program benefit plan described brochure otherwise time however following change control merck defined change control separation benefits plan certain limitations apply mercks ability amend terminate benefit plans addition employee whose employment terminated without cause within two years following change control also entitled receive retirement bridge provided change control separation benefits plan current intention merck also may extend decrease enhance special separation program future sign return separation letter separation letter return date later amendment termination decrease increase amount separation pay eligible receive special separation program notwithstanding anything special separation program contrary benefits program subject section internal revenue code amended adjusted avoid excise tax section merck take steps determines necessary sole absolute discretion adjust benefits special separation program avoid excise tax section including limited reducing eliminating benefits changing time form payment benefits etc payments made account separation service limited six months following termination employment specified employee defined treas reg sec successor thereto general includes top employees company ranked compensation notwithstanding anything contained special separation program contrary covered employee specified employee separation date extent required section internal revenue code amended payments made sixmonth period following termination employment instead amounts would otherwise paid sixmonth period accumulated paid without interest soon administratively feasible following end sixmonth period termination employment glossary definitions used document following terms following meanings company merck means merck co inc credited service defined retirement plan retirement plan means retirement plan salaried employees merck co inc separation benefits plan means merck co inc separation benefits plan nonunion employees separated retirement eligible employees certain nonunionized merck co inc employees experience separation service defined separation benefits plan january december last day employment merck separation date least age least years credited service defined retirement plan least age separated retirement eligible employees employees designated merck separated retirement eligible employees separated retirement eligible employees include employees terminate employment way constitute separation service defined separation benefits plan determined merck including employees resign reason separation date means separated retirement eligible employees last day employment merck separation letter means companyprovided letter describe special separation program benefits include release claims company may include terms nonsolicitation noncompetition provisions company determines separation letter return date date stated separation letter separated retirement eligible employees must sign return company separation pay period number full partial workweeks separated retirement eligible employee paid separation pay special separation program means separation benefits separated retirement eligible employees receive sign revocation period applicable revoke separation letter exhibit merck co inc supplemental retirement plan amended restated effective january table contents article purpose article ii definitions article iii benefits payable plan article iv payments benefits article v plan administration article vi claims appeal procedure article vii amendment termination article viii miscellaneous article ix change control merck co inc supplemental retirement plan purpose merck co inc supplemental retirement plan plan intended provide additional benefits executive participants merck co inc retirement plan salaried employees qualified plan follows benefits payable qualified plan limitations benefits payable qualified plan set forth sections andor internal revenue code amended ii benefits payable qualified plan exclusion deferred compensation qualified plan iii minimum aggregate benefit incumbents time actual retirement positions designated bona fide executive high policymaking companys corporate policy executive retirement iv enhanced benefit certain individuals held positions prior january ii definitions adeaexempt employee means employee occupies position designated bona fide executive high policy making companys corporate policy executive retirement basic supplemental benefit means benefit described section hereof beneficiary means individual individuals entity entitled receive death survivor benefit qualified plan pursuant section code means internal revenue code amended committee means us compensation benefits committee company management committee appointed compensation benefits committee board directors company company means merck co inc successor thereto compensation means compensation defined qualified plan provided however employee defers mandatory deferral portion award incentive plan year deferred amount included compensation year notwithstanding subsequent forfeiture credited service means credited service defined qualified plan director means global benefits leader successor thereto employee means employee company subsidiaries participant qualified plan following employees person independent contractor company affiliates agrees agreed independent contractor company agreement understanding company affiliates person employee even person previously employee employed temporary employment agency regardless amount control supervision training provided company affiliates leased employee defined section n code foregoing exclusion applies even court agency authority rules person happens common law employee company affiliates employee also excludes individuals included unit employees covered collective bargaining agreement employee representatives one employers provided however employee may eligible employee period covered covered collective bargaining agreement participates qualified plan enhanced credited service means credited service defined section enhanced supplemental benefit means benefit described section incentive plan means merck co inc annual incentive plan executive incentive plan subsidiary incentive plan calgon vestal annual incentive plan kelco annual incentive plan participant means employee benefit plan plan means merck co inc supplemental retirement plan amended time time post accruals means benefits accrued accrue within meaning section code plan january pre accruals means benefits accrued within meaning section code plan december prior benefit means benefit described section qualified plan means retirement plan salaried employees merck co inc effect time time supplemental benefits means benefits provided pursuant article iii iii benefits payable plan employee entitled basic supplemental benefit amount equal excess b benefit would paid employee hisher beneficiary qualified plan provisions administered without regard limitations set forth section andor section code definition compensation set forth herein substituted definition compensation qualified plan b benefit payable employee hisher beneficiary qualified plan employee time termination employment death adeaexempt employee b case termination employment prior normal retirement date immediately prior retirement least ten years credited service entitled normal retirement date basic supplemental benefit amount equal excess per year life income basis benefit payable employee hisher beneficiary qualified plan provision plan case early disability retirement death prior normal retirement date benefit reduced prior reduction set forth section multiplying fraction numerator employees years credited service date early disability retirement death denominator employees years credited service assuming heshe terminated employment company affiliate hisher normal retirement date adeaexempt employees employees march mandatorily retired normal retirement date entitled enhanced supplemental benefit determined follows month credited service earned qualified plan adeaexempt employee prior period employee adeaexempt employee employee granted additional month credited service aggregate maximum years additional credited service constituting enhanced credited service employee b employees basic supplemental benefit determined using formula set forth section definition enhanced credited service set forth substituted definition credited service qualified plan resulting increased benefit less employees basic supplemental benefit benefit payable employee qualified plan reduced benefit paid payable employee retirement plan except retirement plan sponsored whole part company affiliates ever participated regardless nature sponsor including without limitation governmentsponsored plans prior benefit resulting amount employees enhanced supplemental benefit benefit amounts used determining enhanced supplemental benefit determined company lumpsum basis utilizing actuarial interest rate assumptions employed date retirement qualified plan case prior benefit previously distributed employee using interest rates company deems appropriate circumstances c subject section employee nonforfeitable right enhanced supplemental benefit time nonforfeitable right benefit qualified plan time employee becomes adeaexempt employee promptly provide company confirmation detail may time time required company nature amount prior benefit company may establish rules regulations deems appropriate confirming existence nature terms payments prior benefit failure employee comply rules regulations company requests regard result forfeiture enhanced supplemental benefit company determine whether plan employee participated plan providing prior benefit determine amount thereof decisions final binding respects e enhanced credited service used calculate employees enhanced supplemental benefit described purpose plan qualified plan f case early disability retirement death prior normal retirement date adeaexempt employee would eligible enhanced supplemental benefit upon retirement normal retirement date enhanced supplemental benefit payable consent compensation benefits committee board directors company g effective january accruals enhanced supplemental benefit provisions plan except individuals listed exhibit one hereto continue accruals terms conditions set forth section iv payment benefits respect pre accruals payment supplemental benefits hereunder governed terms qualified plan including limited actuarial reductions relative termination employment early retirement applicable elections thereunder respect date commencement form benefit payments event death vesting term condition election applicable benefits section notwithstanding respect pre accruals employee elects lumpsum payment qualified plan may elect receive hisher supplemental benefits form allowed qualified plan election must made later end calendar year preceding year employee retires year annuity starting date qualified plan provided however elections made election shall become effective first anniversary date received company event participant makes election heshe designate beneficiary receive death survivor benefit may become payable hereunder b employee prohibited electing form benefit qualified plan spousal consent obtained required section aa code may elect receive hisher supplemental benefit form allowed qualified plan election must made later end calendar year preceding year employee retires provided however elections made election shall become effective first anniversary date received company event participant makes election heshe designate beneficiary receive death survivor benefit may become payable hereunder c employee eligible make election paragraphs b section may elect lump sum plan paid first january following employees normal retirement date regardless whether employee dies date amount lump sum exact amount would paid employee elected lump sum payable hisher actual retirement date election must made later end calendar year preceding year employee receives benefit qualified plan provided however elections made election shall become effective first anniversary date received company event employee makes election heshe designate beneficiary receive death benefit may become payable hereunder employee qualifies disability retirement defined qualified plan receive pre accruals plan time manner benefits paid qualified plan without regard previous election section respect post accruals effective january benefits commence post start date shall later first day first month following participants post separation service within meaning section code ii participants attainment age benefits payable lump sum calculated manner lump sums calculated qualified plan annuity starting dates post start date unless participant elected defer receipt accordance b c b participant may make election initial election receive benefits form five annual installments shall commence post start date amount installments shall equal present value amount described payable five equal annual installments subject rounding using interest rate compounded monthly provided notwithstanding foregoing post start date amount calculated section exceed annual compensation limit effect section internal revenue code successor thereto year lumpsum payment calculated section instead made c december participant may elect defer receipt post accruals making election deferral election less months post start date participant may make one deferral election deferral election irrevocable effective first anniversary date received company deferral election shall become payable either case participant younger first day month following later attainment age separation service ii case participant older first day month following th anniversary separation service payment benefits participants benefit shall form x lump sum five annual payments z annual payments form lump sum amount shall equal future value lump sum calculated pursuant section using interest rate used section expressed monthly rate compounded monthly form annual payments amounts shall equal present value amount described c payable five equal annual installments subject rounding using interest rate compounded monthly provided c notwithstanding foregoing time first payment paid lump sum amount calculated section c exceed annual compensation limit effect section internal revenue code successor thereto year lumpsum payment calculated section c instead made notwithstanding foregoing participant dies begun receive post accruals shall paid lump sum beneficiary current spouse within meaning qualified plan beneficiary designated estate spouse beneficiary designated participant soon administratively feasible death using assumptions applicable qualified plan participant begun receive installments post accruals dies receiving last installment beneficiary spouse estate shall paid present value remaining unpaid payments soon administratively feasible following death using lumpsum interest rate qualified retirement plan used pursuant section e anything plan contrary notwithstanding participant prior separation service becomes disabled within meaning treas reg sec ahi successor thereto post start date shall mean first day th month onset disability within meaning section code unless prior thereto participant recovers returns service company benefit shall distributed lump sum shall reduced early commencement actuarially otherwise accruals shall apply participant plan event participant dies prior th month benefit shall paid accordance section creation assignment recognition right benefit payable respect participant pursuant domestic relations order hereinafter defined must accordance section event right benefit hereunder established pursuant domestic relations order benefit otherwise payable participant hisher beneficiary hereunder shall appropriately reduced reflect effect domestic relations order purposes plan alternate payee means person would alternate payee section p code plan subject section code domestic relations order purports applicable qualified plan apply plan unless satisfies requirements section domestic relations order shall mean judgment decree order including approval property settlement agreement provided order relates provision child support alimony marital property rights made pursuant state domestic relations community property laws b order creates recognizes existence alternate payees right receive portion participants benefit plan c order specifies name last known mailing address participant alternate payee covered order order precisely unambiguously specifies amount percentage participants benefit paid alternate payee manner amount percentage determined e order clearly specifies applies plan f order require plan provide type benefits form benefits otherwise provided plan g respect post accruals order provides alternate payee shall receive interest plan form time participant receives benefit h companys legal department delegate determines order satisfies requirements article benefit payments paid cash general funds company special separate fund established segregation assets made assure payment distributions nothing contained plan action taken pursuant provisions create construed create trust kind extent person acquires right receive benefits company subsidiaries plan right greater right unsecured creditor company subsidiaries v plan administration plan operated direction board directors company administered director employee benefits committee rules general application qualified plan may adopted administration plan extent consistent purposes plan director employee benefits committee full discretionary power authority make factual determinations interpret plan make benefit eligibility determinations resolve questions arising administration interpretation application plan correct defect reconcile inconsistency supply omission respect plan corrections reconciliations interpretations completions plan provisions final binding conclusive upon parties including company employees participants alternate payees affiliates families dependents beneficiaries heirs successors assigns vi claims appeals procedure determination claim employee hisher authorized representative may present claim benefits director director make determinations employees claim benefits plan director grants claim benefits payable plan paid employee soon feasible thereafter director denies whole part claim benefit plan heshe furnish claimant notice decision later days receipt claim special circumstances require extension time processing claim director provide written notice extension initial day period case decision rendered days receipt claim written notice director provide every claimant denied claim benefits set forth manner calculated understood claimant specific reason reasons denial b specific reference pertinent plan provisions denial based c description additional material information necessary claimant perfect claim explanation material information necessary appropriate information steps taken claimant wishes submit hisher claim review appeal denied claim claimant hisher authorized representative may request review denied claim employee benefits committee request made writing presented employee benefits committee days receipt claimant written notification denial claim employee benefits committee render decision review later days receipt claimants request review unless special circumstances require extension time case decision rendered soon possible later days receipt request review decision review writing include specific reasons decision erisa section intended claims procedure plan administered accordance regulations department labor issued erisa section limitation action action law equity action shall maintained participant beneficiary individual entity party including limited person determined participant beneficiary claimant plan company affiliates agents fiduciaries officers directors employees successors assigns plans collectively plan group unless claimant presented every basis argument support action claim strict accordance sections claim denied whole part b unless action commenced later one year date company provides notice adverse decision pursuant section company puts claimant notice companys plans intention respect basis argument support action claimant must commence process described section within one year notice claim includes limited claim benefits purported actual fiduciary breach member plan group limitation action may tolled writing executed director vii amendment termination committee concurrence chief executive officer company right alter amend plan including right merge plan retirement plan company qualified section code provided amendments result significant cost increase ii would significant adverse effect rights employees including termination plan iii would significant effect longterm rights liabilities company must approved board directors company plan amended rights employee hisher accrued benefits plan determined date amendment nonforfeitable extent amendment would reduce employees accrued benefits hereunder company terminates plan rights employee hisher accrued benefits nonforfeitable company terminates qualified plan respect participants therein pre accruals payable affected employees accordance terms conditions applicable employees benefits qualified plan event termination respect post accruals benefits shall payable lump sum earliest time permitted otherwise provided treas reg sec ajix successor thereto viii miscellaneous except otherwise provided section right payment interest employee hisher beneficiary assignable subject attachment execution levy kind nothing plan construed giving employee participant right continued employment company supplemental benefit deemed salary compensation employee purpose computing benefits heshe may entitled qualified plan plan binding upon inure benefit company successors assigns employee hisher beneficiary company may withhold benefits payable plan taxes required withheld pursuant law governmental regulation ruling amounts deemed owing company reason within companys reasonable discretion plan intended qualified section code plan established maintained pursuant written plan document may amended altered terminated administered except provided herein plan document constitutes complete plan benefits provided hereunder supersedes agreements understandings oral written relate subject matter plan plan nonqualified deferred compensation plan within meaning section code anything plan contrary notwithstanding respect post accruals plan shall interpreted operated compliance requirements section successor thereto effect time time including limited applicable regulations us department treasury internal revenue service including limited treas reg secs successor thereto payment called plan subject section designated date shall made later date within tax year participant march following year later date specified treas reg sec successor thereto provided participant permitted designate taxable year payment b anything plan contrary notwithstanding extent required section respect post accruals distributions account separation service specified employee term defined section may made date six months date separation service earlier date death employee payment would made specified employee within sixmonth period payment one series annual payments first payment shall delayed necessary remaining payments shall made according elected schedule notwithstanding delay two otherwise annual payments may made single year ix change control article describes benefits plan provided participant also participant cic participant defined merck co inc change control separation benefits plan cic plan cic participant signs returns release claims use cic plan generally cic participants limited certain employees bands cic participants employment terminated circumstances entitling severance benefits term defined cic plan provided section b cic plan cic participant participates plan termination date term defined cic plan least age least ten years credited service qualified plan would attain least age least ten years credited service qualified plan within two years following date change control term defined cic plan assuming continued employment entirety twoyear period cic participant shall deemed eligible subsidized early retirement benefit plan commencing earlier age based credited service plan accrued termination date b cic participant participates plan termination date least age would attain least age within two years following date change control without regard years credited service assuming continued employment entirety twoyear period cic participant shall deemed eligible benefit unreduced early commencement plan upon commencement benefit plan c cic participant participates plan termination date eligible rule transition benefit term defined qualified plan would eligible rule transition benefit within two years following date change control assuming continued employment entirety twoyear period cic participant shall deemed eligible rule transition benefit upon commencement benefit plan cic participants employment terminated circumstances entitling severance benefits provided section cic plan cic participant participates plan time prior termination date company shall adjust benefit payable thereunder adding number years additional credited service cic participants existing credited service termination date equal multipleas term defined cic plan assuming years credited service added pursuant section cic participants compensation term defined qualified plan equal sum cic participants base salary bonus amount adding number years age cic participant thereunder equal multiple calculating cic participants pension accordance formula provided therein immediately prior change control greater termination date b anything section contrary notwithstanding application multiple additional years age shall cause cic participants total years credited service age exceed amount would applied cic participant employment continued age benefits payable article shall times forms provided article iv exhibit one none effective january exhibit merck co inc plan deferred payment directors compensation amended restated january table contents article purpose article ii election deferral investment alternatives distribution schedule article iii valuation deferred amounts article iv redesignation within deferral account article v payment deferred amounts article vi designation beneficiary article vii plan amendment termination article viii section compliance imerck co inc plan deferred payment directors compensation purpose merck co inc plan deferred payment directors compensation plan provides unfunded arrangement directors merck co inc current employees value account ultimately distribute amounts deferred voluntarily case annual retainers board committee meeting fees ii mandatorily certain cases described herein ii election deferral investment alternatives distribution schedule election voluntary deferral amount prior december year director may irrevocably elect initial election defer termination service director later following together voluntary deferral amount respect months beginning april next calendar year initial election board retainer b committee chairperson retainer c audit committee member retainer board committee meeting fees prior commencement duties director within first days following commencement services director newly elected appointed board calendar year may make initial election portion voluntary deferral amount applicable directors first year service part thereof voluntary deferral amount shall credited follows board committee meeting fees deferred credited last business day calendar quarter board retainer lead director retainer committee chairperson retainer andor audit committee member retainer deferred prorata share deferred retainer credited last business day calendar quarter dates voluntary deferral amount parts thereof credited directors deferred account hereinafter referred voluntary deferral dates effective december initial election made shall continue apply successive years terms conditions director makes new initial election b mandatory deferral amount friday following companys annual meeting stockholders mandatory deferral date director credited amount equivalent annual cash retainer month period beginning theapril preceding annual meeting mandatory deferral amount mandatory deferral amount measured merck common stock account director newly elected appointed board mandatory deferral date credited pro rata portion mandatory deferral amount applicable directors first year service part thereof pro rata portion shall credited directors account first day directors service c automatic deferral executive committee fees june april directors served either chairperson member boards executive committee lieu cash payment service credited amount provided way retainer meeting fees automatic deferral amount automatic deferral amount measured merck common stock account election investment alternatives initial election shall include election investment alternatives value amounts deferred measured accordance article iii investment alternatives available plan shall investment alternatives available time time merck co inc deferral program executive deferral program provided however times shall merck common stock fund investment alternatives merck common stock referred herein investment alternatives e initial election distribution schedule initial election shall include election year distribution date defined shall occur shall apply voluntary deferral amounts mandatory deferral amounts automatic deferral amounts credited period distribution date shall th day month day business day next business day calendar quarter following directors termination service director number years thereafter would permitted distributions elected executive deferral program f changes distribution schedule extent participants executive deferral program permitted make redeferral elections time time participants plan may elect defer distribution dates subject restrictions applicable executive deferral program provided however redeferral election may effect accelerating distribution prior directors termination service death iii valuation deferred amounts merck common stock initial crediting annual mandatory deferral amount shall used determine number full partial shares merck common stock amount would purchase closing price common stock new york stock exchange nyse mandatory deferral date automatic deferral amount used determine number full partial shares merck common stock amount would purchased closing price common stock nyse portion voluntary deferral amount allocated merck common stock shall used determine number full partial shares merck common stock amount would purchase closing price common stock nyse applicable voluntary deferral date plan unfunded time shares merck common stock purchased earmarked deferred amounts rights shareholder exist respect amounts dividends directors account credited additional number full partial shares merck common stock would purchasable dividends shares previously credited account closing price common stock nyse date dividend paid distributions distributions merck common stock account valued closing price merck common stock nyse distribution date purposes valuation merck common stock merck common stock longer traded nyse publicly traded exchange references nyse shall mean exchange merck common stock publicly traded committee corporate governance board directors determines measurement merck common stock mandatory voluntary deferral date distribution date would constitute fair market value committee shall decide date method determine fair market value shall accord requirements set forth section successor thereto b investment alternatives initial crediting amount allocated investment alternative shall used determine full partial investment alternative shares amount would purchase closing net asset value investment alternative shares mandatory voluntary deferral date whichever applicable directors account credited number full partial investment alternative shares determined time investment alternative shares purchased earmarked deferred amounts rights shareholder exist respect amounts dividends directors account credited additional number full partial investment alternative shares would purchasable closing net asset value investment alternative shares date dividend paid investment alternative shares dividends would paid number shares previously credited account including pro rata dividends partial shares distributions investment alternative distributions valued based closing net asset value investment alternative shares distribution date c adjustments event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares company investment alternative number kind shares units shall adjusted accordingly iv redesignation within deferral account general director may redesignate account invested among investment alternatives redesignation redesignation affects investment alternatives affect timing distributions plan amounts deferred using merck common stock method earnings attributable deferrals may redesignated prior first anniversary termination directors service change effective closing price day redesignation request received pursuant administrative guidelines established human resources financial services area provided request received prior close nyse day ii next following business day request received nyse closed b redesignation may occur active service limit number times director may redesignate portion hisher deferred account permitted redesignated request shall irrevocable redesignated whole percentages dollar amount death following death director legal representative beneficiary director may redesignate subject rules active directors set forth article iv section b c valuation amounts redesignated portion directors account redesignated valued cash equivalent cash equivalent converted shares units investment alternatives purposes redesignations cash equivalent value investment alternative shares shall closing net asset value investment alternative day redesignation request received pursuant administrative guidelines established human resources financial services area treasury department provided request received prior close nyse day ii next following business day request received nyse closed v payment deferred amounts payment payments directors amounts deferred cash distribution date distributions shall pro rata investment alternative distributions shall paid soon administratively feasible distribution date b forfeitures directors deferred amount attributable mandatory deferral amount earnings thereon shall forfeited upon removal director upon determination committee corporate governance sole discretion director joined board managed operated participated material way entered employment performed consulting services otherwise connected material manner company corporation enterprise firm limited partnership partnership person sole proprietorship business entity determined committee corporate governance sole discretion competitive business company subsidiaries affiliates competitor ii directly indirectly acquired equity interest percent greater competitor iii disclosed material trade secrets material confidential information including customer lists relating company business company others including competitor vi designation beneficiary event death director deferred amount date death shall paid last named beneficiary beneficiaries designated director beneficiary designated legal representative directors estate b lump sum distribution remaining account balance made directors beneficiary estates legal representative soon administratively feasible following death whether director service time death commenced receive payments account balance distribution date distribution shall th day month day business day next business day calendar quarter following date company learns death vii plan amendment termination committee corporate governance shall right amend terminate plan time reason viii section compliance anything plan contrary notwithstanding plan shall comply section internal revenue code successor thereto shall interpreted accordance therewith payment called plan soon administratively feasible designated date shall made later date within tax year director march following year later time permitted treas reg sec ad successor thereto provided director permitted designate taxable year payment plans obligation pay unclear including dispute proper beneficiary director dies payment shall made soon adminstratively feasible programs obligation becomes clear time permitted treas reg sec ag successor thereto exhibit merck co inc subsidiaries computation ratios earnings fixed charges millions except ratio data years ended december income taxes add subtract onethird rents interest expense gross interest capitalized net amortization equity income loss affiliates net distributions preferred stock dividends net tax earnings defined onethird rents interest expense gross preferred stock dividends fixed charges ratio earnings fixed charges purposes computing ratios earnings consist income continuing operations taxes onethird rents deemed company representative interest factor inherent rents interest expense net amounts capitalized equity income loss affiliates net distributions dividends preferred stock subsidiary companies fixed charges consist onethird rents interest expense reported companys consolidated financial statements dividends preferred stock subsidiary companies interest expense reflect interest financial accounting standards board interpretation accounting uncertainty income taxes interpretation fasb statement fin liabilitiesexhibit merck co inc subsidiaries following list subsidiaries company business name stated country state name incorporation abmaxis inc delaware ancare australia pty limited australia ancare ireland limited ireland animal health care south africa pty limited south africa asp inc georgia banyu pharmaceutical co ltd japan beijing merial vital laboratory animal technology co ltd china brc ltd bermuda charles e frosst uk limited united kingdom chibret pharmazeutische gmbh germany cloverleaf international holdings sarl luxembourg comsort inc delaware coophavet sas france crosswinds bv netherlands dieckmann arzneimittel gmbh germany european insurance risk excess limited ireland farmacoxcompanhia farmaceutica lda portugal farmasixprodutos farmaceuticos lda portugal financiere msd sas france fontelaborprodutos farmaceuticos lda portugal fregenal holdings sa panama frosst iberica sa spain frosst laboratories inc delaware frosst portuguesa produtos farmaceuticos lda portugal glycofi inc delaware hangzhou msd pharmaceutical company limited china hawk falcon llc delaware heptafarma companhia farmaceutica lda portugal im merial holdings llc delaware international indemnity ltd bermuda istituto di richerche di biologia molecolare spa italy istituto gentili spainc italydelaware johnson johnson merck consumer pharmaceuticals company new jersey johnson johnson consumer pharma canada canada kbi inc delaware kbi sub inc delaware kbie inc delaware kbip inc delaware kiinteisto oy viistotie finland laboratoires merck sharp dohmechibret snc francecountry state name incorporation laboratorios abello sa spain laboratorios biopat sa spain laboratorios chibret sa spain laboratorios frosst sa spain laboratorios medichip sl spain laboratorios merial peru sa peru laboratorios neurogard sa spain laboratorios quimicofarmaceuticos chibret lda portugal lospar partnership delaware maple leaf holdings srl barbados mcm vaccine co pennsylvania merck company incorporated delaware merck borinquen holdings inc delaware merck capital ventures llc delaware merck cardiovascular health company nevada merck frosst canada ltd canada merck frosst company canada merck frosst finco lp canada merck frosst schering pharma gp canada merck hdac research llc delaware merck holdings ii corp delaware merck holdings llc delaware merck respiratory health company nevada merck sh inc delaware merck sharp dohme argentina inc delaware merck sharp dohme asia limited hong kong merck sharp dohme australia pty limited australia merck sharp dohme china limited hong kong merck sharp dohme enterprises bv netherlands merck sharp dohme europe inc delaware merck sharp dohme holdings bv netherlands merck sharp dohme holdings limited united kingdom merck sharp dohme ia corp delaware merck sharp dohme international limited bermuda merck sharp dohme investments bv netherlands merck sharp dohme ireland ltd bermuda merck sharp dohme israel company ltd israel merck sharp dohme italia spa italy merck sharp dohme lebanon sal lebanon merck sharp dohme middle east limited cyprus merck sharp dohme new zealand limited new zealand merck sharp dohme panama sa panama merck sharp dohme puerto rico ltd bermuda merck sharp dohme singapore ltd bermuda merck sharp dohme sweden ab sweden merck sharp dohme switzerland gmbh switzerland merck sharp dohme asia pacific services pte ltd singapore merck sharp dohme bv netherlands merck sharp dohme biologics ireland ltd bermuda country state name incorporation merck sharp dohme bulgaria eood bulgaria merck sharp dohme chibret ag switzerland merck sharp dohme comercializadora de rl de cv mexico merck sharp dohme doo croatia merck sharp dohme de espana sa spain merck sharp dohme de mexico sa de cv mexico merck sharp dohme de puerto rico inc delaware merck sharp dohme de venezuela srl venezuela merck sharp dohme farmaceutica ltda brazil merck sharp dohme finance europe limited united kingdom merck sharp dohme gmbh austria merck sharp dohme idea ag switzerland merck sharp dohme industria quimica e veterinaria limitada brazil merck sharp dohme inovativna zdravila doo slovenia merck sharp dohme international services bv netherlands merck sharp dohme ireland human health ltd ireland merck sharp dohme sland hf iceland merck sharp dohme japan co ltd japan merck sharp dohme limited united kingdom merck sharp dohme manufacturing ireland merck sharp dohme manufacturing holdings bermuda merck sharp dohme ou estonia merck sharp dohme peru srl peru merck sharp dohme pharmaceuticals llc russia merck sharp dohme pharmaceuticals srl barbados merck sharp dohme quimica de puerto rico ltd bermuda merck sharp dohme quimica de puerto rico inc delaware merck sharp dohme research ltd bermuda merck sharp dohme romania srl romania merck sharp dohme de rl de cv mexico merck sharp dohme sa morocco merck sharp dohme sia latvia merck sharp dohme singapore trading pte ltd singapore merck sharp dohme tunisie sarl tunisia merck sharp dohme limitada portugal merck sharp dohme holdings de mexico sa de cv mexico merck sharp dohme ilaclari limited sirketi turkey merck technology us company inc nevada merial ia llp puerto rico merial thailand ltd thailand merial animal health co ltd china merial animal health limited uk united kingdom merial animal health limited ireland merial argentina sa argentina merial asia pte ltd singapore merial australia pty ltd australia merial bv netherlands merial belgium belgium merial canada inc canada country state name incorporation merial colombia sa colombia merial de mexico sa de cv mexico merial distribution sas france merial finance llc delaware merial gmbh germany merial hong kong limited hong kong merial inc delaware merial international trading shanghai co ltd china merial italia spa italy merial japan limited japan merial korea ltd korea merial laboratorios sa spain merial limitedllc united kingdomdelaware merial mexico sa de cv mexico merial nanjing animal health co ltd china merial new zealand limited new zealand merial norden denmark merial philippines inc philippines merial portuguesa saude animal lda portugal merial production sas france merial sa uruguay merial sas france merial saude animal ltda brazil merial select inc georgia merial south africa proprietary limited south africa merial taiwan co ltd taiwan merial technologies inc delaware merial venezuela ca venezuela ml holdings canada inc canada msd nippon holdings bv netherlands msd norge norway msd proprietary limited south africa msd shanghai pharmaceuticals consultancy co ltd china msd thailand ltd thailand msd australia superannuation pty ltd australia msd brazil investments bv netherlands msd chibropharm gmbh germany msd china investments bv netherlands msd eurofinance lp bermuda msd finance bv netherlands msd finland oy finland msd international holdings inc delaware msd investment holdings ireland ireland msd ireland holdings sarl luxembourg msd ireland resources ireland msd korea ltd korea msd latin america services de rl de cv mexico msd limited united kingdom msd magyarorszg kereskedelmi es szolgaltato kft hungary country state name incorporation msd mexico investments bv netherlands msd overseas manufacturing co ireland ireland msd overseas manufacturing co bermuda msd pharmaceuticals private limited india msd polska spzoo poland msd puerto rico holdings inc puerto rico msd regional business support center gmbh germany msd scandinavia norway msd sharp dohme gmbh germany msd stamford singapore pte ltd singapore msd technology singapore pte ltd singapore msd tuas singapore pte ltd singapore msd unterstutzungskasse gmbh germany msd ventures singapore pte ltd singapore msd vostok bv netherlands msdessex gmbh switzerland msdj holdings canada inc canada msdsp ltd united kingdom msp distribution services c llc nevada msp distribution services r llc nevada msp singapore company llc delaware msp technology us company llc delaware neopharmed spa italy nomad new jersey inc new jersey novacardia inc delaware pt merck sharp dohme indonesia indonesia pasteur vaccins sa france rhonemerieux limited united kingdom rosetta biosoftware uk limited united kingdom rosetta inpharmatics llc delaware sanofi pasteur msd denmark sanofi pasteur msd ab sweden sanofi pasteur msd ag switzerland sanofi pasteur msd aps denmark sanofi pasteur msd norway sanofi pasteur msd gestion sa france sanofi pasteur msd gmbh austria sanofi pasteur msd gmbh germany sanofi pasteur msd ltd united kingdom sanofi pasteur msd ltd ireland sanofi pasteur msd nvsa belgium sanofi pasteur msd oy finland sanofi pasteur msd sa portugal sanofi pasteur msd sa spain sanofi pasteur msd spa italy sanofi pasteur msd snc france sfpa inc delaware sharp dohme sa spain sirna therapeutics inc delaware country state name incorporation telerx marketing inc pennsylvania msd foundation limited united kingdom thomas morson son limited united kingdom transrow manufacturing ltd bermuda uab merck sharp dohme lithuania variopharm arzneimittel gmbh germany vinmex sa mexico less exhibit power attorney undersigned hereby appoint celia colbert bruce n kuhlik severally hisher true lawful attorney attorneys execute behalf undersigned whether behalf company officer director thereof attesting seal company otherwise annual report merck co inc fiscal year ended december securities exchange act including amendments thereto